Anticoagulation Program Coordinator
Pharmacy Services, UK HealthCare
Associate Adjunct Professor, Pharmacy Practice & Science
University of Kentucky College of Pharmacy

Section Editors (Edition 37-now)
Brian Gardner, PharmD
Pediatric Team Coordinator
Kentucky Children's Hospital
UK HealthCare

Aaron M. Cook, PharmD, BCPS
Clinical Coordinator Neuroscience-Pulmonary/Critical Care
Pharmacy Services, UK HealthCare
Associate Adjunct Professor, Pharmacy Practice & Science
University of Kentucky College of Pharmacy

Donna Burgess, PharmD
Antimicrobial Stewardship Pharmacist
Pharmacy Services, UK HealthCare

Past Editors:
Editions 28-34, 2006-2012
Daniel Lewis Pharm.D, BCPS
Clinical Specialist, Pharmacy
South Pointe Hospital, Warrensville Hts, OH

Editions 1-19 (1987-97)
Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAHS
Professor, Faculty of Pharmaceutical Sciences, and
Distinguished University Scholar, The University of British Columbia
Clinical Pharmacy Specialist, Children's and Women's Health Centre of British Columbia

Disclaimer:

The Clinical Pharmacokinetics Service and Anticoagulation Guidelines are provided to assist with clinical pharmacokinetic monitoring and anticoagulation management of selected drugs for the Pharmacy Services at UK HealthCare. Although the information contained in the guidelines has been obtained from reputable sources in accordance with currently available information, the editors do not assume any liability in connection with the use of any specific information contained herein. While great care has been taken to ensure the accuracy of the information presented, the reader is advised that it is possible that these pages contain some errors and omissions. If you find an error, please report it to George Davis at georgedavis@uky.edu or (859) 323-1789.

The information provided in the guidelines is not intended to replace sound clinical judgment in the delivery of healthcare. Dosing of monitorable drugs and anticoagulation management require independent and informed decisions by appropriate healthcare professionals. Also, the information in this manual may not be applicable to other healthcare institutions. Complete information concerning drug administration, dosage, sampling times, clinical laboratory procedures, pharmacokinetic data, and pharmacological and toxic effects of monitorable drugs should be assessed and contrasted with other sources prior to its clinical use.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK Pharmacy Services on Clinical Pharmacokinetics Service</td>
<td>1</td>
</tr>
<tr>
<td>Therapeutic Drug Monitoring (TDM) Laboratory Critical Value Call Policy</td>
<td>4</td>
</tr>
<tr>
<td>List of Monitorable Drugs and Therapeutic Ranges</td>
<td>5</td>
</tr>
<tr>
<td>Basic Pharmacokinetic Concepts</td>
<td>7</td>
</tr>
<tr>
<td>Guidelines for Pharmacokinetic Monitoring</td>
<td>14</td>
</tr>
<tr>
<td>General Equations for BSA, IBW, and Clcr</td>
<td>16</td>
</tr>
<tr>
<td>Monitorable Drugs</td>
<td></td>
</tr>
<tr>
<td><em>Aminoglycosides – Conventional Dosing</em></td>
<td>19</td>
</tr>
<tr>
<td><em>Aminoglycosides – High Dose Extended Interval</em></td>
<td>31</td>
</tr>
<tr>
<td><em>Carbamazepine</em></td>
<td>41</td>
</tr>
<tr>
<td><em>Digoxin</em></td>
<td>44</td>
</tr>
<tr>
<td><em>Lidocaine</em></td>
<td>51</td>
</tr>
<tr>
<td><em>Lithium</em></td>
<td>53</td>
</tr>
<tr>
<td><em>Methotrexate</em></td>
<td>57</td>
</tr>
<tr>
<td><em>Pentobarbital</em></td>
<td>60</td>
</tr>
<tr>
<td><em>Phenobarbital</em></td>
<td>63</td>
</tr>
<tr>
<td><em>Phenytoin</em></td>
<td>66</td>
</tr>
<tr>
<td><em>Phenytoin, Free</em></td>
<td>75</td>
</tr>
<tr>
<td><em>Theophylline</em></td>
<td>76</td>
</tr>
<tr>
<td><em>Valproic Acid</em></td>
<td>83</td>
</tr>
<tr>
<td><em>Valproic Acid Continuous Intravenous Infusion Protocol</em></td>
<td>87</td>
</tr>
<tr>
<td><em>Vancomycin</em></td>
<td>89</td>
</tr>
<tr>
<td>Anticoagulation Guidelines</td>
<td></td>
</tr>
<tr>
<td><em>UK Pharmacy Services Policy on Anticoagulation</em></td>
<td>99</td>
</tr>
<tr>
<td><em>Warfarin</em></td>
<td>101</td>
</tr>
<tr>
<td><em>Heparin, Unfractionated</em></td>
<td>107</td>
</tr>
<tr>
<td><em>Enoxaparin</em></td>
<td>108</td>
</tr>
<tr>
<td><em>Direct Thrombin Inhibitors</em></td>
<td>110</td>
</tr>
<tr>
<td><em>Heparin Induced Thrombocytopenia (HIT) Guidelines</em></td>
<td>113</td>
</tr>
<tr>
<td><em>Direct Oral Anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)</em></td>
<td>118</td>
</tr>
<tr>
<td><em>VTE Prophylaxis Assessment and Management</em></td>
<td>120</td>
</tr>
</tbody>
</table>
SUBJECT: Clinical Pharmacokinetics Service Policy/Procedures
PURPOSE: To establish a standardized pharmacokinetic monitoring approach for patients receiving drugs that are routinely monitored utilizing serum drug concentrations at the University of Kentucky Hospital.

FUNCTIONS AFFECTED: Clinical Pharmacist Specialists, Clinical Staff Pharmacists, Pharmacy Residents, and Pharmacy Students

GENERAL: The Clinical Pharmacokinetics Service (CPS) Guidelines were developed to ensure safe and efficacious dosage regimens through the application of pharmacokinetic/pharmacodynamic principles and the determination of drug serum concentrations. The policy/procedure manual outlines standard guidelines which should be followed when providing clinical pharmacokinetic monitoring of the following drugs: aminoglycosides, carbamazepine, digoxin, fosphenytoin, lidocaine, lithium, phenobarbital, phenytoin (free and total), procainamide, quinidine, theophylline, valproic acid, and vancomycin. In addition to the above list, the CPS will also provide monitoring for warfarin for patients without assigned pharmacists.

Monitoring Responsibility
Within the pharmaceutical care process, the primary pharmacist/resident who attends rounds or precepts pharmacy students on the primary medical team is responsible for providing appropriate and cost-conscious therapeutic drug monitoring and provision of clinical pharmacokinetic evaluations. The CPS is responsible for overseeing the kinetic monitoring process for all patients and providing pharmacokinetic assessments for any patient that does not have an assigned primary pharmacist/resident. This responsibility is met through a team approach including a faculty member who serves as the Manager of Clinical Pharmacokinetics Service along with Pharmacy Practice Residents and PY4 pharmacy students as part of a resident/student rotation in Clinical Pharmacokinetics.

Patients with serum drug concentrations on non-covered services are identified on a daily basis utilizing Sunrise Clinical Manager (SCM). Also, the Therapeutic Drug Monitoring (TDM) Laboratory provides an electronic report of all completed serum drug concentrations of patients admitted to the hospital twice daily. This allows for identification of any non-covered patients who are prescribed monitorable drugs which have not obtained serum concentrations. Physicians may also initiate a request for pharmacy to provide a clinical pharmacokinetic evaluation by verbal communication or through a pharmacy to dose requisition in (SCM).

TDM Notification of Supratherapeutic Concentrations
The Therapeutic Drug Monitoring Laboratory is responsible for the analysis of all "routine" serum drug assays evaluated by pharmacy during a pharmacokinetic evaluation. The TDM Lab notifies the primary pharmacist of any supratherapeutic concentrations between 8AM-4PM during the week; after 4PM and on weekends and holidays the Pharm D resident on-call (UK Pager #330-7400) is notified. The TDM Lab notifies the clinical pharmacokinetic service of any supratherapeutic levels for any uncovered service. All other TDM issues should be directed to George Davis (UK Pager #330-2093).
**Documentation in the Patient Medical Record**

When a patient has a serum drug concentration drawn, the primary pharmacist should write a “Clinical Pharmacokinetics” note in the patient’s chart within 24 hours for normal or subtherapeutic concentrations. For concentrations that are supratherapeutic, the medical team should be notified immediately if clinically warranted and a chart note should be written as soon as possible, but no more than 12 hours after the concentration is reported. The chart note should contain all relevant patient information and pharmacokinetic parameters necessary to produce the dosing and monitoring recommendations. Please refer to the CPS Policy/Procedure Manual for guidelines for documentation of pharmacokinetic evaluations for specific monitorable drugs. Notes written by students and non-licensed pharmacists/residents must be co-signed by a Kentucky-licensed pharmacist within 24 hours.

**Pharmacy to Dose Orders**

**Purpose:**
To provide a policy/procedure for provision of pharmacy-directed monitoring in patients on medication regimens that lend themselves to therapeutic monitoring. Therapeutic drug monitoring is the utilization of pharmacokinetic and pharmacodynamic principles (often through drug concentrations) to optimize the safety and efficacy of a medication regimen.

**Information:**
All new orders for monitorable drugs will be assessed by a clinically trained pharmacist within 48 hours of initiation. If further monitoring is determined to be necessary by the pharmacist, the primary service will be contacted with the initial recommendation. At that time, the consulting pharmacist may request a verbal order for a pharmacy to dose order for that patient’s medication regimen in order to continue to follow the medication regimen. Alternatively, at any time, a physician may choose to order a pharmacy to dose consult.

**Pharmacy to Dose:**
1. Any physician may request a pharmacist to provide therapeutic dosing and/or monitoring services for any specified pharmacologic agent. Such a request may be made by submitting a pharmacy to dose order in Sunrise Clinical Manager (SCM) or by giving a verbal order entered on his/her behalf.
   a. Such requests by the physician will result in the pharmacist being authorized to write orders for the initial drug dose, laboratory tests relevant to monitoring the drug, and/or subsequent orders for dosing adjustments as deemed appropriate by the pharmacist. Examples of these include ordering drug concentrations and/or assessments of renal/hepatic function relative to the dosing of an agent.
   b. At any time, the physician may alter the dosing and/or monitoring orders that have been initiated by the pharmacist.
   c. At any time, the physician may request the pharmacist discontinue the dosing/monitoring consult services being provided to a particular patient.
2. Upon receiving an order for pharmacy to dose a specific medication, a pharmacist will assess the patient and collect relevant information necessary to appropriately dose/monitor the specified drug so as to achieve therapeutic drug levels and minimize any potential risks of toxicity. Such items of information may include, but are not limited to:
   a. Indication for therapy (i.e. type and site of infection for antibiotic dosing/monitoring consults)
   b. Age
   c. Sex
d. Height/Weight  
e. Renal/Hepatic function  
f. Estimated pharmacokinetic parameters  
g. Medication history and/or time of last dose (if applicable)  
h. Current/last known serum drug concentration (if applicable)

3. Upon selecting a dosing and/or monitoring plan, the pharmacist will enter applicable orders into SCM. Any orders written by the pharmacist in response to a pharmacy to dose order will be entered under the requesting physician with the specified source of “Per Protocol”.

4. The pharmacist will provide a progress note in the chart to provide information regarding the course of the dosing and/or monitoring services in accordance with department of pharmacy policies PH-02-04 and PH-02-05.

5. The pharmacist will be responsible for follow-up monitoring and/or dose adjustments if the pharmacist deems such actions necessary as documented in the progress notes.

**Pharmacokinetic Guidelines**  
Refer to *Clinical Pharmacokinetics Service and Anticoagulation Guidelines (updated annually)*
Clinical Laboratory Policy

Subject: Therapeutic Drug Monitoring (TDM) Laboratory Critical Value Call Policy

Purpose: To define guidelines for communicating supratherapeutic critical values at the University of Kentucky Medical Center.

Information:
• Supratherapeutic critical values for common TDM medications are listed in Appendix I.

• Supratherapeutic critical values (except cyclosporine, tacrolimus, and sirolimus) for patients admitted to a hospital service will be called to a pharmacist 24 hours a day based on the following schedule:
  o Monday through Friday from 8:00AM – 4:00PM: Critical values will be called to the pharmacist covering the medical service (list of service coverage will updated monthly by the Department of Pharmacy Services and provided to the TDM Lab Manager)
    ▪ If no response in 30 minutes from initial page, then TDM lab will page the Pharmacy Resident on Call (Pager #330-7400)
    ▪ If no response in 30 minutes from initial page, then TDM lab will contact the pharmacist in the Central Pharmacy at 3-5641.
  o Monday through Friday from 4:00PM – 8:00AM: Critical values will be called to the Pharmacy Resident on Call (Pager #330-7400)
    ▪ If no response in 30 minutes from initial page, then TDM lab will contact the pharmacist in the Central Pharmacy at 3-5641.
  o On weekends (beginning Friday at 4:00PM and ending Monday at 8:00AM) and holidays, critical values will be called to the Pharmacy Resident on Call (Pager #330-7400)
    ▪ If no response in 30 minutes from initial page, then TDM lab will contact the pharmacist in the Central Pharmacy at 3-5641.

• Supratherapeutic critical values for patients located in the Emergency Department will be called to a pharmacist 24 hours a day based on the following schedule:
  o Daily from 1:00PM - 11:00PM: Critical values will be called to the ED Clinical Pharmacist Specialist (Pager# 330-4327)
    ▪ If no response in 30 minutes from initial page, then TDM lab will page the Pharmacy Resident on Call (Pager #330-7400)
    ▪ If no response in 30 minutes from initial page, then TDM lab will contact the pharmacist in the Central Pharmacy at 3-5641.
  o Daily from 11:00PM – 1:00PM: the Pharmacy Resident on Call (Pager #330-7400)
    ▪ If no response in 30 minutes from initial page, then TDM lab will contact the pharmacist in the Central Pharmacy at 3-5641.

• Immunosuppressants (cyclosporine, tacrolimus, and sirolimus) will be called to the transplant coordinator on the transplant service.
  o Heart/Lung: 330-2484
  o Renal: 323-5953, 323-6099, 323-5737
  o Liver: 323-4661

• Supratherapeutic critical values for patients in the University of Kentucky Clinics will be called directly to the ordering physician.
List of monitorable drugs and therapeutic ranges.

<table>
<thead>
<tr>
<th>Monitorable Drugs</th>
<th>Lab Abbr.</th>
<th>Therapeutic Range</th>
<th>Metric Units</th>
<th>Supratherapeutic values called to PHARMACIST</th>
<th>Lower Limit of Clinical Reportable Range</th>
<th>Upper Limit of Clinical Reportable Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>ACAM</td>
<td>10 – 30</td>
<td>µg/mL</td>
<td>&gt;35.0</td>
<td>10.0</td>
<td>900</td>
</tr>
<tr>
<td>amikacin (peak)</td>
<td>AMIKP</td>
<td>25 – 35</td>
<td>µg/mL</td>
<td>&gt;35.0</td>
<td>3.0</td>
<td>End Point</td>
</tr>
<tr>
<td>amikacin (trough)</td>
<td>AMIKT</td>
<td>5 – 10</td>
<td>µg/mL</td>
<td>&gt;10.0</td>
<td>3.0</td>
<td>End Point</td>
</tr>
<tr>
<td>amikacin (random)</td>
<td>AMIKR</td>
<td>variable</td>
<td>µg/mL</td>
<td>&gt;35.0</td>
<td>3.0</td>
<td>End Point</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>CRBZ</td>
<td>4 – 12</td>
<td>µg/mL</td>
<td>&gt;15.0</td>
<td>0.2</td>
<td>60</td>
</tr>
<tr>
<td>carbamazepine (saliva)</td>
<td>FCRBZS</td>
<td>1.4 – 3.5</td>
<td>µg/mL</td>
<td>&gt;6.0</td>
<td>0.5</td>
<td>20</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>CSA</td>
<td>renal 100 – 200</td>
<td>ng/mL</td>
<td>&gt;400 called to transplant coordinator</td>
<td>25</td>
<td>2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cardiac 100 – 300</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>hepatic 100 – 300</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>lung 150 – 350</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>digoxin</td>
<td>DIG</td>
<td>0.8 – 2.0</td>
<td>ng/mL</td>
<td>&gt;2.3</td>
<td>0.5</td>
<td>13.5</td>
</tr>
<tr>
<td>gentamicin (peak)</td>
<td>GENTP</td>
<td>5 – 10</td>
<td>µg/mL</td>
<td>&gt;10.0</td>
<td>0.5</td>
<td>36.0</td>
</tr>
<tr>
<td>gentamicin (trough)</td>
<td>GENTT</td>
<td>&lt;2.0</td>
<td>µg/mL</td>
<td>&gt;2.0</td>
<td>0.5</td>
<td>36.0</td>
</tr>
<tr>
<td>lidocaine*</td>
<td>LIDO</td>
<td>1.5 – 6.5</td>
<td>µg/mL</td>
<td>&gt;6.5</td>
<td>1.0</td>
<td>10.0</td>
</tr>
<tr>
<td>lithium</td>
<td>LIT</td>
<td>0.6 – 1.2</td>
<td>mmol/L</td>
<td>&gt;1.5</td>
<td>0.1</td>
<td>End point</td>
</tr>
<tr>
<td>methotrexate</td>
<td>MTRX</td>
<td>≥5 @ 24hrs</td>
<td>µmol/L</td>
<td></td>
<td>0.01</td>
<td>2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥0.5 @ 48hrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥0.05 @ 72hrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥0.02 @ 1-2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phenobarbital</td>
<td>PHNO</td>
<td>15 – 40</td>
<td>µg/mL</td>
<td>&gt;45.0</td>
<td>5.0</td>
<td>240</td>
</tr>
<tr>
<td>phenobarbital (saliva)</td>
<td>FPHNOS</td>
<td>5 – 15</td>
<td>µg/mL</td>
<td>&gt;18</td>
<td>5</td>
<td>240</td>
</tr>
<tr>
<td>phenytoin (total)</td>
<td>PHTN</td>
<td>10 – 20</td>
<td>µg/mL</td>
<td>&gt;22.0</td>
<td>2.5</td>
<td>40.0</td>
</tr>
<tr>
<td>phenytoin (free)</td>
<td>FPHTN</td>
<td>0.8 – 1.6</td>
<td>µg/mL</td>
<td>&gt;1.6</td>
<td>0.5</td>
<td>12.0</td>
</tr>
<tr>
<td>phenytoin (saliva)</td>
<td>FPHTN</td>
<td>1 – 2</td>
<td>µg/mL</td>
<td>&gt;2.2</td>
<td>0.5</td>
<td>4.0</td>
</tr>
<tr>
<td>primidone*</td>
<td>PMDN</td>
<td>5 – 12</td>
<td>µg/mL</td>
<td>&gt;15.0</td>
<td>0.1</td>
<td>End point</td>
</tr>
<tr>
<td>procainamide*</td>
<td>PROC</td>
<td>4 – 10</td>
<td>µg/mL</td>
<td>sum &gt;30</td>
<td>0.2</td>
<td>End point</td>
</tr>
<tr>
<td>(N-acetyl) procainamide*</td>
<td>NAPA</td>
<td>NA</td>
<td>µg/mL</td>
<td>sum &gt;30</td>
<td>0.3</td>
<td>End point</td>
</tr>
<tr>
<td>quinidine*</td>
<td>QUIN</td>
<td>2 – 5</td>
<td>µg/mL</td>
<td>&gt;5</td>
<td>0.2</td>
<td>End point</td>
</tr>
<tr>
<td>salicylate</td>
<td>ASAS</td>
<td>&lt; 25</td>
<td>µg/mL</td>
<td>&gt;30.0</td>
<td>5.0</td>
<td>300</td>
</tr>
</tbody>
</table>
List of monitorable drugs and therapeutic ranges. (cont.)

<table>
<thead>
<tr>
<th>Monitorable Drugs</th>
<th>Lab Abbr.</th>
<th>Therapeutic Range Metric Units</th>
<th>Supratherapeutic values called to PHARMACIST</th>
<th>Lower Limit of Clinical Reportable Range</th>
<th>Upper Limit of Clinical Reportable Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>sirolimus</td>
<td>SIRO</td>
<td>3-20 ng/mL</td>
<td>&gt;15 called to transplant coordinator</td>
<td>2.0</td>
<td>50.0</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>TACRO</td>
<td>4-17 ng/mL</td>
<td>&gt;25 called to transplant coordinator</td>
<td>2.0</td>
<td>50.0</td>
</tr>
<tr>
<td>theophylline</td>
<td>THEO</td>
<td>10 – 20 µg/mL (bronchodilator)</td>
<td>&gt;22.0</td>
<td>2.0</td>
<td>120.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 – 13 (neonatal apnea)</td>
<td>&gt;13.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tobramycin (peak)</td>
<td>TOBP</td>
<td>5 – 10 µg/mL</td>
<td>&gt;10.0</td>
<td>0.5</td>
<td>36.0</td>
</tr>
<tr>
<td>tobramycin (trough)</td>
<td>TOBT</td>
<td>&lt; 2.0 µg/mL</td>
<td>&gt;2.0</td>
<td>0.5</td>
<td>36.0</td>
</tr>
<tr>
<td>valproic acid</td>
<td>VALP</td>
<td>50 – 100 µg/mL</td>
<td>&gt;120.0</td>
<td>10.0</td>
<td>450.0</td>
</tr>
<tr>
<td>vancomycin (peak)</td>
<td>VANCP</td>
<td>20 – 40 µg/mL</td>
<td>&gt;50.0</td>
<td>5.0</td>
<td>150.0</td>
</tr>
<tr>
<td>vancomycin (trough)</td>
<td>VANCT</td>
<td>10 – 20 µg/mL (life threatening infections)</td>
<td>&gt;25.0</td>
<td>5.0</td>
<td>150.0</td>
</tr>
</tbody>
</table>

*Sent to outside laboratory and may require 2-3 days to report results. End point = sample can be diluted up to 3X.
*Basic Pharmacokinetic Concepts:*

**Linear pharmacokinetics:**
- Serum concentrations change proportionally with increase in dose (e.g., increase dose from 500mg/day to 1000mg/day, concentrations and AUC double).
- Most drugs follow linear pharmacokinetics

![Linear Pharmacokinetics Graph]

**Nonlinear or Michaelis-Menten pharmacokinetics:**
- As dose increases, a disproportionately greater increase in plasma concentration is achieved
- \( \text{Vmax} = \) maximum amount of drug that can be metabolized per unit time (mg/day)
- \( \text{Km} = \) Michaelis-Menten constant, representing the concentration of phenytoin at which the rate of this enzyme-saturable hepatic metabolism is one-half of maximum
- Classic example: phenytoin

![Nonlinear Pharmacokinetics Graph]

\[
\text{Drug elimination rate} = \frac{dX}{dt} = \frac{\text{Vmax} \times C_{ss}}{\text{Km} + C_{ss}}
\]

\[
C_{ss} = \left( \frac{\text{Dose}}{\tau} \right) \left( S \right) \left( F \right) \left( K_m \right)
\]

\[
\left( \frac{\text{Vmax}}{\tau} \right) \left( \frac{\text{Dose}}{\left( S \right) \left( F \right)} \right)
\]
Clearance (Clₕ):  
- Represents the volume of plasma (or blood) from which drug is removed, in a given time period.
- Expressed in volume/time (e.g., ml/min, L/hr).
- Most IMPORTANT pharmacokinetic parameter: $Cl_s = Cl_{\text{Hep}} + Cl_{\text{Ren}} + Cl_{\text{Other}}$.
- Model-independent parameter used to estimate average steady-state concentrations and adjust maintenance doses ("c-bar equation"): 
  \[
  \bar{C} = \frac{K_0}{Cl_s}; \quad \bar{C} = \frac{S \cdot F \cdot X_0}{Cl_s \cdot \tau} \quad \text{or} \quad Cl_s = \frac{S \cdot F \cdot X_0}{\bar{C} \cdot \tau} \quad \text{or} \quad X_0 = \frac{Cl_s \cdot \bar{C} \cdot \tau}{S \cdot F}
  \]
- Relationship between K, Vd, and Cl: 
  \[
  K = \frac{Cl_s}{Vd} \quad \text{or} \quad Cl_s = Vd \cdot K; \quad \text{NOTE: Vd and Cl} \_s \ \text{are INDEPENDENT VARIABLES}
  \]
- Hepatic Clearance (Clₜₜₚₑₜ)  
  Extraction (E) = \[
  f_{ub} \cdot \frac{Cl_{\text{int}}}{Q_H + (f_{ub} \cdot Cl_{\text{int}})}
  \]
  where $Q_H =$ hepatic blood flow; $f_{ub} =$ fraction unbound; $Cl_{\text{int}} -$ intrinsic clearance

\[
Cl_{\text{Hep}} = Q_H \times E
\]

\[
Cl_{\text{Hep}} = \frac{Q_H \cdot f_{ub} \cdot Cl_{\text{int}}}{Q_H + (f_{ub} \cdot Cl_{\text{int}})}
\]

For HIGH EXTRACTION (>70%) drug, $f_{ub} \cdot Cl_{\text{int}} \ggggggg Q_H$, the equation reduces to:

$Cl_{\text{Hep}} = Q_H$

For LOW EXTRACTION (<30%) drug, $Q_H \ggggggg f_{ub} \cdot Cl_{\text{int}}$, the equation reduces to:

$Cl_{\text{Hep}} = f_{ub} \cdot Cl_{\text{int}}$

- Renal Clearance (Clₚₑₚₚₑₜ)  
  \[
  Cl_{\text{Ren}} = Cl_{\text{GFR}} + Cl_{\text{TS}} - Cl_{\text{TR}}
  \]
  GFR = glomerular filtration rate, TS = tubular secretion, TR = tubular reabsorption
**Half-life ($t\frac{1}{2}$) & elimination rate ($K$):**

- Elimination $t\frac{1}{2}$ = time required for serum concentration to decrease by $\frac{1}{2}$ after absorption & distribution phase
- Expressed in hours or minutes
- Takes approximated 3-5 half-lives to reach steady-state
- Dependent variable (depends on Cls and Vd): $t\frac{1}{2} = \frac{0.693 \cdot Vd}{Cl}$ or $t\frac{1}{2} = \frac{0.693}{K}$
- Clinically, can be calculated by 2 concentrations: $t\frac{1}{2} = \frac{\ln C_1}{C_2}$
- Most drugs follow first-order elimination

\begin{align*}
\text{Plasma drug concentration versus time after an intravenous (bolus) drug dose, assuming a one-compartment model with first-order elimination (linear y-scale).}
\end{align*}

- $K = \text{fraction of the drug in the body eliminated over time}$:
  \[ K = \frac{\ln C_1}{T'} \] or \[ K = \frac{0.693}{t\frac{1}{2}} \]

\begin{align*}
\text{Same with a log scale y-axis.}
\end{align*}

\begin{align*}
\text{K} &= \frac{\ln 5 \text{ mg/L}}{2.5 \text{ mg/L}} = 0.173 \text{ hr}^{-1} \\
\text{t1/2} &= \frac{0.693}{0.173} = 4 \text{ hrs}
\end{align*}
Volume of distribution (Vd):

- Vd is a hypothetical volume that is the proportionality constant that relates amount of drug in body to the serum concentration.
- Expressed in liters (L) or liter/kg (L/kg).
- Drugs distribute based on composition of body fluids and tissues.
- \( Vd = \frac{X_o}{C_o} \) where \( X_o = \) dose administered; \( C_o = \) initial concentration
- Useful for calculating loading dose: \( LD = Vd \cdot C \)
- Can calculate Vd using steady-state peak concentration after multiple dosing:
  \[ Vd = \frac{K_s(1 - e^{-Kt})}{C_{pk} \cdot K(1 - e^{-Kr})} \]

One-compartment model

- 1-compartment model with first-order elimination following IV bolus:

![Cartesian graph paper](image1)

![Semi-log paper](image2)
Two-compartment model:
- Many drugs follow 2-compartment model (see model and concentration-time plot below)
- However, 1-cpt model is sufficient to individualize doses of selected drugs (e.g., aminoglycosides, vancomycin) in the clinical setting if concentrations are drawn appropriately.
Multiple dosing and steady-state equations:

\[ C_{pk}^{ss} = \frac{K_o (1 - e^{-Kt}) e^{-KT}}{Vd \cdot K (1 - e^{-Kr})} \]

\( C_{pk}^{ss} \) = concentration (referred to as peak) drawn at \( T \), time post infusion

\( K_o \) = dosing rate in mg/hr

\( K \) = elimination rate in hr\(^{-1}\)

\( t \) = infusion time in hours (e.g., usually 0.5hrs for aminoglycosides)

\( T \) = post infusion time in hours that corresponds with \( C_{pk}^{ss} \) (e.g., usually 0.5hrs for aminoglycosides)

\( Vd \) = Volume of distribution in liters

\( r \) = Tau, dosing interval in hours

This equation is used for aminoglycosides and vancomycin which when dosed as intermittent IV infusion.

You can build the steady-state multiple dosing equation using the following equations (also see next page):

1. The infusion (e.g., 30 min for aminoglycosides, 60 min for vancomycin) is a continuous infusion:

\[ C = \frac{K_o (1 - e^{-kt})}{Cl} \quad \text{or} \quad \frac{K_o (1 - e^{-kt})}{Vd \cdot K} \quad \text{where} \quad t = \text{infusion time} \]

This above equation will calculate the concentration at the end of an intermittent IV infusion following the first dose (assuming 1-cpt model and 1st order elimination).

2. Peak concentrations are obtained post-distributional to fit a 1-cpt model so the concentration must be eliminated the time after the end of the infusion (e.g., aminoglycosides = 30min; vancomycin = 60min). This can be accounted for by eliminating the concentration by multiplying the concentration by \( e^{-kT} \) where \( T \) = time post infusion resulting in the following equation:

\[ C_{1st \ dose}^{pk} = \frac{K_o (1 - e^{-kt})}{Vd \cdot K} \cdot e^{-kT} \]

3. Concentrations are obtained at steady-state so accumulation must be considered using the following equation: \( \frac{1}{1-e^{-kr}} \) resulting in the final equation:

\[ C = \frac{K_o (1 - e^{-kt})}{Vd \cdot K} \cdot e^{-kT} \cdot \frac{1}{1-e^{-kr}} = \frac{K_o (1 - e^{-Kt}) \cdot e^{-KT}}{Vd \cdot K (1 - e^{-Kr})} \]

\[ C_{pk}^{ss} = \frac{K_o (1 - e^{-Kt}) \cdot e^{-KT}}{Vd \cdot K (1 - e^{-Kr})} \]
Multiple dosing of intermittent infusion (0.5 hr infusion every 8 hrs)

\[ \frac{K_0}{V_k} \left(1 - e^{-kt}\right) e^{-kT} \]

\[ \frac{1}{1 - e^{-kT}} \]
GENERAL GUIDELINES FOR PHARMACOKINETIC MONITORING

I. When a patient is on a monitorable drug

A. Assess the necessity for serum drug concentrations and address this issue with the medical team.

B. Avoid problems with interpretation of upcoming concentrations by:
   1. Obtaining the concentration at steady-state if possible.
   2. Avoiding ordering concentrations during third shift.
   3. Ascertaining that the nurse has marked the appropriate dose for obtaining concentrations on the EMAR (ex. Doses may have been given in the ER or documented in different areas of the medical records).
   4. Staggering penicillin doses away from the dose of an aminoglycoside around which concentrations are drawn (ideal if penicillin dose is given at least 2 hours apart from aminoglycoside dose).

II. When a concentration is obtained

A. Using the collect/received time reported in the lab computer and the EMAR, verify that the concentration is a peak or a trough.

B. Document that the doses preceding the concentration were on time to verify that the concentration represent steady-state conditions.

C. Calculate the appropriate pharmacokinetic parameters and compare with predicted population values.

D. Write concise notes including kinetic parameters on all concentrations, whether therapeutic or subtherapeutic. (See sample notes on pages 25 & 100)

E. Document any information, not retrievable from the medical records, that was used in making your calculations or recommendations (weight, height, or information obtained directly from the patient or healthcare provider).

Remember… appropriate documentation will:
   1. Improve the quality of care;
   2. Allow continuity of care when changing services;
   3. Document your role in patient management;
   4. Protect you legally;
   5. Protect you professionally in audits on quality of care.
III. How does Clinical Pharmacokinetic Monitoring fit into the Pharmaceutical Care Process?

Pharmacist’s primary responsibilities in PCare:
- Identifying a patient’s actual and potential drug-related problems
- Resolving the patient’s actual drug-related problems
- Preventing the patient’s potential drug-related problems from becoming actual problems

Clinical Pharmacokinetics role in PCare:
Identifying and resolving potential problems if the patient is:
- Taking or receiving the wrong dose of the correct drug
- Experiencing an adverse drug reaction
- Experiencing a drug-drug or drug-food interaction

Pharmacist’s Role in Clinical Pharmacokinetic Monitoring
(Am J Health Syst Pharm. 1998 Aug 15;55(16):1726-7)

- Designing patient-specific drug dosage regimens based on pharmacologic characteristics of the drugs used, the objectives of drug therapy, concurrent diseases & drug therapy, and other pertinent patient factors.
- Monitoring & adjusting dosage regimens based on pharmacologic responses and on biological fluid (e.g. plasma, serum, blood, CSF) and tissue drug concentrations in conjunction with clinical signs and symptoms or other biochemical parameters.
- Evaluating unusual patient responses to drug therapy for possible pharmacokinetic and pharmacologic explanations.
- Communicating, verbally and in writing, information on patient-specific drug therapy to physicians, nurses, and other clinical practitioners.
- Educating pharmacists, physicians, nurses, and other clinical practitioners on pharmacokinetic principles and/or appropriate indications for clinical pharmacokinetic monitoring.
- Recommending assays or procedures for the analysis of drug concentration in order to facilitate the evaluation of dosage regimens.
- Developing quality assurance programs to document improved patient outcomes and economic benefits resulting from clinical pharmacokinetic monitoring.
GENERAL EQUATIONS for BSA, IBW, and Clcr

Equations for body surface area (BSA):

\[
\text{BSA (m}^2\text{)} = \left[ \frac{\text{Wt(kg)}^{0.425} \times \text{Ht(cm)}^{0.725} \times 71.84}{10,000} \right] \quad (\text{Dubois; Arch Internal Med 1916;17:863})
\]

\[
\text{BSA (m}^2\text{)} = \frac{\text{Ht(cm)} \times \text{Wt(kg)}}{60} \quad (\text{Mosteller; NEJM 1987;317:1098})
\]

Equation for Ideal Body Weight (IBW):

\[
\text{IBW (male, kg)} = 50 + (2.3 \times \text{ea. inch over 5 ft})
\]
\[
\text{IBW (female, kg)} = 45 + (2.3 \times \text{ea. inch over 5 ft})
\]

(Devine: Drug Intell Clin Pharm 1974;8:650)

Estimation of GFR using serum creatinine (Scr)

- Creatinine is endogenous substance derived from muscle metabolism, small & not bound to plasma proteins, maintains a fairly constant level, and predominantly filtered ~85% (~15% TS) with minimal non-renal elimination.
- Proportional to muscle mass & body weight
- Normal 24-hour excretion: 20-25 mg/kg IBW (males) and 15-20mg/kg (females)
- Creatinine production decreases with age: 2mg/kg/24hrs per decade
- Several equations have been published to predict GFR using creatinine clearance (Clcr)

Estimation of GFR using Cockcroft-Gault Equation:

\[
\text{(Male) Clcr}_{(\text{ml/min})} = \frac{(140-\text{age})(\text{ABW})}{(72)(\text{Scr})} \quad \text{(Female) Multiply by 0.85}
\]

ABW = actual body weight

Note: Use ABW unless obese (>125% ideal body weight), suggest use Salazar & Corcoran equation.

\[
\text{Clcr (standardized to BSA, ml/min/1.73m}^2\text{)} = \text{Clcr} \times \frac{1.73m^2}{\text{BSA}}
\]

- Most commonly used equation for estimating GFR in clinical practice
- Derived from multiregression analysis
- Relationship includes corrections of creatinine production for age, weight, and gender
- Several limitations (best for patients with average muscle mass and stable production of creatinine)
- \textit{Should be used with caution in patients with changing Scr (e.g., acute renal failure), low Scr (e.g., lack of mobility, patients with loss of muscle mass, spinal cord injury), and severe renal insufficiency.}
Estimation of GFR in obese patients (>125% X IBW) using Salazar-Corcoran Equation:

\[
\begin{align*}
(Male) \text{Clcr}_{(ml/min)} &= \frac{[137-Age] \times [(0.285 \times Wt) + (12.1 \times Ht^2)]}{(51 \times Scr)} \\
(Female) \text{Clcr}_{(ml/min)} &= \frac{[146-Age] \times [(0.287 \times Wt) + (9.74 \times Ht^2)]}{(60 \times Scr)}
\end{align*}
\]

Wt = actual body weight in kg; Ht = height in meters

Note: Ht should be converted to meters before squared (i.e. 6'0" = 72" = 183cm = 1.83m)

Estimation of GFR by calculating Clcr from 24-hour urine collection:

\[
\text{Cl}_{cr} \ (ml/min) = \frac{\text{creatinine production rate (mg/1440min)}}{\text{Scr (mg/100ml)}} \\
= \frac{\text{Ucr} \times \left(\frac{1dL}{100ml}\right) \times \text{Uvol} \times \left(\frac{1}{1440min}\right)}{\text{Scr} \times \left(\frac{1dL}{100ml}\right)}
\]

Ucr = urine creatinine concentration (mg/dL);
Uvol = total urine volume (ml/24 hrs);
Scr = serum creatinine (mg/dL)


MDRD study equation:

\[
\text{GFR (ml/min/1.73m}^2\text{)} = 170 \times [\text{Scr}]^{-0.999} \times [\text{Age}]^{-0.176} \times [\text{BUN}]^{-0.170} \times [\text{Alb}]^{0.318} \times [0.762, \text{if female}] \times [1.18, \text{if patient is African-American}]
\]

Abbreviated MDRD study equation (ml/min/1.73m^2):

\[
\text{GFR} = 186 \times [\text{Scr}]^{-1.154} \times [\text{Age}]^{-0.203} \times [0.742, \text{if female}] \times [1.210, \text{if patient is African-American}]
\]

- Among adults, the MDRD Study equation provides a clinically useful estimate of GFR (up to ~ 90 mL/min/1.73 m^2)
- The MDRD Study equation derived based on:
  - GFR measured directly by urinary clearance of 125I-lothalamate;
  - A large sample of >500 individuals with a wide range of kidney diseases;
  - Inclusion of both European-American and African-American participants;
  - Validated in a large (n > 500) separate group of individuals
- This equation provides estimates of GFR standardized for BSA.
• The abbreviated version (J Am Soc Nephrol. 2000;11: A0828) requires only serum creatinine, age, sex, and race.
• Basic metabolic panel at UKCMC uses the abbreviated equation to report GFR.
• Per National Kidney Foundation recommendations: “Nonetheless, questions remain about the equation’s generalizability because it has not been validated in diabetic kidney disease, in patients with serious comorbid conditions, in normal persons, or in persons older than 70 years of age. Clinical conditions in which it may be necessary to measure GFR by using clearance methods include extremes of age and body size, severe malnutrition or obesity, diseases of skeletal muscle, paraplegia or quadriplegia, vegetarian diet, rapidly changing kidney function, and calculation of the dose of potentially toxic drugs that are excreted by the kidneys.” Many of these limitations also apply to the use of Cockcroft-Gault.
• Please note there are not sufficient studies to date that use the MDRD equation for adjusting drug dosages for patients with renal insufficiency. This may change in the near future as more studies with the MDRD equation are published.

---

**Estimation of Clcr in Pediatrics:**

<table>
<thead>
<tr>
<th>Equation Description</th>
<th>Formula</th>
</tr>
</thead>
</table>
| Clcr (infants up to 1 year of age, mL/min/1.73m²) | \[
\text{Clcr} = \frac{0.45 \times \text{Ht (cm)}}{\text{Scr}}
\] |
| Clcr (children 1 to 16 years of age, mL/min/1.73m²) | \[
\text{Clcr} = \left(0.413 \times \text{Height in cm}\right) / \text{Creatinine in mg/dL}
\] |

AMINOGLYCOSIDES - CONVENTIONAL DOSING

1. Time of Sampling
   a. Relative to Dose
      - $C_{pk}$ at 30 min after end of 30 min infusion (IV); 1 hr after injection (IM)
      - $C_{tr}$ within 30 min prior to dose
      - at ss (4 to 5 estimated half-lives; normal renal function: $t\frac{1}{2} = 2-3$ hrs)
        usually around 3rd maintenance dose (or later) preferably during day

2. Recommended Frequency of Sampling
   a. Routine Use In "Uncomplicated" Patients
      - initial $C_{pk}$ and $C_{tr}$
      - repeat $C_{pk}$ and $C_{tr}$, at new steady state, if initial values differ $\geq 25\%$ from predicted (i.e. suggestive of unusual kinetic parameters or deviation from sampling guidelines)
      - $Scr$ and BUN at least 2x/week; monitor other signs of renal function
      - repeat $C_{pk}$ and $C_{tr}$ q 1-2 wks, when duration of therapy $\geq 2$ wks
   b. Use in "Complicated" patients (e.g., diminished or changing hydration status and/or renal function, concurrent ototoxic or nephrotoxic drugs)
      - initial $C_{pk}$ and $C_{tr}$ at steady state
      - $Scr$ and BUN daily
      - repeat $C_{pk}$ and $C_{tr}$ weekly (or more frequently as dictated by clinical condition).
3. **Therapeutic Range (Conventional Dosing)**

*Patients with normal renal function:* Conventional dosing for gentamicin and tobramycin ~1-2 mg/kg-DBW/dose q8hrs and amikacin ~5mg/kg-DBW/dose q8hrs. **NOTE:** Elderly patients often require a q12hr or longer dosing interval.

- Primarily used as double coverage or synergy with β-lactams for aerobic gram-negative infections (e.g. *Pseudomonas, Enterobacter, Proteus, E. coli, Serratia*)
- Can be used for synergy with some gram-positive infections (e.g. *Enterococcus, Staphylococcus*)

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Suggested Target Peak Concentrations (mg/L) (gentamicin or tobramycin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( C_{pk} ) (mg/L)</td>
<td>5 - 10 ( )</td>
</tr>
<tr>
<td>( C_{tr} ) (mg/L)</td>
<td>0.5 - 2 ( )</td>
</tr>
</tbody>
</table>

*Desired \( C_{pk} \) and \( C_{tr} \) concentrations for conventional aminoglycoside dosing should be determined clinically by site and severity of infection, causative organism and its MIC, immunocompetence of patient, intent of therapy, etc. See table below for general recommendations for desired \( C_{pk} \) based on type of infection. *Final decision for desired concentrations should be based on clinical outcomes in addition to a pharmacokinetic assessment.*

<table>
<thead>
<tr>
<th>Types of infections*</th>
<th>Suggested Target Peak Concentrations (mg/L) (gentamicin or tobramycin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal infections</td>
<td>6-8</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>6-8</td>
</tr>
<tr>
<td>Empiric therapy in cystic fibrosis</td>
<td>8-12</td>
</tr>
<tr>
<td>Endocarditis, Bacterial (prevention &amp; treatment) gram positive (synergy: 1mg/kg/q8hrs)</td>
<td>3-5</td>
</tr>
<tr>
<td></td>
<td>8-10</td>
</tr>
<tr>
<td>Endocarditis, Bacterial (prevention &amp; treatment) gram negative</td>
<td></td>
</tr>
<tr>
<td>Eye infections</td>
<td>6-8</td>
</tr>
<tr>
<td>Meningitis</td>
<td>8-10</td>
</tr>
<tr>
<td>Neutropenic patients</td>
<td>6-10</td>
</tr>
<tr>
<td>Peritonitis</td>
<td>6-8</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>8-10</td>
</tr>
<tr>
<td>Skin and soft tissue infections</td>
<td>6-8</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>4-6</td>
</tr>
</tbody>
</table>
4. General Guidelines for Monitoring

a. Initial Dosing

1. Select desired C_{pk} and C_{tr} based on site and severity of infection, causative organism and MIC, immunocompetence of patient, intent of therapy.

2. Estimate Cl_{cr}; standardize Cl_{cr} to 1.73 m^2 if BSA known:

\[
Cl_{cr (std)} = Cl_{cr} \times \frac{1.73 \text{ m}^2}{\text{actual BSA}}
\]

For obese patients use DBW = \left[IBW + 0.4 (TBW-IBW)\right] in the Cockcroft-Gault equation to estimate Clcr and standardize to 1.73m\(^2\) to estimate aminoglycoside K. (Leader WG, Tsubaki T, Chandler MHH. Am J Hosp Pharm 1994; 51:2125-30)

3. Estimate K:

\[K = 0.00293 \times Cl_{cr (std)} + 0.014\]

4. Estimate t\(\frac{1}{2}\):

\[t\frac{1}{2} = \frac{0.693}{K}\]

5. Estimate Vd*:

\[Vd = 0.25 \text{ L/Kg}, \text{ average}\]
\[Vd = 0.20 \text{ L/Kg}, \text{ if dehydrated}\]
\[Vd = 0.30 \text{ L/Kg}, \text{ with CHF, volume overload, ICU patients}\]

*Use ABW unless patient is obese (>125% IBW or TBW/IBW > 1.25)
If obese use dosing body weight: DBW = IBW + 0.4 (TBW-IBW)

6. Calculate dosing interval (\(\tau\)):

\[
\tau = \frac{\ln(C_{pk}/C_{tr})}{K} + t + T
\]

\(t = \text{infusion time (e.g., 0.5hr)}\)
\(T = \text{time between end of infusion & } C_{pk} (\text{e.g., 0.5hr})\)

7. Calculate maintenance dose (\(K_0\)) using target \(C_{pk}\):

\[
K_0 = \frac{C_{pk}^{ss} \cdot Vd \cdot K \cdot (1-e^{-K\tau})}{(1-e^{-Kt}) \cdot e^{KT}}
\]

\(t = \text{infusion time (e.g., 0.5hr)}\)
\(T = \text{time between end of infusion & } C_{pk} (\text{e.g., 0.5hr})\)

**NOTE that \(K_0 = \text{mg/HOUR} \) and the dose must be adjusted to account for 0.5hr infusion. (e.g. If \(K_0 = 200\text{mg/HR}, \text{then the dose = 100mg/30min for ½ hr infusion})
8. Round dose to nearest 10mg or available stock bag dose (e.g., 80,100,120mg) then recalculate the actual $C_{\text{pk}}$:

$$\text{desired } C_{\text{pk}} \times \frac{\text{actual (rounded) dose}}{\text{calculated dose}} = \text{actual } C_{\text{pk}}$$

9. Estimate trough: $C_{\text{tr}}^{\text{ss}} = C_{\text{pk}}^{\text{ss}} \cdot e^{-KT'}$

$T' = \text{time between } C_{\text{pk}} \text{ and } C_{\text{tr}}$

10. If necessary, calculate loading dose ($K_0^*$):

$$K_0^* = \frac{K_0}{(1-e^{-K'T'})} \text{ or } \frac{C_{\text{pk}} \cdot V \cdot K}{(1-e^{-K'T'})} \text{ or } V \cdot C_{\text{pk}}^{\text{ss}}$$

Weight-based method: 1.5 to 2 mg/kg (use DBW if obese)

b. Dosage Adjustment Using Sawchuk-Zaske Method:

**Assumptions:** Concentrations represent steady-state conditions; 1-compartment model; principle of superposition; linear elimination.

1. Verify administration and sampling times.

2. Calculate $K$:

$$K = \frac{\ln \left( \frac{C_{\text{pk}}^{\text{ss}}}{C_{\text{tr}}^{\text{ss}}} \right)}{T'}$$

$T'$ is determined by subtracting the time difference between $C_{\text{pk}}$ and $C_{\text{tr}}$ from the Tau. For example, if the time difference between $C_{\text{pk}}$ and $C_{\text{tr}}$ was 1.5hrs and the Tau = q8hrs, then $T' = (8 - 1.5) = 6.5$hrs.

3. Calculate $t\frac{1}{2}$:

$$t\frac{1}{2} = \frac{0.693}{K}$$

4. IF peak concentration is drawn late, calculate if drawn at correct time:

$$C_{\text{pk}}^{\text{ss}} = \frac{C_{\text{pk}}}{e^{-Kt'}}$$

where $C_{\text{pk}}^{\text{ss}} = \text{peak concentration drawn at appropriate time}$;

$C_{\text{pk}} = \text{peak concentration drawn late}; t' = \text{time between late } C_{\text{pk}} \text{ and } C_{\text{pk}}$
5. IF trough concentration is drawn early (e.g., >30 min prior to dose), calculate if drawn at correct time:

\[ C_{tr}^{ss} = C_{tr} \cdot e^{-K't} \]

where \( C_{tr}^{ss} \) = trough concentration drawn at appropriate time (e.g., suggest use dose administration time)

\( C_{tr} = \) trough concentration drawn early; \( t' = \) time between early \( C_{tr} \) and \( C_{tr}^{ss} \)

6. Calculate Vd:

If doses have reached **steady state** (e.g., previous doses on time, concentrations drawn appropriately), use:

\[
Vd = \frac{K_o \left(1 - e^{-Kt} \right) e^{-KT}}{C_{pk}^{ss} \cdot K \left(1 - e^{-Kt'} \right)}
\]

\( t = \) infusion time (e.g., 0.5 hr)

\( T = \) time between end of infusion & \( C_{pk}^{ss} \) (e.g., 0.5 hr)

If doses have **NOT** reached **steady state** **AND** there are at least 3 concentrations after a multiple dose (e.g., trough, peak, & random) or 2 concentrations after the 1st dose (e.g., peak and random or 2 random concentrations) use:

\[
Vd = \frac{K_o \left(1 - e^{-Kt} \right)}{K \left(C_{pk}^{max} - C_{tr} e^{-Kt'} \right)}
\]

\( C_{pk}^{max} = \) peak extrapolated to END of infusion

\( t = \) time of infusion

\( t' = \) time between \( C_{tr} \) and \( C_{pk}^{max} \)

To use above equation, calculate peak at end of infusion:

\[
C_{pk}^{max} = \frac{C_{pk}}{e^{KT}}
\]

\( T = \) time between \( C_{pk} \) and \( C_{pk}^{max} \)

7. IF measured \( C_{tr} \) is high, calculate time required to achieve desired \( C_{tr} \):

\[
t' = \frac{\ln \left( \frac{C_{tr_1}}{C_{tr_2}} \right)}{K}
\]

\( C_{tr_1} = \) high \( C_{tr} \); \( C_{tr_2} = \) desired \( C_{tr} \)

\( t' = \) time required from \( C_{tr_1} \) to \( C_{tr_2} \)

8. Calculate new dosing interval (\( \tau \)):

\[
\tau = \frac{\ln(C_{pk}/C_{tr})}{K} + t + T
\]

\( t = \) infusion time (e.g., 0.5 hr)

\( T = \) time between end of infusion & \( C_{pk} \) (e.g., 0.5 hr)
9. Calculate new dosing rate:

\[ K_o = \frac{C_{ss} Vd K(1-e^{-K_T t})}{(1-e^{-K_T}) e^{-K_T T}} \]

\( t = \) infusion time (e.g., 0.5hr) \\
\( T = \) time between end of infusion & C_{pk} (e.g., 0.5hr)

**NOTE that \( K_o = \) mg/HOUR and the dose must be adjusted to account for ½ HOUR infusion. (e.g. If \( K_o = 200\text{mg/HR}, \) then the dose = 100mg/30min for ½ hr infusion)

10. Round dose to nearest 10mg or available stock bag dose (80,100,120mg) then recalculate the actual C_{pk}:

\[
\text{desired } C_{pk} \times \frac{\text{actual (rounded) dose}}{\text{calculated dose}} = \text{actual } C_{pk}
\]

11. Estimate trough to be obtained with above \( K_o \) and \( \tau \):

\[ C_{tr}^{ss} = C_{pk}^{ss} e^{-K_T T} \]

12. Document the pharmacokinetic assessment in the medical records.

Document pertinent clinical monitoring parameters, dose recommendations and estimated and/or calculated pharmacokinetic parameters in the medical record. (Also refer to Department of Pharmacy Guidelines for Writing Notes in Patient Charts, PH-02-04)

- Briefly describe the rationale of the drug and determine if warranted based on clinical and patient information.
- Document the current day of therapy and goal length of therapy (e.g., Day #2/10 gentamicin), and any concomitant antibiotics.
- Document the collect times of the reported concentrations and note if the samples were obtained appropriately. For example, if actual C_{pk} was drawn late, also document the estimated C_{pk} if drawn correctly.
- Include the calculate PK parameters: \( K \) (hr⁻¹), \( \tau \frac{1}{2} \) (hrs), Vd (L) and Vd (L/kg – DBW).
- Write a new dosage in mg and mg/kg-DBW/dose (e.g., gentamicin 100 mg IV q8hrs, 1.5mg/kg/dose).
- When changing a dosage, include the start time of new dosing regimen with the order (very helpful for the pharmacist entering the order and the nurse administering the drug).
- Include a range for the predicted concentrations with the new dosage recommendation: (e.g., \( C_{pk} = 8-10\text{mg/L}; C_{tr} <2\text{mg/L}, \sim 1\text{mg/L}.\))
- Include other pertinent information used to assess the patient: weight (ABW, IBW, DBW), height, BSA, Scr, Clcr, BUN, urine output, I/Os, cultures, Tmax, WBC, differential, allergies, and other nephrotoxic medications (e.g., furosemide, amphotericin, vancomycin).
- Sample note provided on next page.
**Clinical Pharmacokinetics Service**  
**RE: Tobramycin Day #2/14**

Patient is 50yo WM being treated with tobramycin 120mg IV q8hrs (1.45 mg/kg/dose) and Zosyn 3.375gm IV q6hrs for nosocomial pneumonia based on positive sputum cultures for *Pseudomonas aeruginosa*. Current Tmax 102.5, WBC = 15K.

Tobramycin concs drawn around 3rd dose on 9/2:
- Trough = 2.2 mg/L C: 07:30
- Dose = 120 mg IV infused from 08:00 – 08:30
- Peak = 7 mg/L C: 09:00

**Assessment of concs:** Previous doses administered on time & represent steady-state; Ctr & Cpk drawn appropriately; Cpk is below recommended range for pneumonia (8-10mg/L) & Ctr above therapeutic range (<2mg/L). Renal function stable.

**PK parameters:** $K = 0.18hr^{-1}$; $t_{1/2} = 3.9$ hrs; $Vd = 19.6L$ (0.24 L/kg)

**Recommendations:**

1. Suggest changing tobramycin to 160mg IV q12hrs (1.9 mg/kg/dose) to yield a Cpk ~8-10 mg/L & Ctr ~1mg/L; begin next dose at 20:00 today when conc. = 1mg/L; discussed with resident on primary team.
2. Not necessary to recheck Cpk & Ctr unless change in clinical status or renal function; if continue therapy > 7 days, would suggest recheck concentrations to assess for drug accumulation.
3. Suggest checking Scr/BUN at least 2X/week to assess renal function.

George Davis, Pharm.D. #330-4215

<table>
<thead>
<tr>
<th>Date</th>
<th>Clinical Pharmacokinetics Service</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/2/2001</td>
<td><strong>RE: Tobramycin Day #2/14</strong></td>
</tr>
<tr>
<td>12:00</td>
<td>Patient is 50yo WM being treated</td>
</tr>
<tr>
<td></td>
<td>with tobramycin 120mg IV q8hrs 1.45</td>
</tr>
<tr>
<td></td>
<td>mg/kg/dose and Zosyn 3.375gm IV q6hrs</td>
</tr>
<tr>
<td></td>
<td>for nosocomial pneumonia based on</td>
</tr>
<tr>
<td></td>
<td>positive sputum cultures for</td>
</tr>
<tr>
<td></td>
<td><em>Pseudomonas aeruginosa</em>.</td>
</tr>
<tr>
<td></td>
<td>Current Tmax 102.5, WBC = 15K.</td>
</tr>
<tr>
<td>ABW = 90kg</td>
<td>Tobramycin concs drawn around 3rd</td>
</tr>
<tr>
<td>Ht = 6'0&quot;</td>
<td>dose on 9/2:</td>
</tr>
<tr>
<td>IBW = 77.6kg</td>
<td>Trough = 2.2 mg/L C: 07:30</td>
</tr>
<tr>
<td>DBW = 82.6kg</td>
<td>Dose = 120 mg IV infused from 08:00</td>
</tr>
<tr>
<td>BSA = 2.13m²</td>
<td>Peak = 7 mg/L C: 09:00</td>
</tr>
<tr>
<td>Scr = 1.2 (today)</td>
<td>Assessment of concs: Previous doses administered on time &amp; represent steady-state; Ctr &amp; Cpk drawn appropriately; Cpk is below recommended range for pneumonia (8-10mg/L) &amp; Ctr above therapeutic range (&lt;2mg/L). Renal function stable.</td>
</tr>
<tr>
<td>Clcr = 86ml/min</td>
<td>PK parameters: $K = 0.18hr^{-1}$; $t_{1/2} = 3.9$ hrs; $Vd = 19.6L$ (0.24 L/kg)</td>
</tr>
<tr>
<td>Clcr (std) = 70ml/min/1.73m²</td>
<td>Recommendations:</td>
</tr>
<tr>
<td></td>
<td>1. Suggest changing tobramycin to 160mg IV q12hrs (1.9 mg/kg/dose) to yield a Cpk ~8-10 mg/L &amp; Ctr ~1mg/L; begin next dose at 20:00 today when conc. = 1mg/L; discussed with resident on primary team.</td>
</tr>
<tr>
<td></td>
<td>2. Not necessary to recheck Cpk &amp; Ctr unless change in clinical status or renal function; if continue therapy &gt; 7 days, would suggest recheck concentrations to assess for drug accumulation.</td>
</tr>
<tr>
<td></td>
<td>3. Suggest checking Scr/BUN at least 2X/week to assess renal function.</td>
</tr>
</tbody>
</table>

George Davis, Pharm.D. #330-4215
Neonatal Guidelines (gentamicin, tobramycin):

<table>
<thead>
<tr>
<th><strong>Gestational Age</strong></th>
<th><strong>Dosage</strong></th>
</tr>
</thead>
</table>
| <= 29 weeks         | <= 7 postnatal days: 5 mg/kg IV Q48H  
8 to 28 days: 4 mg/kg IV Q36H  
> 28 postnatal days: 4 mg/kg IV Q24H |
| 30 – 34 weeks       | <= 7 postnatal days: 4.5 mg/kg IV Q36H  
> 7 postnatal days: 4 mg/kg IV Q24H |
| >= 35 weeks         | 4 mg/kg IV Q24H |
| HIE (Hypoxic Ischemic Encephalopathy) | 4 mg/kg IV Q36H |

**Comments:**
- Don’t confuse “once daily” dosing with every 24-hour dosing interval in neonates.
- Neonates require a longer dosing interval (decreased clearance) and larger mg/kg dose (increased volume).
- Concentrations may not be warranted in all neonatal patients.
- If extended therapy is indicated (e.g., positive blood culture), concentrations (peak and trough) should be obtained with the 3rd dose.
- If urine output decreases < 1ml/kg/hr for at least 8 hours, concentrations are warranted.
- Goal concentrations usually: peak = 5-8mg/L; trough < 2mg/L.

Dose may be infused over 30 minutes (always check administration technique as possible source of error).
### Pediatric Guidelines (gentamicin, tobramycin)

#### Infant and children dosing guidelines (gentamicin, tobramycin)

Assume Vd (0.3 - 0.35 L/kg)

<table>
<thead>
<tr>
<th>Age</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants: ≥1 month &lt;10 years</td>
<td>2.5mg/kg/dose IV q8hrs</td>
</tr>
<tr>
<td>Children: ≥10 –14 years</td>
<td>1.7-2.5 mg/kg/dose IV q8hrs</td>
</tr>
<tr>
<td>Children: &gt;14 years - adult</td>
<td>1-2 mg/kg/dose IV q8hrs</td>
</tr>
</tbody>
</table>

#### Pediatric cystic fibrosis (CF) patients dosing guidelines (gentamicin, tobramycin)

Vd = 0.4 – 0.45 L/kg

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| 5-7 mg/kg/dose IV q12hrs or 10-14 mg/kg/dose IV q24hrs (concurrent Vancomycin therapy or past history dictates) | ✓ Q12hr dosing should be considered for patients started on aminoglycosides for first time and if documented half-life is <2 hours based on patient-specific PK parameters  
✓ Q24hr dosing should be considered in patients on other nephrotoxins (e.g., vancomycin)  
✓ Larger Vd (0.4-0.45 L/kg) due to decreased body fat and increased CI due to increased GFR.  
✓ Pediatric CF patients are excluded from the once-daily aminoglycoside dosing but some patients may be receiving a “high dose regimen” twice a day.  
✓ For CF patients, levels are usually obtained on the 3rd day rather than the 3rd dose to allow for rehydration.  
✓ Concentrations should be obtained at 4 and 10 hours post dose (12 hours may not be measurable). Peak and trough levels appropriate for q8h dosing.  
✓ Usually require higher doses to achieve desired concentrations (Cpk > 12 mg/L; Ctr < 1mg/L).  
✓ Must be very cautious of nephrotoxicity and ototoxicity because of long term and recurrent use.  
✓ Repeat concentrations are usually not obtained unless significant changes in dose are warranted (e.g., >30%), available concentrations are not reliable, or therapy is continued beyond 14 days.  
✓ If duration of concentration < 0.5 mg/L is greater than 6-8 hours with q24hr dosing, may need to consider lower dosing at more frequent dosing intervals |
6. **Guidelines for Dosing in End Stage Renal Disease (ESRD)**
   - Defined as GFR < 15 ml/min or on renal replacement therapy (RRT)

**Gentamicin and Tobramycin Dosing/Monitoring – Conventional IHD**

Monitor based on duration of therapy

1. Serum concentrations not necessary in patients on therapy <5 days
2. Serum concentrations recommended in patients with culture positive infection or expected duration of therapy > 5 days.

**Guidelines for Monitoring**

1. Initial dosing
   a. Assume Vd – 0.3-0.35 L/kg
   b. Synergy dosing
      i. Loading dose 1.5-2 mg/kg (DBW)
      ii. Maintenance dose 1mg/kg (DBW) after each hemodialysis
   c. Moderate to severe infections (aggressive management)
      i. Loading dose 2-2.5 mg/kg (DBW)

**Effect of hemodialysis**

1. Removes approximately 30-50% with typical HD session (e.g., 3-4 hour)
2. Levels taken 1 hour post dialysis are true troughs; levels taken prior to dialysis can be used during the 30-50% removal assumption.

**Concentrations**

1. Single drug level approach (synergy dosing)
   a. **Most commonly utilized approach at UK**
   b. Pre-dialysis (random) concentration
   c. Extrapolate post-dialysis concentration (trough) by assuming 50% drug removal during a 4 hour dialysis session
   d. Target of trough < 2 mg/L to conserve remaining kidney function and minimize risk for ototoxicity.
2. Multiple drug level approach (aggressive management)
   a. Peak concentration drawn 2 hours after dose
   b. Pre-dialysis (random) concentration

**Maintenance dosing (multiple drug levels)**

1. Calculate $K_{eoff \ IHD}$
   a. $K_{eoff \ IHD} = (\ln \ C_p1/C_p2)/t$
      
      \[ C_p1 = Peak \ concentration; \ C_p2 = Pre-dialysis \ (random) \]
      \[ t = time \ between \ C_p1 \ and \ C_p2 \]
   b. Extrapolate actual peak concentration

2. Calculate half-life off IHD
   a. $t_{1/2} = 0.693/K_{eoff \ IHD}$
c. Extrapolate post-dialysis concentration (trough) by assuming 50% drug removal during dialysis

3. Determine Vd
4. Calculate maintenance dose using desired peak concentration ($C_{pk}$)
   a. $K_o = (C_{pk(des)} - C_{tr}) \times Vd$
   b. Typical dosing 1-1.8 mg/kg after each dialysis session

Dialysis factors that may lead to lower percentage of drug removed
1. Dialysis duration <2 hours
2. Blood flow reduced to <200 mL/min
3. Ultrafiltration only (no hemodialysis)
4. Less permeable dialyzers (filters) used
5. Patient is volume overloaded

**Aminoglycoside Dosing/Monitoring – CRRT**

Dosing recommendations for critically ill adults receiving CVVHD/CVVHDF*

<table>
<thead>
<tr>
<th>Aminoglycoside</th>
<th>Infection with Gm positive bacteria</th>
<th>Infection with gram-negative bacteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentamicin</td>
<td>Synergy dosage</td>
<td>Loading dose</td>
</tr>
<tr>
<td>1 mg/kg q24-36h</td>
<td>3 mg/kg</td>
<td>2 mg/kg q24-48h</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>Not applicable</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>2 mg/kg q24-48h</td>
<td>2 mg/kg q24-48h</td>
<td></td>
</tr>
<tr>
<td>Amikacin</td>
<td>Not applicable</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>7.5 mg/kg q24-48h</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Use calculated dosing body weight. Target peak and trough levels vary depending on type of infection.


**Guidelines for Monitoring**
1. Typical dosing interval during CRRT is q24-48h
2. Synergy dosing yields target peaks of 3-4 mg/L
3. Higher target peaks require longer dosing intervals

**Levels**
1. Two random serum concentrations will be obtained 4 and 12 hours after completion of the 1st dose.
2. Determine appropriate maintenance dose based upon calculated PK parameters (ensure CRRT uninterrupted between concentrations)

**Factors that may lead to changes in amount of drug removed**
1. Changes in ultrafiltration rate
2. Dialysis interrupted (i.e. filter clotted, particularly overnight)
3. Alterations in existing renal function (ARF vs CRF)

**Useful References**
Suggested References for Influences of Pathophysiological States on Aminoglycoside Kinetics:

**Ascites:**

**Burn Patients:**

**Critically Ill Patients:**

**Cystic Fibrosis:**

**Elderly:**

**Obesity:**

**Pediatrics:**
HIGH-DOSE EXTENDED INTERVAL DOSING (HDEI)

There are several studies suggesting that larger doses of aminoglycosides with extended intervals (e.g., q24hrs) are just as effective, and less toxic, than conventional dosing given three times a day. HDEI regimens take advantage of concentration-dependent killing through the optimization of peak concentration / MIC ratios. In addition, there are potential cost savings for nursing, pharmacy, and laboratory personnel. The HDEI policy has been used on the Trauma Surgery Service at the University of Kentucky Chandler Medical Center since 1993. This is also referred to as “Once daily aminoglycoside dosing”.

Inclusion Criteria: All adult patients ordered aminoglycosides for prophylaxis, empiric therapy, or documented infection. (Aminoglycosides are usually indicated as synergistic or adjunctive therapy with other antibiotics as double coverage for gram-negative infections).

Exclusion criteria:
1. Patients with ascites
2. Patients with burns on >20% of total body surface area
3. Pregnant patients
4. Patients on dialysis
5. Patients with gram positive bacterial endocarditis
6. Pediatric patients (<18yo) – please refer to pediatric dosing guidelines
7. Patients with cystic fibrosis (with/without lung transplant) – please refer to specific guidelines for CF patients

Initial Dose: Doses should be based on DOSING BODY WEIGHT, ideal body weight plus 40% of estimated adipose tissue mass above IBW (see Dosing Guidelines).

- Patients with estimated Clcr $\geq 40 \text{ mL/min/1.73m}^2$ will receive initial gentamicin/tobramycin dose of 7 mg/kg-DBW, infused over 30 minutes. Amikacin dosage is 15-20mg/kg/day-DBW.

- Alternative dosing in special populations include:
  - Orthopedic Surgery services commonly will use gentamicin 5mg/kg-DBW for prophylaxis/pre-emptive therapy with open fracture
  - Obstetrics which use gentamicin 5mg/kg -post-partum dosing body weight (see page 36 for OB guidelines)
  - Cystic fibrosis patients (Without lung transplant) - Guidelines on page 26 for pediatric CF dosing and page 35 for adult CF dosing.
  - Cystic fibrosis patients with lung transplant have been shown to have altered aminoglycoside pharmacokinetics (increased half life) following transplant and dosing should be individualized based on concentrations.

- Patients with estimated creatinine clearances $< 40 \text{ mL/min/1.73m}$ will receive an initial gentamicin dose of 3 mg/kg, infused over 30 minutes.
INITIAL DOSING GUIDELINES FOR ADULTS:

1. Estimate Creatinine Clearance (Cl\textsubscript{cr}) using Actual Body Weight (ABW) for non-obese patients; in obese patients (>125% IBW) use Dosing Body Weight (see below for equation).

\[
\text{Males } \quad \text{Cl}_{\text{cr}} = \frac{(140-\text{Age}) \times \text{ABW}}{72 \times \text{Scr}}
\]

\[
\text{Females } \quad \text{Cl}_{\text{cr}} = \text{Cl}_{\text{cr}} \times 0.85
\]

2. Estimate Body Surface Area (BSA) using the Mosteller equation:

\[
\text{BSA (m}^2) = \sqrt{\frac{\text{Ht(cm)} \times \text{Wt(kg)}}{60}}
\]

3. Calculate Standardized Creatinine Clearance:

\[
\text{Cl}_{\text{cr(Std)}} = \frac{\text{Cl}_{\text{cr}} \times 1.73m^2}{\text{BSA}}
\]

4. Determine Ideal Body Weight (IBW).

\[
\text{IBW (kg)} = 50 \text{ (kg)} + (2.3 \text{ (kg)} \times \text{ea. inch over 5 ft)} \text{ male}
\]

\[
= 45 \text{ (kg)} + (2.3 \text{ (kg)} \times \text{ea. inch over 5 ft)} \text{ female}
\]

5. Calculate Dosing Body Weight (DBW):

\[
\text{DBW} = \text{IBW} + 0.4 \text{ (ABW-IBW)} \quad \text{(If ABW<IBW, then DBW = ABW)}
\]

6. Calculate the patient’s dose (gentamicin & tobramycin) based on Dosing Body Weight.

a) If Cl\textsubscript{cr(Std)} \geq 40 ml/min/1.73m\textsuperscript{2}, then give 7 mg/kg-DBW.

b) If Cl\textsubscript{cr(Std)} < 40 ml/min/1.73m\textsuperscript{2}, then give 3 mg/kg-DBW.

**Amikacin:** Doses used for single daily administration of amikacin range from 15 to 20 mg/kg/day (Marik et al, 1991; Maller et al, 1993 - 20mg/kg/dose: Cpk ~40mg/L and Cl\textsubscript{f24hr} <4mg/L).

7. Dilute dose in 100 ml of either 5% Dextrose or Normal Saline and infuse over 30 minutes.

8. Order two concentrations at 4 and 12 hours after the end of 1\textsuperscript{st} dose.
Monitoring: Two concentrations (ordered as “random” concentrations) will be obtained:

1) 1<sup>st</sup> concentration will be drawn ~4 hours* after completion of the 1<sup>st</sup> dose.

**NOTE:** The random concentration at 4 hours post-infusion may range from 4-13 mg/L depending on renal function and volume status. Patients with normal renal function (>100 ml/min) usually average a 4-hour random ~5-8 mg/L (see mean concentration-time curve on page 41).

The rationale for obtaining a “4-hour” sample versus a “peak” is to determine the serum concentration after the distribution phase. A prolonged distribution phase has been described in trauma patients (Jennings HR, et al. Pharmacotherapy. 2000;20(10):1265) and healthy volunteers (McNamara DR, et al. J Clin Pharmacol 2001 Apr;41(4):374-7) who received 7 mg/kg. Post-distribution concentrations provide a more accurate calculation of elimination rate and the estimation of the 24-hour concentration.

2) 2<sup>nd</sup> concentration will be drawn ~12 hours after completion of the 1<sup>st</sup> dose.

**NOTE:** The concentration at 12 hours post-infusion will vary depending on renal function. The 12-hour concentration may be <1 mg/L in patients with normal renal function.

Subsequent Doses: The goal of the initial concentrations after the 1<sup>st</sup> dose is to verify that the drug is eliminated appropriately before the 2<sup>nd</sup> dose and to establish the dosing interval. Subsequent doses will be the same as the initial dose, but the dosing intervals will be adjusted to achieve troughs < 1 mg/L. Appropriate dosing intervals include every 24, 36, or 48 hours. Scr/BUN should be measured at baseline and 2X/week thereafter.

- Patients with normal renal function will usually have a “drug-free” period with an undetectable trough concentration < 0.3 mg/L.
- For patients with trough concentration > 0.3 mg/L, renal function should be monitored closely and risks of nephrotoxicity and ototoxicity evaluated carefully.
- If the serum concentration following a 7mg/kg dose requires > 48 hours to decline to <1mg/L, then 3mg/kg or conventional dosing may be warranted.
- Patients should not receive a single dose of 7mg/kg more frequently than every 24 hours until more studies are available.

Follow-up monitoring: If ODA therapy is continued for > 7 days, a trough concentration should be obtained weekly to check for drug accumulation and assess risk of nephrotoxicity. Scr/BUN should also be monitored at least 2X/week to assess any changes in renal function and risk of nephrotoxicity. Concomitant nephrotoxic drugs should be avoided if possible.

Ototoxicity should be monitored closely. Ototoxicity results from damage to the vestibular and cochlear portions of the eighth cranial nerve. **Auditory symptoms include tinnitus, roaring, ringing, or “buzzing” in the ears, and varying degrees of hearing impairment.** Loss of high-frequency perception is only detectable by audiometric testing and usually occurs before clinical hearing loss. **Vestibular symptoms include nausea, vomiting, dizziness, vertigo, nystagmus, oscillopsia,** and ataxia. A feeling of fullness in the ears and tinnitus are early signs of ototoxicity. Symptoms are exacerbated in the dark. Hearing loss may be irreversible, but patients usually retain normal conversational hearing. Other ototoxic drugs (e.g., lasix) should be avoided if possible.
CALCULATE PARAMETERS:

1) Calculate K:

\[
K = \ln\left(\frac{C_{1\text{random}}}{C_{2\text{random}}}ight)
\]

where
- \(C_{1\text{random}}\) is the 1st random ~4hrs after dose
- \(C_{2\text{random}}\) is the 2nd random ~12 hrs after dose
- \(T'\) is the time between \(C_{1\text{random}}\) and \(C_{2\text{random}}\)

2) Calculate \(C_{\text{pk}}\) at 0.5hr after 1st dose (30-min infusion):

\[
C_{\text{pk}}^{0.5\text{hr}} = \frac{C_{1\text{random}}}{e^{KT'}}
\]

where
- \(T'\) is the time between \(C_{1\text{random}}\) and \(C_{\text{pk}}^{0.5\text{hr}}\)

3) Calculate \(C_{\text{tr}}\) at 24 hours:

\[
C_{\text{tr}}^{24\text{hr}} = C_{\text{pk}}^{0.5\text{hr}} e^{-K \times 23}
\]

If 24hr \(C_{\text{tr}} \leq 1\) mg/L continue q24hr dosing
If 24hr \(C_{\text{tr}} > 1\) mg/L extend dosing interval

4) Calculate \(V\) using \(C_{\text{pk}}^{\text{max}}\) (peak extrapolated to the END of infusion)

\[
C_{\text{pk}}^{\text{max}} = \frac{C_{\text{pk}}^{0.5\text{hr}}}{e^{-Kt}}
\]

\[
V = \frac{K_p (1 - e^{-Kt})}{K(C_{\text{pk}}^{\text{max}})}
\]

where
- \(t = 0.5\) hr (time between \(C_{\text{pk}}^{\text{max}}\) and \(C_{\text{pk}}^{0.5\text{hr}}\))
- \(t = \) infusion time

If assistance is required in selecting patients or determining the proper dose or dosage interval, contact the pharmacist rounding with the service, the Clinical Pharmacokinetics Service (257-3378, UK beeper #1740), the Pharm.D. Resident on call (UK beeper #1875), or the Infectious Disease Service.

**SUGGESTED REFERENCES:**
J Infect Dis 1987; 155:93-9
J Infect Dis 1990; 162:414-20
Pharmacotherapy 1995; 15:297-316
Pharmacotherapy 1995; 15:201-9
Ther Drug Monit 1996; 18:263-6

**HDEI in Pediatrics:**
J Antimicrob Chemo 1997; 39:431-33. (cystic fibrosis patients)
HDEI Dosing for Adult Cystic Fibrosis Patients:

Inclusion criteria:

✓ Adult patients 18-35 years of age
✓ Estimated Clcr > 60ml/min
✓ Must obtain baseline Scr in patients at increased risk of renal insufficiency
  o History of renal dysfunction
  o Diabetes mellitus
✓ Must consider if CF patient is post-lung transplant and the time since transplant due to altered pharmacokinetics:
  o Tobramycin pharmacokinetics have been shown to be altered in patients with CF after bilateral lung transplantation (Walsh KA et al. Transplant Infect Dis 2011).
    ▪ Concentrations were evaluated at 0-3 weeks and ≥6 weeks post-transplant.
    ▪ Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1/h (P<0.001), with a related increase of 200% in half-life from 2.8±0.8 to 8.4±8.7 h (P<0.001). Clearance decreased 25% post-transplant from 67.3±32.3 to 50.2±15.9 mL/min (P=0.04).
    ▪ Dosage requirements after transplantation were significantly lower, 10.7±2.5 and 7.6±1.6 mg/kg/day, pre- and post-transplant, respectively (P<0.001).
    ▪ Cl and Vd ≥6 weeks post-transplant did not significantly differ from pre-transplant values (P=0.28 and 0.54, respectively), suggesting that changes may be temporary.
    ▪ PK parameters should be reassessed during each treatment course post-transplant to determine appropriate dosage.
  o CF patients post-lung transplant may require a lower initial dose and extended dosing interval. Subsequent doses should be determined based on indication, risk of nephrotoxicity, concentrations, and individual PK parameters.

Dosing and monitoring recommendations (Tobramycin):

✓ 12 mg/kg (DBW) IV q24 hours
✓ Obtain 4 and 10 hour concentrations following infusion of third dose
  o Goal Ctr < 0.5 mg/L
  o If 12 hour concentration is <1 mg/L, consider increasing dose to 15 mg/kg/day or shorten dosing interval (i.e. 7-8 mg/kg IV q12h).
  o If estimated (calculated) trough level prior to next dose (Ctr) is >0.5 mg/L, calculate new dose to achieve Ctr <0.5mg/L
✓ Repeat trough concentrations indicated if significant changes in dose occur or if therapy is to continue an additional 7 days
  o Draw trough concentration once weekly, goal Ctr ≤0.5mg/L
  o If patient on other nephrotoxic medications (e.g., vancomycin), more frequent monitored may be warranted
  o Assess renal function at least 2x weekly while patient on therapy

SUGGESTED REFERENCES:

ODA Dosing for Postpartum Endometritis
(Revised July 2014)

Indications:
• Postpartum endometritis
• Postpartum treatment of chorioamnionitis
  ○ Prior to delivery, use conventional gentamicin dosing (e.g., 1-2 mg/kg/dose ABW IV q8hrs); start once daily dosing 8 hours after conventional dose. Some practitioners may also utilize high dose extended interval dosing using 5mg/kg of antepartum actual body weight q24hrs for treatment of chorioamnionitis prior to delivery. Literature suggests that many patients will have resolution of symptoms with short course therapy (stop after 1 dose post-delivery) compared with standard treatment of 24-48hrs after symptom resolution.

Inclusion criteria:
• Current postpartum weight
• Age ≥ 18 years old, or if deemed medically appropriate in younger patients
• Normal renal function (serum creatinine < 1.4mg/dL)
  ○ Obtain baseline serum creatinine in patients with increased risk for renal insufficiency prior to receiving once daily gentamicin including:

Exclusion criteria:
• History of renal dysfunction
• Diabetes mellitus
• Preeclampsia
• Toxemia

Dosing Recommendation:
1. Identify patient weight
   a. Obtain a postpartum actual body weight per nursing
   b. If patient cannot be weighed, a postpartum actual body weight (PPABW) can be calculated by subtracting ~5.5kg from actual body weight at time of delivery of a term gestation. If needed, may adjust the calculation if neonatal weight significant varies from 3kg. Approximately 2.5kg is attributed to placental weight and fluids. At 1 week post-delivery weight loss is ~8kg.

2. Use ACTUAL postpartum body weight (PPABW):
   a. GENTAMICIN DOSAGE = 5mg/kg X PPABW IV q24hrs
   b. Maximum dose of 500mg
Aminoglycosides – High-dose, Extended Interval Dosing

Follow-up Monitoring:
1. SERUM GENTAMICIN CONCENTRATIONS are NOT warranted unless the patient meets at least one of the following criteria:
   a. Increased risk for renal insufficiency (risk factors listed above)
   b. Duration of gentamicin therapy is continued for > 3 days
   c. Patient is not responding to antibiotic therapy

2. If serum gentamicin concentrations are warranted (refer to list above):
   a. TWO GENTAMICIN CONCENTRATIONS should be obtained 4 AND 12 hours after the dose (order as “4 and 12 random gentamicin concentrations”)
   b. A pharmacist will assess the concentrations and calculate the gentamicin trough (goal: <1mg/L) and recommend a new dosage if necessary.
   c. A pharmacy resident on-call (#330-7400) is also available after 5pm and weekends if necessary.

3. Additional monitoring:
   a. If duration of aminoglycoside therapy continues > 3 days, suggest checking a serum creatinine
   b. If duration of aminoglycoside therapy continues > 7 days, suggest checking follow-up gentamicin TROUGH CONCENTRATION to assess for potential accumulation

References
Other methods used for ODA dosing (NOTE: This information is provided for comparison only, please refer to UKCMC approved protocol):

Hartford Hospital Nomogram (Nicolau et al Antimicrob Agents Chemother 1995;39.)

- Dose = 7mg/kg IV q24hrs for Clcr > 60ml/min (also refer to table below)
- Interval based on nomogram using SINGLE random concentration between 6-14 hours
  - Computer simulated dosing nomogram
    - Designed to achieve Cpk ~20 mg/L
    - Tested with PK parameters of patients on conventional dosing regimens
    - Confirmed in patients (n=20) receiving 7 mg/kg

- Assumes one-compartment model
- Assumes 60 min distribution phase
- May not be accurate for doses less than 7mg/kg (e.g., 5mg/kg)

Comparison of different methods:

<table>
<thead>
<tr>
<th>Nomogram</th>
<th>Gentamicin Dose (mg/kg)</th>
<th>Dosing Interval (hrs)</th>
<th>Clcr ≥ 60 ml/min</th>
<th>Clcr 40-59 ml/min</th>
<th>Clcr 20-39 ml/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartford Hospital*</td>
<td>7</td>
<td>24</td>
<td>36</td>
<td>36</td>
<td>48</td>
</tr>
<tr>
<td>Barnes-Jewish Hospital*</td>
<td>5</td>
<td>24</td>
<td>36</td>
<td>36</td>
<td>48</td>
</tr>
<tr>
<td>University of Rochester*</td>
<td>5</td>
<td>24</td>
<td>36</td>
<td>36</td>
<td>48</td>
</tr>
<tr>
<td>UKCMC</td>
<td>7</td>
<td>24</td>
<td>24</td>
<td></td>
<td>Use 3mg/kg IV q24hrs</td>
</tr>
</tbody>
</table>

*Source: Pharmacotherapy. 2002 Sep;22(9):1077-83.
### Sanford Guide 2004 – Recommended Gentamicin/Tobramycin Dosing Regimen

<table>
<thead>
<tr>
<th>Clcr (ml/min)</th>
<th>Dose (mg/kg)</th>
<th>Interval (hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 80</td>
<td>5.1 (7 if critically ill)</td>
<td>24</td>
</tr>
<tr>
<td>60-79</td>
<td>4.0</td>
<td>24</td>
</tr>
<tr>
<td>40-59</td>
<td>3.5</td>
<td>24</td>
</tr>
<tr>
<td>30-39</td>
<td>2.5</td>
<td>24</td>
</tr>
<tr>
<td>20-29</td>
<td>4.0</td>
<td>48</td>
</tr>
<tr>
<td>10-19</td>
<td>3.0</td>
<td>48</td>
</tr>
<tr>
<td>&lt;10</td>
<td>2.0</td>
<td>48</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Clcr (ml/min)</th>
<th>Starting Dose (mg/kg)</th>
<th>Target AUC</th>
<th>Time of Second Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;66</td>
<td>5, 6, or 7</td>
<td>72, 86, 101</td>
<td>6-14 hr</td>
</tr>
<tr>
<td>54-66</td>
<td>5 or 6</td>
<td>86, 101</td>
<td>8-16 hr</td>
</tr>
<tr>
<td>42-53</td>
<td>5</td>
<td>101</td>
<td>10-18 hr</td>
</tr>
<tr>
<td>30-41</td>
<td>4</td>
<td>101</td>
<td>12-20 hr</td>
</tr>
<tr>
<td>21-29</td>
<td>3</td>
<td>101</td>
<td>14-22 hr</td>
</tr>
<tr>
<td>&lt;21</td>
<td>Seek specialist advice</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Administer dose over 30 minutes
- Take blood sample 30 minutes after end of infusion (Cpk)
- Take second blood sample within time frame indicated in table
- Calculate the patient’s aminoglycoside AUC using:
  \[
  \text{AUC (0-24hrs)} = 1.065 \left( \frac{C_{\text{end of infusion}} - C_{24}}{K} \right)
  \]

- Calculate 2\textsuperscript{nd} dose:
  \[
  \text{Dose 2} = \frac{AUC_{\text{target}}}{AUC_{\text{observed}}} \times \text{Dose 1}
  \]

- Administer 2\textsuperscript{nd} dose 24hrs after the first dose
- Monitor as above every 48hrs or according to the patient’s clinical condition
CARBAMAZEPINE

1. Time of Sampling
   a. Relative to Dose
      - trough within 1 hour prior to dose
      - at ss

2. Recommended Frequency of Sampling
   a. Initially after reaching steady-state (2 to 10 days of chronic dosing); "true" steady-state may not be reached for several weeks, due to autoinduction, which results in increasing clearance. Induction begins within 3 to 4 days of therapy and is maximal after 3 to 4 weeks.
   b. After each dosage adjustment at ss.

3. Therapeutic Range
   4 – 12 µg/ml (8-12 µg/ml reported by UKCMC TDM Lab)
   1.4 – 3.5 µg/ml (saliva)

   Note: Carbamazepine used as single anticonvulsant therapy may require higher serum concentrations than when used in a multiple anticonvulsant regimen.

4. General Guidelines for Monitoring
   a. Initial Dosing
      - epilepsy 200 mg PO BID
      - trigeminal neuralgia 100 mg PO BID

   b. Maintenance Dose
      - Increase dose by 100-200 mg/day every week
      - Based on initial level and response to therapy, dosage may have to be gradually increased during the first few weeks, due to autoinduction.
      - Final maintenance dose is usually:
         - epilepsy 10-20 mg/kg/day
         - trigeminal neuralgia 3-20 mg/kg/day
      - Best to give in divided doses, usually q 12 o (or q 8 o), rather than in a single daily dose.
      - Dosing best at mealtime.
      - Maximum dose - usually 1200 mg/day
c. **Dosage Adjustment**

The \( \bar{c} \) equation may be used once "true" steady-state is achieved.

\[
\bar{c} = \frac{S \times F \times X_0}{\text{Cl}_s \times \tau}
\]

\( S = 1; F = 0.7-1.0 \) (Tegretol)

d. **Available products at UK Hospital**

Tegretol® 200mg tablets, 100mg chew tabs, 100mg/5ml suspension

5. **Pediatric Guidelines**

- Initial dose - 10 mg/kg/day
- Maintenance dose - 20-35 mg/kg/day (gradually increase weekly from initial dose)
- Also see #9 - Miscellaneous

6. **Other Monitoring Guidelines**

- Baseline CBC
- CBC every month (x 2), then every 6 months after stabilized

7. **Drug Interactions**

- CBZ induces its own metabolism (P450 3A4) during prolonged treatment, and is complete 3 to 5 weeks with a fixed dosing regimen (Prod Info Tegretol(R), 1998).
- Active metabolite: carbamazepine-10,11-epoxide
- Since CBZ is an enzyme inducer of many P450 enzymes (3A4, 2D6, 2C), it may enhance the elimination of other drugs (e.g. ethosuximide, warfarin, and benzodiazepines that undergo hydroxylation).
- Enzyme inhibitors may increase CBZ levels (e.g. cimetidine, erythromycin, isoniazid, propoxyphene, and verapamil)
- Phenytoin - CBZ interaction is variable. Phenytoin levels may increase, decrease, or stay the same. CBZ levels usually decrease.

8. **Adult Pharmacokinetic Parameters**

- \( V_d \) = 1.4 ± 0.4 L/kg
- \( \text{Cl} \) = 1.3 ± 0.5 ml/min/kg (multiple dosing)
  = 0.4 ± 0.1 ml/min/kg (single dose)
- \( t\frac{1}{2} \) = 15 ± 5 hours (multiple dosing)
  = 36 ± 5 hours (single dose)
9. **Miscellaneous**

- Absorption is variable, depending on factors such as age, nutritional status, presence of food, and product formulation.

- Protein binding is approximately 70% (binds to both albumin and α-1 AGP).

10. **Suggested References**

   **General:**


   **Drug Interactions:**

   Phenytoin Zielinski (1985) Ther Drug Monit 7:51.


DIGOXIN

1. Time of Sampling
   a. Relative to Dose
      • Drug concs should be drawn during the post-absorptive, post-
        distributive phase of drug elimination, ie, during the 6 to 24 hour
        interval following the previous dose
      • Prefer trough within 1h prior to dose
      • At ss (usually 5-7 days; if normal renal/hepatic fx: t½ = 36 ± 8hrs,
        adults)

2. Recommended Frequency of Sampling
   a. Routine Use in "Uncomplicated" Patients
      • Initial level at ss
   b. Use in Unstable Patients
      • Initial level at ss
      • Repeat level every 5 to 7 days, or as dictated by a change in
        concurrent disease state/drug therapy, lack of adequate response to
        a previously adequate dose, or occurrence of adverse effects
        attributable to digoxin.

3. Therapeutic Range**
   UK: 0.8-2.0 ng/ml (conversion note: 1ng/ml = 1µg/L)
   CHF: 0.5-1.0 ng/ml

   Arrhythmias: may require higher concs for atrial fibrillation

** Establishment of a true therapeutic range is complicated by effects of
electrolyte imbalances and of assay interference by digoxin-like
immunoreactive substances (DLIS) and digoxin metabolites. (see 4b.
Dosing Adjustments)
4. **General Guidelines for Monitoring**

a. **Loading Dose**

Rapid digitalization can typically be achieved utilizing loading doses of 8-12 mcg/kg LBW (normal renal function). Use LBW, since digoxin does not distribute appreciably into body fat.

\[
X_0^* = \frac{C \times V}{S \times F}
\]

\( S = 1 \)

\( F = 0.7 \) (tablet)

\( = 0.8 - 0.85 \) (elixir; capsule)

\( V = 7.3 \) L/Kg in normal renal function**

** For patients with compromised renal function:

\[
V_{(L/1.73m^2)} = \frac{226 + \frac{298 \times Cl_{cr} \text{ (stdz to 1.73m}^2)}{29.1 + Cl_{cr} \text{ (stdz to 1.73m}^2)} \text{ (stdz to 1.73m}^2)}
\]

\( \text{e.g. std Cl}_{cr} = Cl_{cr} \times \frac{1.73m^2}{\text{actual BSA}} \)

\[
V_{(L/70 Kg)} = 269 + 3.12 \times Cl_{cr} \text{ (stdz to 70 Kg})
\]

\( \text{e.g. std Cl}_{cr} = Cl_{cr} \times \frac{70 \text{ Kg}}{\text{actual LBW (Kg)}} \)

The loading dose should be given in divided doses so that the patient can be evaluated for toxicity and efficacy prior to receiving total load. (e.g. usually give 1/2 of the calculated load initially, followed by 1/4 in 6h and the remaining 1/4 in 6h after the second dose, making sure to monitor the patient after each dose).

b. **Maintenance Dose:**

\[
X_o (mcg) = \frac{c \times Cl_s \times \tau}{F \times S}
\]

(Helpful hint: use mcg/L for c, 24hrs for \( \tau \), and L/hr for Cl)

**For patients without HF:**

\( Cl_s = 1.303 \) (Clr, std to 1.73 m²) + 40 ml/min/1.73 m² (ml/min/1.73m²)

**Patients with uncompensated HF (e.g. pitting edema, hepatic congestion):**

\( Cl_s = 1.303 \) (Clr, std to 1.73m²) + 20 ml/min/1.73m² (ml/min/1.73m²)

** To calculate estimated Cls for specific patient, need to unstandardize, i.e., multiply Cls calculated above by "actual BSA/1.73m²"
Dosing Adjustments

Calculate actual \( Cl_s \), based on \( C \) (level, usually obtained at \( \tau \)), \( F \), and \( X_0 \) (dose administered).

\[
Cl_s = \frac{S \cdot F \cdot X_0}{C \cdot \tau}
\]

Calculate new maintenance dose.

\[
X_0 = \frac{C \cdot Cl_s \cdot \tau}{F \cdot S}
\]

One should check if the therapeutic response to digoxin correlates well with the level(s) obtained, prior to making dosage adjustment(s). The failure of digoxin levels to correlate with therapeutic/toxic response is often due to aberrations in serum and tissue concentrations of sodium, potassium, magnesium, and calcium. Patients with low potassium, magnesium, or sodium levels or high calcium levels may be more sensitive to digoxin or due to presence of DLIS in certain subpopulations (e.g. renal failure patients, combined renal and hepatic failure patients, pregnant women, neonates, infants).

Chart note

Monitoring parameters should include heart rate, ECG, serum electrolytes (K, Mg, Na, Ca), Scr, Clcr, interacting medications and monitoring for signs and symptoms of toxicity. PK parameters should include digoxin Cls in ml/min.

5. Factors Influencing Digoxin Pharmacokinetics/Pharmacodynamics

- Renal dysfunction, obesity, CHF (see 4a.)
- Hypothyroidism: ↓ digoxin Cls
- Hyperthyroidism: ↑ digoxin Cls
- Hypokalemia, hypomagnesemia, hypercalcemia: ↑ digoxin cardiac effects
- Drug interactions:
  - Drugs associated with ↓ digoxin absorption include: antacids, cholestyramine, colestipol, kaolin-pectin, metoclopramide, neomycin, sulfasalazine; ↑ absorption include: propantheline.
  - Quinidine - ↓ digoxin Cls; multiply digoxin Cls by 0.5
  - Verapamil - ↓ digoxin Cls; multiply digoxin Cls by 0.7
  - Spironolactone - ↓ digoxin Cls; multiply digoxin Cls by 0.5
  - Amiodarone - ↓ digoxin Cls; multiply digoxin Cls by 0.7
6. **Pediatric Guidelines**

**Dosage Recommendations for Digoxin**

<table>
<thead>
<tr>
<th>AGE</th>
<th>Total Digitalizing Dose* (mcg/kg)</th>
<th>Daily Maintenance Dose# (mcg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Preterm neonate</td>
<td>20-30</td>
<td>15-25</td>
</tr>
<tr>
<td>Full-term neonate</td>
<td>25-35</td>
<td>20-30</td>
</tr>
<tr>
<td>1 mo - 2 yrs</td>
<td>35-60</td>
<td>30-50</td>
</tr>
<tr>
<td>2 - 5 yrs</td>
<td>30-45</td>
<td>25-35</td>
</tr>
<tr>
<td>5 - 10 yrs</td>
<td>20-35</td>
<td>15-30</td>
</tr>
<tr>
<td>&gt;10 yrs</td>
<td>10-15</td>
<td>8-12</td>
</tr>
</tbody>
</table>

**Average Dosage Recommendations for Adults (mg)**

| Adults | 0.75-1.5mg | 0.5-1mg | 0.125-0.5mg | 0.1-0.4mg |


* Administer ½ of the total digitalizing dose in the initial dose, then ¼ of the total dose in each of two subsequent doses at 6-8 hour intervals. The doses are divided to allow sufficient time for distribution and maximum effect to assess for therapeutic response and potential toxicity after each dose.

# Divided every 12 hours in infants and children ≤ 10 years of age. Administered once daily for children > 10 years of age and adults.

7. **Other Considerations**

Vd: 6-20 L/kg  
(caution: wide patient variability may be secondary to design problems in initial studies)

- **DLIS (digoxin-like immunoreactive substance):** very common in newborn infants.
- Serum concentrations may not be warranted in every patient.
- Digoxin therapy should first be evaluated based on response and toxicity versus measuring drug concentrations.
8. **Dosage forms on UK formulary**

Digoxin tablets 0.125mg, 0.125mg  
Digoxin injection 500 mcg AMP/2ML; 250mcg TUBEX  
Digoxin elixir 50 mcg/ml 60ml BTL; 250mcg 5ml TUB; 125mcg 2.5ml TUB  

Digoxin injection (PEDIATRIC STRENGTH): 100 mcg/ml (1ml AMP);  
*Also 10mcg/ml *DILUTED*  

9. **Suggested References for Factors Influencing Digoxin Disposition**


Drug interactions:  
Digoxin Immune Fab (DIGIBIND®, DIGIFAB®)

1. Indications

a. Manifestations of severe toxicity: ventricular arrhythmias, progressive bradyarrhythmias, 2nd or 3rd degree heart block not responsive to atropine, refractory hypotension.

b. Potassium concentration >5 mEq/L in patients with manifestations of severe cardiac glycoside toxicity

c. Significant risk of cardiac arrest: ingestion of >10 mg in an adult, >4 mg in a child, level >10 ng/mL post-distribution (generally 6-8 hours postingestion), progressive increase in potassium level postingestion.

d. Unresponsiveness to immediately available conventional therapy.

e. Digoxin serum levels of >10 ng/mL by 6 hours after the overdose, even in asymptomatic patients, is considered an indication for digoxin immune FAB by some authors (Bailey et al, 1997).

2. Recommended dosing for adults

a. Acute ingestion of known amount: Each vial of Digoxin Immune Fab will bind approximately 0.5mg of digoxin. Can calculate the total number of vials required by dividing the total digitalis body load by 0.5mg/vial:

\[
\text{Total body load (mg)} = 0.8 \times \text{[amount (mg) digoxin tablets or elixir ingested]}
\]

\[
\text{Dose (in # of vials)} = \frac{\text{Total digitalis body load in mg}}{0.5 \text{ mg of digitalis bound/vial}}
\]

b. Based on steady-state digoxin concentrations Pediatric and Adult dose estimate of Digoxin Immune Fab (in mg for pediatrics and # of vials for adults) is represented in the table below or can be estimated using the following equation:

\[
\text{Dose (in # of vials)} = \frac{(\text{Serum digoxin concentration in ng/ml})(\text{weight in kg})}{100}
\]

<table>
<thead>
<tr>
<th>Patient Weight (kg)</th>
<th>Serum Digoxin Concentration @ Steady State (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>0.4 mg&lt;sup&gt;A&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>1 mg&lt;sup&gt;A&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>2 mg&lt;sup&gt;A&lt;/sup&gt;</td>
</tr>
<tr>
<td>10</td>
<td>4 mg</td>
</tr>
<tr>
<td>20</td>
<td>8 mg</td>
</tr>
<tr>
<td>40</td>
<td>0.5V</td>
</tr>
<tr>
<td>60</td>
<td>0.5V</td>
</tr>
<tr>
<td>70</td>
<td>1V</td>
</tr>
<tr>
<td>80</td>
<td>1V</td>
</tr>
<tr>
<td>100</td>
<td>1V</td>
</tr>
</tbody>
</table>

<sup>V = vials;</sup> <sup>A</sup>Dilution of reconstituted vial to 1 mg/mL may be desirable
3. **Total Serum Digoxin Levels After Digoxin Immune Fab Administration:**

*Purpose:*

Total serum digoxin levels obtained immediately after administration are unreliable. The Fab fragments bind to free digoxin, causing tissue-bound digoxin to be released from receptors and subsequently bind to the Digoxin Immune Fab. Digoxin levels drawn within 72 hours (for patients with normal renal function) or 7 days (in patients with renal failure) of administration will be falsely elevated.

*Policy regarding total serum digoxin levels:*

a. The pharmacist will alert TDM lab when Digoxin Immune Fab is ordered for any patient in the hospital.

b. TDM lab will not measure total serum digoxin levels for a period of at least 72 hours following administration for patients with normal renal function.

c. TDM lab will not measure total serum digoxin levels for a period of at least 7 days following administration for patients with severely impaired renal function.

d. If a digoxin level is ordered within the above times.

*References*


LIDOCAINE

1. **Time of Sampling**
   a. **Relative to Dose**
      - 2h after load or 6-12h after initiation of therapy without load (ie @ ss)
      - Send out lab, may take 2-3 days for results to be reported

2. **Recommended Frequency of Sampling**
   - when toxicity is suspected
   - when ventricular arrhythmias occur (or recur) despite lidocaine administration
   - patients with suspected cardiac or hepatic insufficiency may require intensive serum concentration monitoring

3. **Therapeutic Range**
   1.5 - 6.0 mcg/ml

4. **General Guidelines for Monitoring**
   a. **Initial Dosing**
      - **Load**
      - **MULTIPLE-BOLUS REGIMEN:**
        Initial 75-100 mg (1 mg/kg) bolus, followed by 50 mg in 5-10 min. One to two additional 50 mg bolus doses may be given in 5-10 min intervals thereafter if necessary.
      - **RAPID-INFUSION METHOD:**
        Initial 75-100 mg bolus (over 2 min) and loading infusion of 150-200 mg (over 20 to 25 min).
1-4 mg/min (15-50 µg/min/kg, recommended for patient of lighter bodyweight)

Mean Systemic Clearance and Recommended Infusion Rates for Selected Patient Populations

<table>
<thead>
<tr>
<th>Population</th>
<th>Systemic clearance (ml/min/kg) Mean ± SD</th>
<th>Infusion rate (µg/kg/min) to achieve 3 µg/ml Mean (Range)</th>
<th>Infusion rate (mg/min/70kg) Mean (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>15.6±4.6</td>
<td>47 (33-61)</td>
<td>3.3 (2.3-4.3)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>5.5±1.7</td>
<td>17 (11-22)</td>
<td>1.2 (0.8-1.5)</td>
</tr>
<tr>
<td>Acute myocardial infarction**</td>
<td>9.1±2.0</td>
<td>27 (21-33)</td>
<td>1.9 (1.5-2.3)</td>
</tr>
<tr>
<td>Congestive heart failure plus acute myocardial infarction</td>
<td>6.3±1.4</td>
<td>19 (15-23)</td>
<td>1.3 (1.1-1.6)</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>6.0±3.2</td>
<td>18 (8-27)</td>
<td>1.3 (0.6-1.9)</td>
</tr>
<tr>
<td>Renal disease</td>
<td>13.2±3.2</td>
<td>40 (30-49)</td>
<td>2.8 (2.1-3.4)</td>
</tr>
<tr>
<td>Propranolol co-administration</td>
<td>9.4±3.1</td>
<td>28 (19-38)</td>
<td>2.0 (1.3-2.7)</td>
</tr>
</tbody>
</table>


* For obese patients, it has been suggested that loading doses be based on TBW and maintenance infusions be based on IBW. [Abernathy (1984) Am J Cardiol 53: 1183].

** α-1 acid glycoprotein (AAG) concs are elevated in AMI patients. Plasma protein binding of lidocaine is also conc-dependent. Consequently, free concentrations may be more useful for monitoring therapy.

Dosing Adjustments: \[ \frac{\text{c}}{\text{Cl}} = \frac{\text{Kc}}{\text{Cl}} \]

5. Other Factors Which Influence Lidocaine Disposition (See Table above)

Cimetidine co-administration:

Elderly patients:
LITHIUM

1. **Time of Sampling**
   
a. **Relative to Dose**
   
   - At least 12 hours after the previous evening's dose (obtain concentration at same time of day).
   - At steady state ~ 5 days; t½ ~24hrs with normal renal function.

2. **Recommended Frequency of Sampling**
   
a. **Routine Use in Stable Patients**
   
   - Initial level (at steady-state)

b. **Use in Unstable Patients**
   
   - Initial level (at estimated steady-state)
   - Subsequent levels are appropriate with changes in renal function, to assess compliance, addition of concurrent medications that may affect lithium disposition or to assess toxicity.

3. **Therapeutic Range**
   
   - 0.6 to 1.2 mmol/L (Flame Photometry at UKMC)
     
     \( 1 \text{ mmol/L Lithium equals } 1 \text{ mEq/L; } 300 \text{ mg lithium carbonate } = 8.12 \text{ mEq Li} \)
   - Concentrations from 1.2 to 2.0 mmol/L may be warranted in patients with acute mania.
   - Greater than 2.0 mmol/L are considered toxic.

4. **General Guideline for Monitoring**
   
a. **Initial Dosing**
   
   Use population parameters with C-bar equation using

   \[
   CL_s \approx 0.25 \times CL_{cr} \text{ [L/hr]}
   \]

   \[
   V_d \approx 0.8 \text{ L/kg; } t_{1/2} \approx 18 - 24 \text{ hours}
   \]
b. Empiric Dosing

Usually 600 to 1200 mg/day in 3 to 4 divided doses for immediate release dosage forms (once or twice a day for sustained release formulations).

Initial dose for acute mania: 900-1800 mg/day

Single Point Methods

Cooper Nomogram

- 600mg test dose of lithium carbonate
- One lithium serum concentration 24 hours later
- Converts observed lithium concentration to dosage required to achieve a steady-state concentration of 0.6 – 1.2 mmol/L
- Lithium serum concentration must be zero before test dose administration

<table>
<thead>
<tr>
<th>LITHIUM SERUM CONCENTRATION 24 HOURS AFTER TEST (mmol/L)</th>
<th>LITHIUM CARBONATE DOSAGE REQUIREMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.05</td>
<td>1200mg TID (3600mg/d)</td>
</tr>
<tr>
<td>0.05 – 0.09</td>
<td>900mg TID (2700mg/d)</td>
</tr>
<tr>
<td>0.10 – 0.14</td>
<td>600mg TID (1800mg/d)</td>
</tr>
<tr>
<td>0.15 – 0.19</td>
<td>300mg QID (1200mg/d)</td>
</tr>
<tr>
<td>0.20 – 0.23</td>
<td>300mg TID (900mg/d)</td>
</tr>
<tr>
<td>0.24 – 0.30</td>
<td>300mg BID (600mg/d)</td>
</tr>
<tr>
<td>&gt; 0.30</td>
<td>300mg QD (300mg/d)</td>
</tr>
</tbody>
</table>

Perry Nomogram

- 1200mg test dose of lithium carbonate
- One lithium serum concentration 24 hours later
- Converts observed lithium concentration to maintenance dosage for desired steady-state concentration
- If using in acutely manic patient, anticipate a decrease in lithium maintenance dose once patient starts sleeping due to decrease in lithium clearance

![Lithium Maintenance Dose](https://example.com/lithium-graph.png)

**FIGURE.** Lithium nomogram.\(^7\)

Multiple-Point Method

Perry Method

- 600 – 1500mg test dose
- Two lithium serum concentrations 12 and 36 hours after the test dose
- Calculate elimination rate, half-life, accumulation factor, and so on
- Lithium serum concentration must be zero prior to test dose administration

c. Dosing Adjustments using steady-state concentration:

Calculate Lithium Clearance:

\[ \text{Cl}_S = \frac{S \cdot F \cdot X_o}{C_{ss} \cdot \tau} \quad F = \sim 1.0; \quad S = 1.0 \]

Recalculate Lithium dosing regimen:

\[ X_o = \frac{C_{ss} \cdot \text{Cl}_S \cdot \tau}{S \cdot F} \]

5. Factors affecting Lithium concentration

<table>
<thead>
<tr>
<th>Decrease</th>
<th>Variable or no effect</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetazolamide</td>
<td>Amelioride</td>
<td>ACE Inhibitors</td>
</tr>
<tr>
<td>Aminophylline</td>
<td>Aspirin</td>
<td>Ibuprofen</td>
</tr>
<tr>
<td>Caffeine</td>
<td>Furosemide</td>
<td>Indomethacin</td>
</tr>
<tr>
<td>Osmotic diuretics</td>
<td>Sulindac</td>
<td>Chronic lithium therapy</td>
</tr>
<tr>
<td>Pregnancy*</td>
<td></td>
<td>Phenylbutazone</td>
</tr>
<tr>
<td>Sodium supplements</td>
<td></td>
<td>Thiazides</td>
</tr>
</tbody>
</table>

* Lithium clearance and serum concentrations return to pre-pregnant values after delivery.
## Lithium

### Patient Monitoring

<table>
<thead>
<tr>
<th>MONITORING PARAMETERS</th>
<th>BASELINE</th>
<th>12 MONTHS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac ECG Pulse and Blood Pressure</td>
<td>*</td>
<td>*</td>
<td>Patients older than 50 or those with preexisting cardiovascular disease; measure at baseline and every 6-12 months as indicated</td>
</tr>
<tr>
<td>Hematologic CBC with differential</td>
<td>*</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Metabolic/Endocrine Weight Serum electrolytes (Na, K, Ca, Phos) T₃, T₄, free thyroxine index, TSH</td>
<td>*</td>
<td>*</td>
<td>TSH is a better indicator of hypothyroidism and should be obtained every 3-6 months during maintenance therapy if thyroid function tests change, if TSH &gt;4mIU/mL, or if symptoms of hypothyroidism occur.</td>
</tr>
<tr>
<td>Renal function Scr Urinalysis/osmolatity/specific gravity</td>
<td>*</td>
<td>*</td>
<td>Measure Scr in patients with impaired renal function; 24-hour Clcr indicated at baseline with hx of renal disease or abnormally high Scr or significant increases in Scr</td>
</tr>
<tr>
<td>Pregnancy Test In women of childbearing age</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma lithium concentrations</td>
<td></td>
<td></td>
<td>Measure every 1-3 months during maintenance therapy; every 5-7 days after any dosage change or possible drug interactions; less frequent monitoring in stable patients (every 6-12 months)</td>
</tr>
</tbody>
</table>

6. Products on UK Formulary
   - Lithium carbonate SR TAB 450MG
   - Lithium carbonate CAP 300MG
   - Lithium carbonate SR TAB 300MG
   - Lithium carbonate 300MG TAB
   - Lithium citrate LIQ 8MEQ/5ML 500ML

7. References
METHOTREXATE

Rationale for kinetic monitoring
• Clinically relevant concentration-toxicity response
• Administration of an antidote
  – MTX is unique in that the administration of reduced folate compounds (leucovorin) will bypass the biochemical blockade and reverse the cellular damage

Absorption
• Incomplete & erratic absorption from GI tract
  – Highly variable absorption
    • n = 12 pediatric ALL F = 13-76%, DR=13-120mg/m²)
  – **Dose-dependent absorption** (Michaelis-Menten pharmacokinetics)
    • ↑DOSE = ↓F
  – Generally at lower doses (≤ 25mg/m²) F ~100% but still variable
    • Tmax = 1-5hrs, Cmax = 0.25-1.25µM
  – Rate/extent of absorption affected by:
    • Food, oral nonabsorbable antibiotics, shortened intestinal time
• IM injection
  – Less variable, possible alternative if oral route problem

Distribution
• Very polar, requires active transport mechanisms to enter mammalian cells.
• Drug displays a bi or tri-exponential elimination curve resulting in a 2 or 3 compartment model
• Initial Vd ~ 0.2 L/kg
• Apparent Vd ~ 0.7 L/kg (variable, incr. w/higher concs. due to saturation of active transport system)
• Third spacing (e.g. by ascites or pleural effusion) creates a site of storage and “sustained release” of drug
  – Results in prolonged elevation of plasma concentrations and more severe toxicity and additional doses of antidote
• 50% bound to plasma proteins (albumin)
  – Potential drug interactions:
    • Sulfonamides
    • Salicylate
    • Chloramphenicol
    • Phenytoin
• CSF relatively impermeable, CSF concentrations 3% of plasma concentration; intrathecal administration is usually required

Metabolism
• Metabolism is minimal; 3 metabolic pathways
  – Intracellular polyglutamylation
    • Important pathway for selective retention of folates
    • Addition of up to 5 additional glutamate residues by the enzyme folyl polyglutamate synthetase (FPGS)
    • ACTIVE metabolite, contributes to cytotoxicity
    • Polyglutamylated MTX is potent DHFR inhibitor as MTX
Methotrexate

- Hydroxylation
  - 7-hydroxy metabolite (low H₂O solubility) can accumulate leading to nephrotoxicity
  - 1/100th the affinity for DHFR (inactive)
- Removal of glutamate residue (DAMPA)
  - Conversion performed by intestinal bacteria
  - Low levels in plasma may interact with MTX assay but NOT clinical significant

Excretion
- Excreted unchanged in the urine with minor biliary secretion
- Bi or tri-exponential elimination (see figure below)
  - $\alpha \ t^{1/2} \sim 3 \text{ hrs}$
  - $\beta \ t^{1/2} \sim 10 \text{ hrs}$ - not apparent until concentrations $< 5 \times 10^{-7}$ molar
- Primarily renal eliminated
  - Combination of GFR & TS
- At low concentrations correlates with GFR
  - $\text{MTX } Cl_{(\text{ml/min})} \sim 1.6 \times Clcr_{(\text{ml/min})}$
  - Normal MTX Cl = 40-400ml/min
- High concentrations saturation of TS which ↓ net renal Cl
  - RENAL FUNCTION MOST IMPORTANT DETERMINANT OF MTX PHARMACOKINETICS
- Hydration status and urine pH
  - More acidic pH = decreased Cl
- Drug interactions:
  - Reduce renal blood flow (e.g. NSAIDs)
  - Inhibit renal transport of MTX (e.g. sulfisoxazole, weak acids)
  - Nephrotoxic (e.g. cisplatin)

Adapted from Winters ME. Basic Clinical Pharmacokinetics, 3rd Edition.
MTX is usually administered in mg or gm doses

- PLEASE NOTE: THERE MAY BE PATIENT-SPECIFIC DOSING PROTOCOLS THAT NEED TO BE CONSIDERED WITH MTX DOSING AND MONITORING. Please refer to patient-specific protocol when applicable. 
- Pediatric MTX serum levels and Leucovorin rescue dosing are based on COG protocols. Any change in leucovorin dosing requires approval by attending. 
- Low dose 15-20mg/m² twice weekly up to high dose 1-12 g/m² every 1-3 weeks 
- Plasma concentrations are reported in units of mg/L, µg/mL, and molar or micromolar units (usual range 10⁻⁸ to 10⁻⁴). MW = 454gm/mole 
- 1 micromolar would be equivalent to the following:  
  - 1µM (micromolar)  
  - 0.01 X 10⁻⁴ molar  
  - 0.1 X 10⁻⁵molar  
  - 1.0 X 10⁻⁶ molar  
  - 10 X 10⁻⁷ molar  
  - 0.454 mg/L

**Therapeutic/toxic plasma concentrations**

- Normal therapeutic range – variable
- Toxic plasma range (increased risk)  
  >10 X 10⁻⁶ molar (10 µM) at 24 hrs  
  >1 X 10⁻⁶ molar (1µM) at 48 hrs  
  >0.1 X 10⁻⁶ (0.1µM) or 1 X 10⁻⁷ at 72 hrs
- **NOTE:** This is time after beginning of MTX infusion

**Toxicities**

- Cytotoxic effects due to inhibition of DHFR  
  — Function of both concentration & duration of exposure
- Pancytopenia (sometimes irreversible)  
- Severe mucositis  
- GI and skin desquamation  
- Renal and hepatic dysfunction

**Leucovorin rescue**

- To ensure that MTX toxicities do not occur, rescue factor (citrovorin factor or leucovorin) is administered every 4-6 hours in doses that range from 10 to 500 mg/m². 
- Usual course is 12 to 72 hours until the plasma concentration of MTX falls below the critical value of 1 X 10⁻⁷ molar. 
- If MTX conc. > 1X10⁻⁶ molar at 48 hours, leucovorin rescue dose is usually increased to 50 to 100mg/m² every 3-6 hours until concentration < 1 X 10⁻⁷ molar; also see alternative dosing below:

<table>
<thead>
<tr>
<th>MTX serum concentration ≥42 hr from beginning of infusion</th>
<th>Approximate leucovorin dose required</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-50 µmol</td>
<td>500 mg/m² IV q6hr</td>
</tr>
<tr>
<td>10-20 µmol</td>
<td>200 mg/m² IV q6hr</td>
</tr>
<tr>
<td>5-10 µmol</td>
<td>100 mg/m² IV q6hr</td>
</tr>
<tr>
<td>1-5 µmol</td>
<td>30 mg/m² IV or PO q6hr</td>
</tr>
<tr>
<td>0.6-1 µmol</td>
<td>15 mg/m² PO q6hr</td>
</tr>
<tr>
<td>0.1-0.5 µmol</td>
<td>15 mg/m² PO q12hrs</td>
</tr>
<tr>
<td>0.05-0.1 µmol</td>
<td>5-10 mg/m² PO q 12hrs</td>
</tr>
</tbody>
</table>

PENTOBARBITAL

1. Time of Sampling

   a. Relative to Dose

      2-3h after load (not recommended)
      12 and 24h after maintenance infusion begins (not recommended)

2. Recommended Frequency of Sampling

Dose is based on pharmacologic response (intracranial pressure (ICP) control and electrical burst suppression on EEG), therefore concentrations are usually not warranted to assess efficacy or toxicity.

Serum concentrations may be helpful in determining the persistence of a drug-induced coma after the pentobarbital infusion has been discontinued.

For example, a severe traumatic brain injury patient recently taken off of pentobarbital, but still not demonstrating any neurologic motor function. A serum concentration approximately 24-72 hours after discontinuation of the infusion should provide some idea as to if the persistent lack of neurologic function is due to the patient’s injury or due to continued neurologic suppression from pentobarbital.

3. Therapeutic Range*

   20-40 mcg/ml (therapeutic coma)

   *Variable. Titration to individual patient response (based on neurologic and hemodynamic factors) is required. Therapeutic benefits at levels > 50 mg/ml are yet unproven.

4. General Guidelines for Monitoring

Initial Dose and Infusion (Modified from Eisenberg protocol):

<table>
<thead>
<tr>
<th>Dose</th>
<th>New way</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Loading dose</td>
<td>10 mg/kg IV x1 slow IVP or slow infusion</td>
</tr>
<tr>
<td>Secondary loading dose</td>
<td>6 mg/kg/hr x3 hrs</td>
</tr>
<tr>
<td>Infusion</td>
<td>Reduce rate to 1-2 mg/kg/hr after initial 3hrs of 6 mg/kg/hr</td>
</tr>
</tbody>
</table>

This is a modified version of the Eisenberg protocol that combines the secondary loading doses with the infusion rate to give the secondary load slower to avoid hypotension & make the dosing easier & less error prone.
5. **Dosage Adjustments**

Mini-boosts of 1-5 mg/kg may be given for breakthrough ICP increases. Typically 1-5 mg/kg bolus will lead to an increase in the serum concentration by 1-5 mcg/ml.

Titrate maintenance infusion rate according to clinical response (typically ICP control or cessation of seizure activity).

The following conditions must be met prior to pharmacist involvement in pentobarbital monitoring:

a. Patient must be on a ventilator.

b. An ICP monitor must be in place with an initial pressure reading recorded (goal ICP typically < 20)

c. A CVP line and arterial line should be in place. Cardiac output monitoring should also be considered in some patients. Some patients may not require invasive hemodynamic monitoring. It is recommended to have a vasopressor such as norepinephrine or dopamine on-hand during loading in case of hypotension.

d. A urinary catheter must be in place.

e. Monitoring of cerebral electrical activity via continuous EEG (or BIS monitor as temporary substitute) is recommended.

6. **Factors Altering Pentobarbital Disposition**

Renal failure and dialysis - no specific dosage adjustment appears necessary.


Wermeling (1985) Ther Drug Monit. 7:485.

No specific guidelines or recommendations are available for other patient subpopulations.

Pentobarbital induces the metabolism of other oxidatively metabolized drugs (e.g., phenytoin, corticosteroids). Enzyme inhibitors (e.g. cimetidine) may decrease pentobarbital Cls. Prolonged pentobarbital infusions (typically > 6-7 days) may result in auto-induction & increased dose requirement.

Patients with traumatic brain injury may have an elevated dose requirement due to disease-induced enzyme induction (therefore, typically the Eisenberg protocol is used).
7. **Pediatric Considerations**
   Same as adults

8. **Other Suggested References**
   Heinemeyer (1986) Ther Drug Monit 8:145.
PHENOBARBITAL

1. Time of Sampling
   a. Relative to Dose
      • Trough within 1h prior to dose; any consistent time within dosing interval is acceptable due to long $t_{1/2} \sim 5$ days.
      • at ss $\sim 3 – 5$ weeks

2. Recommended Frequency of Sampling
   a. Routine Use in Stable Patients
      • initial level
   b. Use in Unstable Patients*
      • initial level
      • repeat level, as dictated by changes in concurrent disease state/drug therapy or the lack of adequate response to previously adequate doses, or signs/symptoms of toxicity. Patients in status epilepticus require more intensive monitoring.

   Note: Since at least 15 to 20 days are required to achieve steady state, a loading dose is usually given to rapidly place the patient in the therapeutic range. Levels obtained prior to steady state may be useful in verifying if actual level is close to predicted level (e.g. if 20 mcg/ml is the predicted steady state value, it will take one $t_{1/2}$ to reach a level of 10 mcg/ml).

3. Therapeutic Range
   10 – 40 µg/ml
   5 – 15 µg/ml (saliva)

4. General Guidelines for Monitoring
   a. Initial Dosing
      Load: $X_0^* = \frac{C \cdot V}{S \cdot F}$
      \[ V = 0.7 \text{ L/Kg (adults)} \]
      \[ S = 0.9 \text{ (sodium salt)} \]
      \[ F = 1.0 \]
      or
      20 mg/kg
      *Infusion rate should not exceed 65 mg/min. Respiratory status should be closely monitored.*
b. **Maintenance Dose:**

Usual adult dose: 1-3mg/kg/day in divided doses

\[
X_0 = \frac{c \cdot Cl_s \cdot \tau}{S \cdot F}
\]

- $S = 0.9$ (sodium salt)
- $F = 1.0$
- $Cl_s = 0.096 \text{ L/Kg/D (adults with normal hepatic function)}$

It is common practice to give 25% of the total maintenance dose for one week, ↑ to 50% the second week, ↑ to 75% the third week, and ↑ to the full dose the fourth week to minimize toxicity.

$c$ (at ss) produced by any given maintenance dose is approximately 10 times the daily dose in mg/kg (e.g. 2 mg/kg - 20 mcg/ml).

For patients with liver disease, empirically decrease maintenance dose of phenobarbital by 30%.

c. **Dosing Adjustments**

Calculate actual $Cl_s$, based on $c$ (level, usually obtained at trough), $\tau$, $S$, $F$, and $X_0$ (dose administered). Calculate new maintenance dose.

5. **Factors Influencing Phenobarbital Disposition**

Liver disease: [Alvin (1975) J Pharmacol Exp Ther 192:224].

Pharmacokinetic interactions: PB induces metabolism of other oxidatively metabolized drugs (e.g. carbamazepine, phenytoin, warfarin, steroids, theophylline) but PB itself does not require dosage adjustment. Exceptions include: valproic Acid and chloramphenicol which inhibit PB metabolism and require an empiric PB dosage adjustment downward by 50%.

Pregnancy: ↑ PB $Cl_s$

6. **Pediatric Guidelines:**

**Neonates**

**Loading Dose (Status epilepticus, neonatal seizures):** 15-20 mg/kg/dose; $Vd = 0.7-1.2 \text{ L/Kg}$ – some patients may require additional bolus doses of 5-10 mg/kg/dose based on clinical response (max loading dose 40 mg/kg)

**Maintenance Dose (Seizures):** 3-5 mg/kg/day
Infants and Children

**Loading dose (Status epilepticus):**
- Infants, Children, and Adolescents: IV: Initial: 15-20 mg/kg; maximum dose: 1000 mg; may require additional bolus dose based on clinical response (after 10-15 minutes if needed; maximum total dose: 40 mg/kg;  
  - Vd = 0.6-0.9 L/Kg (Vd in older children approaches that of adults)  
  - Repeat doses administered sooner than 10-15 minutes may not allow adequate time for peak CNS concentrations to be achieved and may lead to CNS depression (Brophy, 2012; Hegenbarth, 2008).  
- Additional respiratory monitoring and support may be required particularly when maximizing loading dose or if concurrent sedative therapy.

**Maintenance Dose (Seizures):**
- Maintenance dose usually starts 12 hours after loading dose:  
  - Usual dosing range: 3-8 mg/kg/day (Lexicomp – Pediatric Dosing)  
    - Infants 5-6 mg/kg/day in 1-2 divided doses  
    - 1-5 years: 6-8 mg/kg/day in 1-2 divided doses  
    - 5-12 years: 4-6 mg/kg/day in 1-2 divided doses  
    - Adolescents: 1-3 mg/kg/day in 1-2 divided doses  
- **Dosage should be individualized based upon clinical response and serum concentration**

**Other Considerations**
Infusion rate should not exceed 1 mg/kg/min (30 mg/min maximum for infants/children and 60 mg/min maximum for ≥ 60kg). Normal loading doses should be administered over 15-20 min. Respiratory depression is more commonly seen in patients who have recently received chloral hydrate or parenteral benzodiazepines prior to initiation of phenobarbital therapy.

Tablet and elixir dosage forms are interchangeable.

**Dosage forms available:**
- **Elixir:** 4mg/ml, 30mg/7.5ml, 20mg/5ml, 15mg/3.75ml
- **Injection:** 10mg/ml
- **Tablets:** 15mg, 30mg, 60mg, 100mg
PHENYTOIN

1. Time of Sampling
   a. Relative to Dose
      ▪ ~ 2 hours after IV loading dose
      ▪ Trough within 1 hr prior to a scheduled maintenance dose
      ▪ At steady state (The time to achieve steady state is variable, ranging from 3 to 50 days, due to saturation kinetics).
        − After oral administration of Kapseals: average half-life ~ 22 hrs
          (Prod Info Kapseals® Dilantin®, 2000) but can range from 7 to 42 hrs; value is variable due to the saturation kinetics
        − After intravenous administration, half-life ranges from 10 to 15 hrs
          (Prod Info Phenytoin Sodium Injection, USP, 2000).

2. Recommended Frequency of Sampling
   a. Routine Use in Stable Patients
      ▪ One steady-state concentration
      ▪ Repeat concentration at steady-state after each dosage adjustment
   b. Use in Unstable Patients
      ▪ After a loading dose, an initial level may be drawn to assess attainment of therapeutic concentrations. (Recommended to be drawn ~2 hours after IV LD and 6-8 h after oral LD).
      ▪ Trough in 3 to 4 days
      ▪ Weekly thereafter
      ▪ The frequency of sampling is also dictated by:
        ▪ Changes in concurrent disease states or drug therapy
        ▪ Lack of adequate response to previously adequate doses
        ▪ Signs/symptoms of toxicity
      ▪ Patients with recurrent status epilepticus require more intensive monitoring

3. Therapeutic Range

Total: 10-20 µg/mL (assuming normal albumin)

Free: 1-2 µg/mL (normal; at body temperature)
0.8 – 1.6 µg/mL* (therapeutic range reported by UKCMC Clinical Lab)

*The reported free concentration at UKCMC is adjusted since the assay is performed at room temperature which alters protein binding.

Saliva: 1-2 µg/mL
4. **General Guidelines for Monitoring**

a. **Loading Dose**

Use **TBW** unless patient is obese (>125% IBW).
If obese: adjusted weight = IBW + (1.33)(TBW-IBW).

```
\[
X'_o = \frac{C \cdot V}{S \cdot F}
\]

V = 0.7 L/kg
S = 0.92 (sodium salt; caps, inject)
F = 1.0 (acid; chewtabs, suspension)

OR

\[
X'_o = 18-20 \text{ mg/kg}
\]

- NOTE that fosphenytoin is preferred dosage form for intravenous administration

- May be administered as one dose, or in 3 divided doses given q 4 h (IV or PO); **Suggested max single oral dose = 400mg due to delayed absorption with higher doses.**

- IV phenytoin infusion rate is usually 10-25 mg/min, although some patients may tolerate up to 50 mg/min (**MAXIMUM RECOMMENDED RATE**). Blood pressure should be checked q 5 min x 3, then q 15 min until 1 hr after the end of the infusion. Fosphenytoin infusion rate is up to 150mg/min.

- When administered on a floor, please refer to floor policy on infusion rate. Some nursing areas may limit max infusion to 10mg/min due to potential for hypotension as result of propylene glycol diluent. Blood pressure should be checked q 15 - 20 min.
b. Maintenance Dose

1. Initial

- Empirically based on body weight: **5-7 mg/kg/day**

*For obese patients, the maintenance dose should be based on IBW.*

- Alternative: Ludden Method and estimate both $K_m$ and $V_m$ from Appendix 1.

\[
Dose = \frac{(V_m) \cdot (C_{ss}) \cdot (\tau)}{(K_m + C_{ss}) \cdot (S) \cdot (F)} \quad F = 1.0 \quad S = 0.92
\]

*If hypoalbuminemia, use the ADJUSTED CONCENTRATION (see 6A)*


Assumptions:
1. Steady state
2. Patient compliance
3. Normal renal and hepatic function
4. Normal albumin

On basis of a **single concentration** at **steady state** with the same dose:

\[
(S) \cdot (F) \cdot \frac{Dose}{\tau} = \frac{(V_m) \cdot (C_{ss})}{(K_m + C_{ss})}
\]

$C_{ss} =$ measured concentration

$Dose =$ present dose

Usually assume $K_m$ (less variable) and rearrange the above equation to estimate $V_m$ using the single steady-state concentration:

\[
V_m = \frac{(S) \cdot (F) \cdot \left(\frac{Dose}{\tau}\right) \cdot (K_m + C_{ss})}{(C_{ss})}
\]

Then calculate a new dosage using the equation below by using the assumed $K_m$, the calculated $V_m$ and the desired concentration and $\tau$.

\[
Dose = \frac{(V_m) \cdot (C_{ss}) \cdot (\tau)}{(K_m + C_{ss}) \cdot (S) \cdot (F)} \quad C_{ss} =$ desired concentration

$Dose =$ new dose

Recalculate $C_{ss}$ after rounding dose:

\[
C_{ss} = \left(\frac{Dose}{\tau}\right) \cdot (S)(F)(K_m)
\]

\[
(V_{max}) - \left[\left(\frac{Dose}{\tau}\right)\cdot (S)(F)\right]
\]
3. **Mini-loading**

Used when patient has sub-therapeutic concentration, to immediately put patient in the therapeutic range before starting new maintenance dose.

\[
\text{Mini-loading dose} = \frac{(V_d) (C_{ss \ \text{desired}} - C_{ss \ \text{measured}})}{S \cdot F}
\]

4. **Toxic levels**

Used when concentration is too high, to determine how long (t) until patient achieves concentration in therapeutic range (C); \(C_0\) = measured concentration.

\[
t_{(\text{days})} = \frac{[K_m \times (\ln \frac{C_o}{C}) \times (C_o - C)]}{V_{max} \times V_d}
\]

(integrated form of Michaelis-Menten equation)

5. **Pediatric Guidelines**

- \(V_d\) – 1-1.2 L/kg (neonates)
  
  0.8-0.9 L/kg (term)
  
  0.7 L/Kg (infants/children)

- \(K_m = 3-9\text{mg/L}; V_m = 5-20\text{mg/kg} (\text{infants/children})\)

- Loading dose: 18-20mg/kg

- Maintenance dose: Initial 5 mg/kg/day; titrated to usual range 6-10 mg/kg/day based on patient age
  
  - Maintenance dose should be administered in 2-3 divided doses (some pediatric patients may require q8hr dosing due to increased clearance; once-daily dosing is usually not possible)

- Infusion rate: 1-3 mg/kg/min (50 mg/min maximum)

- **REMEMBER TO SHAKE THE PHENYTOIN SUSPENSION BOTTLE WELL TO PROVIDE CONSISTENT DOSE!**

- Stagger dosing (at least one hour) with feedings - if on formula (decreases absorption - similar to enteral feeding products)

- Avoid phenytoin in neonates with indirect hyperbilirubinemia requiring phototherapy
6. Other Factors That May Influence Phenytoin Disposition

a) Hypoalbuminemia (normal albumin = 3.2 – 4.6 g/dL):

- ↓ Protein binding sites
- ↑ Free fraction (ff)
- ↓ Total concentration (will not be reflective of free concentration of 1-2 mcg/ml since free fraction is increased)

The total phenytoin concentration*,** can be adjusted to account for the decrease in albumin using the following equation:

\[
C_{\text{predicted}} = \frac{C_{\text{observed}}}{(0.25 \times \text{alb}) + 0.1} \quad C_{\text{predicted}} = C_{\text{total}} \text{ adjusted for } \downarrow \text{ albumin} \quad C_{\text{predicted}} = \text{observed phenytoin concentration}
\]

*Based on protein binding when determined at room temperature (25º C).
**Note this equation is not applicable when other factors affecting protein binding are present such as concomitant valproic acid


The free fraction can also be adjusted using the following equation:

\[
f_{\text{ub}} = \frac{1}{1 + (2.1 \times \text{alb})}
\]


b) Uremia - displacement from protein binding sites

- ↑ free fraction
- ↓ total concentration needed to achieve free phenytoin concentration of 1-2 mcg/ml

\[
V_d \ (\text{Adjust } V_d \text{ for low albumin):} \quad V_d \ (L/kg) = \frac{6.5}{1 + \text{alb}}
\]

c) Obesity

↑ Vd (Use 0.7 L/kg)
 ↔ Free fraction unchanged
 ↔ Clearance unchanged


d) Elderly

↓ $V_m$ (about 21% less phenytoin per day is required to maintain $C_{ss}$ of 15 mcg/ml)
↑ free fraction
↓ total concentration needed to achieve free phenytoin concentration of 1-2 mcg/ml


e) Critically ill

↔ Vd unchanged
↔ $K_m$ unchanged
↑ $V_{\text{max}}$ increases over time in patients with brain injury, other critical illness
↑ free fraction may increase with time (even when albumin is unchanged)
↓ total and free conc. may decrease with time, warranting higher maintenance doses.


f) Drug interactions - several types (phenytoin substrate for CYP 2C9/2C19).

- Displacement from protein binding sites results in ↓ total conc. needed to achieve free conc. of 1-2 mcg/ml. ex. -valproic acid, phenylbutazone, aspirin and sulfa drugs.
- Enzyme Inducers - increase phenytoin Cl ex. -phenobarbital, carbamazepine and folic acid
- Enzyme Inhibitors - decrease phenytoin Cl ex. -cimetidine, chloramphenicol, valproic acid, disulfiram and isoniazid
- Phenytoin is also a potent enzyme inducer and increases Cl of many drugs including theophylline, oral anticoagulants and steroids.
- **HOLD TUBE FEEDS 1 HR BEFORE AND 1 HR AFTER PHENYTOIN SUSPENSION DOSE PER FEEDING TUBE. ADJUST TUBE FEED RATE ACCORDINGLY.**
7. Other Selected References


8. Population Parameters Appendix I.

APPENDIX 1
PHENYTOIN PHARMACOKINETICS

<table>
<thead>
<tr>
<th>AGE (years)</th>
<th>Vmax (mg/kg/day)</th>
<th>Km (mg/L)</th>
<th>Vd (L/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-39</td>
<td>7.5</td>
<td>5.7</td>
<td>0.7</td>
</tr>
<tr>
<td>40-59</td>
<td>6.6</td>
<td>5.4</td>
<td>0.7</td>
</tr>
<tr>
<td>60-79</td>
<td>6.0</td>
<td>5.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Pediatric</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5-3</td>
<td>14.0</td>
<td>6.6</td>
<td>0.7</td>
</tr>
<tr>
<td>4-6</td>
<td>10.9</td>
<td>6.8</td>
<td>0.7</td>
</tr>
<tr>
<td>7-9</td>
<td>10.1</td>
<td>6.5</td>
<td>0.7</td>
</tr>
<tr>
<td>10-16</td>
<td>8.3</td>
<td>5.7</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Dosage forms available:
Capsule 30mg, 100mg
Chewtab 50mg
Suspension 125mg/5ml (5mg/ml)
Injection 100mg/2ml (50mg/ml)
FOSPHENYTOIN

Introduction
- Water soluble prodrug intended for parenteral administration
- Active metabolite is phenytoin
- **Dose should be expressed, labeled, and ordered in phenytoin equivalents (PE).** 1.5mg fosphenytoin = 1mg phenytoin sodium but on vial FOSPHENYTOIN is written as PE/ml, not mg/ml.
- Costs of fosphenytoin and intravenous phenytoin are similar
- Potential advantages:
  1. Less phlebitis & local tissue damage at injection site (fewer return visits, lower tx costs, & fewer lawsuits)
  2. Less risk of hypotension with rapid IV loading
  3. Less frequent need to restart IV lines due to local irritation
  4. Elimination of need of filter in IV line
  5. IM administration possible
  6. Greater patient satisfaction due to less morbidity

Absorption/Bioavailability
- IV: max concentrations achieved after at the end of infusion but
- IM: peak concs ~ 30min post dose

Distribution
- 95 – 99% protein bound, primarily albumin
- increases with dose/rate, ranges from 4.3 to 10.8L

Metabolism/Elimination
- phenytoin cleaved from the prodrug by phosphatase enzymes
- conversion t½ ~ 8-15 minutes
- complete conversion IV ~ 2hrs; IM ~ 4hrs
- NO drugs are known to interfere with the conversion

Dosing Guidelines & Monitoring
- Dosage similar to phenytoin BUT use PHENYTOIN EQUIVALENTS
- Because of risk of hypotension, **NOT recommended to exceed 150 PE/min and for pediatrics rate should not exceed 3 PE/kg/min (max 150 PE/min)**
- Need to wait **at least 2 hours after IV dose and 4 hours after IM dose** for complete conversion to measure serum concentrations

Suggested patient criteria for administration of fosphenytoin*:
  1. Age: <7yo or >60yo
  2. History of underlying cardiovascular problems or preexisting hypotension)
  3. Chronic or acute debilitating illness, emaciation, hyponatremia, peripheral vascular disease, hemodynamic instability, or sepsis
  4. Poor intravenous access qualified by one of the following: size smaller than the antecubital fossa vein, catheter size < 20 gauge, no preexisting central venous catheter
  5. Pain intolerance with phenytoin sodium recognized.

FREE PHENYTOIN

Appendix II.

Free phenytoin concentrations should be reserved for the situations described below. For example, a "normal" patient with normal albumin and normal renal function who is not on concurrent medications that alter phenytoin protein binding or clearance would not warrant a free phenytoin concentration.

A free phenytoin concentration is warranted when:

1. The total phenytoin dosage is >7 mg/kg/day and the total concentration is <10 mcg/ml.
   or

2. A patient is seizure-free at a total level of <10 mcg/ml and you need to determine whether a dosage increase is necessary.
   or

3. A patient is exhibiting signs of toxicity at a dosage of <7 mg/kg/day and has a total concentration of <20 mcg/ml.
   or

4. A patient is in a unique subpopulation (e.g. a pregnant female, a patient on multiple anticonvulsant therapy, pediatric patients < 6 months)
Modified Michaelis – Menten Equation for adjusting phenytoin dosage based on steady-state free concentration.

- Use a steady-state free concentration ($C_{ss}^{free}$) to calculate free fraction ($f_{ub}$) = $\frac{C_{ss}^{free}}{C_{ss}^{total}}$.

- Use $C_{ss}^{free}$, $f_{ub}$, $K_o$, and population $K_m$ to calculate $V_m$ (mg/day) with equation #4.

- Use the desired $C_{ss}^{free}$ (UKCMC range: 0.8-1.6mg/L), $f_{ub}$, $V_m$, and $K_m$ to calculate for a new dosage, $K_o$ (mg/day) with equation #3.

---

**Derivation of the Modified Michaelis - Menten Equation:**

1.) $\frac{K_o}{f_{ub}} = \frac{V_m \cdot C_{ss}^{total}}{f_{ub} \cdot (K_m + C_{ss}^{total})} = \frac{V_m \cdot C_{ss}^{total}}{(f_{ub} \cdot K_m) + (f_{ub} \cdot C_{ss}^{total})}$

Multiply both sides by $f_{ub}$:

2.) $K_o = \frac{V_m \cdot (C_{ss}^{total} \cdot f_{ub})}{f_{ub} \cdot (K_m + C_{ss}^{total})}$

Substitute $C_{ss}^{free}$ for $(C_{ss}^{total} \times f_{ub})$:

3.) $\therefore K_o = \frac{V_m \cdot C_{ss}^{free}}{(f_{ub} \cdot K_m) + C_{ss}^{free}}$

---

Equation rearranged to solve for $V_m$:

4.) $V_m = \frac{K_o \cdot [(f_{ub} \cdot K_m) + C_{ss}^{free}]}{C_{ss}^{free}}$

---

THEOPHYLLINE

1. Time of Sampling

a. Relative to Dose

• Oral (tablet, liquid, S-R preps with duration of absorption < $\tau$, e.g. Slo-Phyllin Gyrocaps).
  • trough within 1h prior to dose

• S-R preps or continuous infusion with duration of absorption ≥ $\tau$ e.g. Theodur
  S-R preps:
  • tr within 1h prior to dose; any consistent time within dosing interval is acceptable if S-R preparation.
  
  Continuous infusion:
  • Single level
    > 24h after dosage adjustment made during continuous infusion (w/o bolus).
  • Multiple levels (for use with Chiou equation):
    Continuous infusion (w/o bolus): anytime during true zero-order infusion with 2 levels separated optimally by one $t^{\frac{1}{2}}$.
    Continuous infusion (with bolus): ≥ 1 hour after bolus as 1st sampling time and one $t^{\frac{1}{2}}$ later as 2nd sampling time.

• Intermittent injection
  • trough within 1h prior to dose

b. Relative to Steady State

After at least 4-5 half-lives (normal $t^{\frac{1}{2}}$ ~8-9hrs)
2. **Recommended Frequency of Sampling**
   a. **Routine Use in Stable Patients**
      - initial level
   b. **Use in Unstable Patients***
      - initial level
      - repeat level every 2 to 3 days
   *The frequency of sampling is dictated by changes in concurrent disease state/drug therapy or the lack of adequate response to previously adequate doses, or signs/symptoms of toxicity. Patients in acute respiratory distress require more intensive monitoring.

3. **Therapeutic Range**
   - 5-15 mcg/ml for asthma
   - 6-12 mcg/ml for apnea of prematurity

4. **General Guidelines for Monitoring**
   a. **Initial Dosing**

<table>
<thead>
<tr>
<th>Age</th>
<th>Loading Dose mg/kg (IBW)*</th>
<th>Maintenance Dose mg/kg/hr (IBW)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (6 weeks – 12 months)</td>
<td>5.7 (4.6)</td>
<td>[(0.008Xage in weeks) + 0.21]/0.79</td>
</tr>
<tr>
<td>Children (1 year – &lt; 9 years)</td>
<td>5.7 (4.6)</td>
<td>1.01 (0.8)</td>
</tr>
<tr>
<td>Children (9 – &lt; 12 years) &amp; young adult smokers</td>
<td>5.7 (4.6)</td>
<td>0.89 (0.71)</td>
</tr>
<tr>
<td>Children (12 - &lt; 16 years)</td>
<td>5.7 (4.6)</td>
<td>0.63 (0.5)</td>
</tr>
<tr>
<td>Otherwise healthy nonsmoking adults</td>
<td>5.7 (4.6)</td>
<td>0.51 (0.4)</td>
</tr>
<tr>
<td>Cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock</td>
<td>5.7 (4.6)</td>
<td>0.25 (0.2)</td>
</tr>
</tbody>
</table>

*Equivalent anhydrous theophylline dose in parenthesis

<table>
<thead>
<tr>
<th>Age</th>
<th>Initial Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Final Dosage&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature neonates:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24 days postnatal</td>
<td>1 mg/kg every 12 hrs</td>
<td></td>
</tr>
<tr>
<td>≥24 days postnatal</td>
<td>1.5 mg/kg every 12 hrs</td>
<td>Dosage should be adjusted based on serum theophylline concentrations to obtain peak steady-state serum theophylline concentrations of 5-10 mg/L for neonates and 10-15 mg/L for infants and older children.</td>
</tr>
<tr>
<td>Full term infants up to 1 yr</td>
<td>Total daily dosage (mg) = [(0.2 x age in weeks) + 5] x (body weight kg) ≤ 26 weeks: divided q8hrs &gt; 26 weeks: divided q6hrs</td>
<td></td>
</tr>
<tr>
<td>Children 1 – 15 yrs&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12 – 14 mg/kg/day divided q4-6hrs (Maximum: 300 mg/day)</td>
<td>After 3 days, if tolerated: 16 mg/kg/day divided q4-6hrs (Maximum: 400 mg/day) After 3 more days, if tolerated: 20 mg/kg/day divided q4-6hrs (Maximum: 600 mg/day)</td>
</tr>
<tr>
<td>&lt; 45kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 45kg and Adults (16 – 60 yrs)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>300 mg/day divided q6-8hrs</td>
<td>After 3 days, if tolerated: 400 mg/day divided q6-8hrs After 3 more days, if tolerated: 600 mg/day divided q6-8hrs</td>
</tr>
</tbody>
</table>

<sup>a</sup> If trough concentrations are low before the next dose, then slow-release products may decrease the fluctuation and permit longer dosing intervals.

<sup>b</sup> Products containing an aminophylline salt should divide the listed dose by 0.8.

<sup>c</sup> Children 1 – 15 years of age, the initial theophylline dose should not exceed 16 mg/kg/day up to a maximum of 400mg/day in the presence of risk factors for reduced theophylline clearance or if not feasible to monitor serum theophylline concentrations.

<sup>d</sup> In adolescents ≥ 16 years, the initial theophylline dose should not exceed 400mg/day in the presence of risk factors for reduced theophylline clearance or if not feasible to monitor serum theophylline concentrations.

**Initial dosing using volume of distribution:**

- **Load dose:** \( X_0 = C \times V_d \)  
  Assume \( V = 0.5 \) L/kg
b. Concentration Predictions/Dosage Adjustments

\[ \text{S-R (e.g. Theodur)} \]
\[
C = \frac{F \cdot S \cdot X_0}{Cl_s \cdot t} \\
S = 1; F = 1
\]

**Continuous infusion**
\[
C = \frac{S \cdot K_o \cdot (1 - e^{-Kt})}{Cl_s} \\
S = 0.8, \text{ if aminophylline} \\
K = Cl_s/V
\]

\[
C = \frac{S \cdot K_o}{Cl_s} \quad \text{at ss}
\]

The Chiou equation may be used to calculate Cls, prior to reaching ss. Basic assumptions: (1) known V; (2) true zero-order infusion between 2 sampling points (C1 and C2). Obtain two levels at 1 and 9h after starting infusion (optimally, one t 1/2 apart).

\[
Cl_s = \frac{2 \cdot K_o \cdot 0.8}{C_1 + C_2} + \frac{2 \cdot V \cdot (C_1 - C_2)}{(C_1 + C_2) \cdot (t_2 - t_1)}
\]

**Oral (rapidly absorbed product)**

\[
C_{tr}^{ss} = C_{pk}^{ss} \cdot e^{-Kt} = \frac{S \cdot F \cdot X_0}{V} \cdot e^{-Kt} \cdot \left( \frac{1}{1 - e^{-Kt}} \right)
\]

**Changing from iv to oral S-R prep (e.g. Theodur)**

Administer oral S-R prep; d/c IV 1 to 2 h later.
5. Selected factors altering theophylline clearance

<table>
<thead>
<tr>
<th>Subpopulation</th>
<th>V (L/kg)</th>
<th>Cl (L/kg/h)</th>
<th>Cls* Factor</th>
<th>t½ (h)</th>
<th>Maintenance Dose (mg/kg/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Amino-phylline</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AGE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmoking adult</td>
<td>0.5</td>
<td>0.040</td>
<td>1.0</td>
<td>8.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Premature infant (3-15 days)</td>
<td>0.7</td>
<td>0.018</td>
<td>0.4</td>
<td>12-48</td>
<td>0.2</td>
</tr>
<tr>
<td>Premature infant (25-57 days)</td>
<td>0.039</td>
<td>0.06</td>
<td>-</td>
<td>0.3</td>
<td>0.24</td>
</tr>
<tr>
<td>Infant (4-18 months)</td>
<td>0.56</td>
<td>0.089</td>
<td>2.0</td>
<td>4.8</td>
<td>1.0</td>
</tr>
<tr>
<td>Children (1-4 yrs)</td>
<td>0.48</td>
<td>0.100</td>
<td>2.0</td>
<td>3.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Children (6-17 yrs)</td>
<td>0.46</td>
<td>0.087</td>
<td>1.6-2.0</td>
<td>3.7</td>
<td>0.8-1.0</td>
</tr>
<tr>
<td>Elderly (&gt;65 yrs)</td>
<td>0.4-0.5</td>
<td>0.036-0.040</td>
<td>0.87-1.0</td>
<td>7.9-8.7</td>
<td>0.4-0.5</td>
</tr>
<tr>
<td><strong>SMOKING</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cigarettes</td>
<td>0.5</td>
<td>0.064</td>
<td>1.6</td>
<td>5.4</td>
<td>0.8</td>
</tr>
<tr>
<td>marijuana</td>
<td>0.5</td>
<td>0.072</td>
<td>1.8</td>
<td>4.8</td>
<td>0.9</td>
</tr>
<tr>
<td>cigarettes / marijuana</td>
<td>0.5</td>
<td>0.090</td>
<td>2.2</td>
<td>3.8</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>DRUG</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cimetidine</td>
<td>0.5</td>
<td>0.025</td>
<td>0.6</td>
<td>13.9</td>
<td>0.3</td>
</tr>
<tr>
<td>erythromycin</td>
<td>0.5</td>
<td>0.028</td>
<td>0.7</td>
<td>12.4</td>
<td>0.35</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>0.5</td>
<td>0.053</td>
<td>1.2</td>
<td>6.5</td>
<td>0.6</td>
</tr>
<tr>
<td>propranolol</td>
<td>0.5</td>
<td>0.030</td>
<td>0.6-0.8</td>
<td>10.8</td>
<td>0.3-0.4</td>
</tr>
<tr>
<td><strong>DISEASE STATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cirrhosis (bilirubin &lt;1.5)</td>
<td>0.6</td>
<td>0.033</td>
<td>0.8</td>
<td>13-17</td>
<td>0.35-0.4</td>
</tr>
<tr>
<td>cirrhosis (bilirubin &gt;1.5)</td>
<td>0.6</td>
<td>0.011</td>
<td>0.25</td>
<td>41-55</td>
<td>0.13</td>
</tr>
<tr>
<td>congestive heart failure</td>
<td>0.5</td>
<td>0.016</td>
<td>0.4</td>
<td>12-24</td>
<td>0.2</td>
</tr>
<tr>
<td>cor pulmonale</td>
<td>0.5</td>
<td>0.016</td>
<td>0.4</td>
<td>22</td>
<td>0.2</td>
</tr>
<tr>
<td>pulmonary edema</td>
<td>0.56</td>
<td>0.017</td>
<td>0.4</td>
<td>22.9</td>
<td>0.2</td>
</tr>
<tr>
<td>viral respiratory illness with COPD, Pneumonia</td>
<td>0.5</td>
<td>0.015</td>
<td>0.4</td>
<td>23</td>
<td>0.2</td>
</tr>
<tr>
<td>severe obstructive pulmonary disease</td>
<td>0.6-0.9</td>
<td>0.032</td>
<td>0.8</td>
<td>13-19</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.032</td>
</tr>
<tr>
<td><strong>WEIGHT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>obesity</td>
<td>0.5</td>
<td>0.04</td>
<td>1.0</td>
<td>8.7</td>
<td>0.5</td>
</tr>
</tbody>
</table>

*The product of all the factors that are present should be multiplied by the average clearance value (0.04 L/kg/h).
6. Pediatric Guidelines

See dosing guidelines.

7. Suggested References for Influences of Pathophysiological States on Theophylline Kinetics

**Age:**

- **adults**

- **premature infants**

- **infants**

- **children**
  - Ellis (1976) Pediatrics 58:542

- **elderly**
  - Chandler (1988) J Geriatric Drug Ther (3:23)

**Smoking:**


**Drug:**

- **cimetidine**

- **erythromycin**

- **propranolol**

- **phenobarbital**
### Disease State:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Reference 1</th>
<th>Reference 2</th>
</tr>
</thead>
</table>

### Weight:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Reference 1</th>
<th>Reference 2</th>
</tr>
</thead>
</table>
VALPROIC ACID

1. Time of Sampling
   a. Relative to Dose
      ♦ trough within 30 min prior to dose
      ♦ at steady state

2. Recommended Frequency of Sampling
   ♦ Initially after reaching steady-state (usually 2-4 days)
   ♦ After each dosage adjustment at steady state
   ♦ Sampling should always be done at the same time before a dose and before the same dose each day. (Preferably before AM dose, due to effects of diurnal variation on clearance).


3. Therapeutic Range
   ♦ 50-100 mcg/ml
   ♦ At times higher concentrations may be recommended by Neurology Service
   ♦ Utility of serum concentration monitoring for valproic acid (VPA) has not been fully determined. This is partially due to concentration-dependent protein binding. It also may take several weeks to achieve a therapeutic effect even after the patient has achieved ss within the therapeutic range. Continued anticonvulsant effects are also seen even after VPA is undetectable in the blood. Studies are controversial in determining an exact relationship between serum concentration and therapeutic effect or toxicity.

4. General Guidelines for Monitoring
   a. Initial Dosing
      ♦ IV loading (see next page)
      ♦ Empiric - 5-10 mg/kg/day
      ♦ Should be given in divided doses, usually TID - due to short t 1/2 and to minimize GI side effects.
      ♦ Utility of QD dosing has been documented, although many patients cannot tolerate the associated GI discomfort.
      ♦ Baseline and follow-up LFTs should be obtained to assess liver toxicity. Hyperammonemia and hyperammonemic encephalopathy; measure ammonia level if unexplained lethargy and vomiting or changes in mental status, and also with concomitant topiramate use; consider discontinuation of valproate therapy
Valproic Acid

### Loading Doses for IV Valproic Acid (Depacon®)

**IV Valproic Acid** has been used in Europe since the 1980s; approved in USA in 1997.

Indicated as an intravenous alternative when oral administration of maintenance doses are temporarily not feasible. Not systemically studied as initial therapy. There are no established guidelines for the use of IV valproic acid as a loading dose.

Recommended doses from package insert: Complex partial seizures: 10-15 mg/kg/day, incr. 5 – 10 mg/kg/week with usually max ~ 60 mg/kg/day. Simple and complex absence seizures 15 mg/kg/day, increase 5 – 10 mg/kg/week.

Recommended infusion rate: Per package insert, no faster than 20mg/min. However, infusion rate appears safe as high as 6mg/kg/min.

Studies describing IV loading doses:

<table>
<thead>
<tr>
<th>Study</th>
<th>Loading Doses</th>
<th>Dose Description</th>
<th>Patients</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheless, 1998</td>
<td>Loading doses of 15-45mg/kg (1050 – 3150mg/70kg) infused over 1 hour (max rate ~ 50mg/min) in epilepsy patients (n=25, ages 4-39 yrs) without active seizures. Average Cpk 10min post infusion: 71-277 (mean, 135.3±59.5ug/ml). No significant adverse effects observed except 1 patient with Cpk &gt; 200ug/ml had mild sedation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venkataraman, 1999</td>
<td>Loading doses of ~25mg/kg infused at 3-6mg/kg per min (82-319 mg/min) in epilepsy patients (n=21, ages 2-54 yrs). Cpk 20min post infusion= 64-204.1ug/ml (mean 132.6ug/ml). Five patients had pain at site of injection due to high concentration of VPA in infusion fluid. Recommended minimal dilution 1:1 with D5W, NS or LR.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hovinga, 1999</td>
<td>Three pediatric patients. Pt#1: 10yo, LD: 20mg/kg followed by 2mg/kg/h infusion; Cpk 1hr post = 69.2ug/ml; 4 hrs later = 40ug/ml. Pt#2: 8yo, LD 13.4mg/kg; Cpk 3hrs post = 33.3ug/ml. Pt#3: 34 months, LD = 20mg/kg over 30min; Cpk 7hrs post = 49ug/ml.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chez, 1999</td>
<td>Three pediatric patients with status epilepticus. Pt#1: 22 months, 30mg/kg over 60min (no side effects); Cpk = 74.9ug/ml. Pt#2: 13 months, 30mg/kg; Cpk 1hr post = 33.9ug/ml additional 30mg/kg given; Cpk = 102.6ug/ml. Pt#3: 8yo: LD = 30mg/kg &amp; MD = 30mg/kg IV q6; Cpk = 100ug/ml, then 2 hours post = 40ug/ml.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White, 1999</td>
<td>Case report in 11yo. LD = 30mg/kg (960mg) over 1hr. BP decr. (130/80 to 70/55) ~39min after start of infusion, respiratory depression, required intubation. Cpk 5hrs post = 104 ug/ml. BP stabilized 14 hrs later after pressor therapy.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naritoku, 1999</td>
<td>Loading doses ~19.4±5.4mg/kg (range 10.6-27.8), ~1420±540mg (range 700-2800mg) at rates of 20-50mg/min in epilepsy patients (n=20, 52.8±23.5yrs). Reported N/V in 2 patients; decr. BP in one patient. Recommended 0.23L/kg (16.1L/70kg) for LD calculation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cloyd, 2003</td>
<td>Loading doses ~15mg/kg infused over 5 min (3mg/kg/min) or 10 min (6mg/kg/min) in 112 patients with epilepsy (mean age = 36±16 yrs; wt = 76.6±25 kg). Mean Vd ~ 0.2 L/kg (range 0.12 – 0.30 L/kg, ~20% CV) but determined with limited sampling strategy (6hrs post dose). Mean (%CV) Cmax at 1hr: Ctotal = 73.5 (22%) mg/L, Cfree = 8.3 (46%) mg/L. Authors recommend using Vd = 0.2 L/kg to estimate loading dose.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**b. Dosage Adjustments**

- Increase dose by 5-10 mg/kg/day every 5-7 days until reach therapeutic effect
- usual maintenance dose: 15 mg/kg/day
- max dose: 60 mg/kg/day
5. **Pediatric Guidelines**

- **dose:** 10-60 mg/kg/day (avg. 30 mg/kg/d)
- **t½:** 10-67 hours in neonates
  7-13 hours in children
- **dosing interval:**
  - syrup q 6-8 h
  - dr tablet q 12 h
  - sprinkle cap q 12 h
  - IV q 6 h
- 90% will have transient increase in LFTs (usually no more than 2x normal) - returns to normal with chronic dosing

6. **Drug Interactions**

- VPA displaces phenytoin from protein binding sites - initially, see ↑ f, ↓ Cₜ.
- Cimetidine inhibits the metabolism of VPA (i.e. up to 20% ↓ in Cl of VPA).

7. **Dosage Forms**

- Syrup - sodium valproate (Depakene) 250mg/5ml
- Capsules - valproic acid (Depakene) 250mg
- Enteric coated tablets - divalproex sodium (Depakote) 125,250,500mg
- Divalproex sprinkle capsules 125mg
- Valproate sodium injection - (Depacon®) 100mg/ml (5ml vial)
- Divalproex sodium extended release (ER) 250, 500mg
• No difference in bioavailability (as measured by AUC) between the three products. Only difference is in the time to peak for each product.

<table>
<thead>
<tr>
<th>Product</th>
<th>Time to Peak</th>
</tr>
</thead>
<tbody>
<tr>
<td>syrup</td>
<td>2 hours</td>
</tr>
<tr>
<td>capsules</td>
<td>3-4 hours</td>
</tr>
<tr>
<td>tablets</td>
<td>3-8 hours</td>
</tr>
</tbody>
</table>

• Food delays the absorption of all three products.

8. Miscellaneous

• $t\frac{1}{2}$ 8-17 h (↑ in hepatic disease, but questionable clinical significance).

• $V_d$ 0.15 L/Kg (range 0.13-0.23 L/Kg)

• $f$ variable; concentration-dependent (with ↑ conc, see ↑ f) clinical significance of variability unknown at 50 mcg/ml, $f \cong 0.05-0.1$
at 70 mcg/ml, $f \cong 0.2$
also affected by disease states (decreased protein binding)renal failure - $f = 0.18$.

liver failure - $f = 0.29$

hypoalbuminemia - $f$ increased depending on severity

• elderly $f$  
$\downarrow Cl$


9. Other Suggested References


Valproic Acid Continuous Intravenous Infusion Protocol
Aaron Cook, PharmD; Last updated 3/5/13

Valproic acid is an anticonvulsant commonly used for the acute treatment of seizures or migraine headache. Intravenous valproate sodium is available for use, but the typical pharmacokinetics of this formulation are somewhat problematic. The pharmacokinetic elimination half-life of valproate is relatively short and does not permit a constant serum concentration during intermittent dosing, particularly in children or other acutely ill individuals who may have elevated metabolic capacity. Rather, due to rapid elimination, there tends to be a peak and trough phenomenon. This phenomenon has the potential to cause difficulty in establishing a safe and effective dose for an individual patient (peak concentrations may be supratherapeutic when targeting goal trough concentrations).

The introduction of delivering valproate via continuous infusion has the potential to address this clinical problem by providing a consistent serum concentration throughout the dosing interval and avoiding serum concentration fluctuation. Thus, patients receiving continuous infusion valproate would be less likely to have serum concentrations that are temporarily above or below the therapeutic range (50-100 mcg/ml). The area under the concentration-time curve required to maintain concentrations in the recommended therapeutic range should be less with continuous infusion. Administering valproate by continuous infusion may diminish the dose requirement in some individuals because of the lack of frequent peak concentrations that occur after intermittent bolus infusions. To this point, clinical experience with this new dosing strategy thus far has indicated that normal daily doses are needed to achieve target concentrations.[1] A more consistent serum concentration may also aid in transitioning patients from intravenous to oral therapy, where an extended-release formulation may be used to mimic continuous delivery of drug. The current dosing of valproate typically includes a loading dose ranging from 20-40mg/kg (infused no faster than 6mg/kg/min). The typical initial maintenance dose ranges from 10-30 mg/kg/day.

UK Protocol

<table>
<thead>
<tr>
<th>Loading Dose</th>
<th>Maintenance Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-40mg/kg IV (&lt; 6mg/kg/min infusion rate)</td>
<td>Begin IV infusion at 0.5-1mg/kg/hr (12-24mg/kg/day)*</td>
</tr>
</tbody>
</table>

*Initial maintenance dose requirements may vary due to concomitant disease states or medications that may displace valproate from albumin binding sites and/or alter metabolic clearance

Ordering Procedure

<table>
<thead>
<tr>
<th>Prescriber</th>
<th>Pharmacy</th>
<th>Nurse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enter COM-valproic acid continuous infusion</td>
<td>Verify as 1000mg VPA in 250ml NS</td>
<td>To run as continuous infusion (based on mg/kg/hr rate)</td>
</tr>
<tr>
<td>Dose (enter as mg/kg/hr)</td>
<td>Frequency = continuous infusion</td>
<td></td>
</tr>
</tbody>
</table>

Monitoring

- Obtain serum valproic acid concentration after loading dose (2 hours, for patients with active seizures to ensure rapid achievement of target concentration)
- Obtain total serum valproic acid concentration approximately 24 hours after infusion initiation
- Utilize continuous infusion equation to determine clearance rate and infusion rate required to achieve desired concentration \( (C_{ss} = \frac{X_{o}}{C_{ls}}) \)**

**where \( C_{ss} = \text{steady state concentration (mg/L)} \), \( X_{o} = \text{infusion rate (mg/hr)} \); \( C_{ls} = \text{systemic clearance (L/hr)} \)

References
**FREE VALPROIC ACID**

**NOTE:** *Free valproic acid concentrations are sent to an outside laboratory; allow 2-3 business days for reporting.*

**Policy:**

1. The pharmacist should make sure that a total concentration, as well as the free valproic acid concentration, is ordered.

2. The therapeutic range of free valproic acid concentrations will be reported as 2.5 to 11.0 mcg/ml.

**Appendix I**

Free valproic acid concentrations should be reserved for the situations described below. For example, a "normal" patient with normal albumin and normal renal function who is not on concurrent medications (that alter valproic acid protein binding or clearance) would not warrant a free valproic acid concentration.

A free valproic acid concentration is warranted when:

5. The total valproic acid dosage is >60 mg/kg/day.

OR

6. A patient is seizure-free at a total level of <50 mcg/ml and you need to determine whether a dosage increase is necessary.

OR

1. A patient is exhibiting signs of toxicity at a dosage of ≤60 mg/kg/day.

OR

7. A patient is in a unique subpopulation (e.g. a pregnant female, a patient on multiple anticonvulsant therapy, etc.)
**VANCOMYCIN**

1. **Time of Sampling**

   **Relative to Dose**
   - Trough within 30 min prior to dose
   - Trough should be at steady-state (24 to 30 hours after initiation of therapy with normal renal function; approximately after the fourth dose in adults)
   - Peak at 1 h after end of 1h infusion (Note that peak concentrations have not been shown to correlate well with toxicity or efficacy and not recommended by 2009 ASHP/IDSA guidelines).

2. **Recommended Frequency of Sampling**

   **Patients in whom vancomycin serum drug concentrations should NOT be obtained:**
   - Adult patients < 60yo with normal body weight, stable renal function with Clcr > 40 ml/min, and short course of therapy (e.g., <3 days)

   **Patients in whom TROUGH vancomycin serum concentrations should be obtained at steady-state:**
   - Patients on vancomycin ≥ 3 days
   - Renal impairment – estimated Clcr < 40ml/min
   - Changing renal function defined by increase in serum creatinine by 0.5 mg/dL or 50% from baseline
   - Special patient populations with altered volume distribution or renal clearance including:
     - Elderly: ≥ 60 years old
     - Burn
     - Cancer
     - Obesity > 125% ideal body weight
     - Pediatric
   - Concomitant nephrotoxic drugs including:
     - Aminoglycosides
     - Amphotericin B
     - Acyclovir (IV)
     - Loop diuretics
     - Vasopressor agents
     - Others (IV contrast dye, ACE inhibitors)

   - **Patients who may require more frequent monitoring to achieve goal concentrations and prevent toxicity:**
     - Higher doses of vancomycin required to penetrate site of infection; treatment of serious life-threatening infections; extended duration of therapy:
       - Meningitis, Endocarditis, Osteomyelitis, Pneumonia, Sepsis
3. **Therapeutic Range**

- **Trough:** 10 – 20 µg/mL
  *Vancomycin troughs of 15-20 mg/L may be warranted for life-threatening infections, organisms with high MICs (e.g., MRSA, MIC = 1), or to ensure vancomycin concentration at the site of infection. Assuming 50% protein binding, target trough concentrations of 8 to 10x MIC for total vancomycin may be warranted.*

- **Peak:** 20 – 40 µg/mL (at 1hr after end of 1hr infusion)

4. **General Guidelines for Dosing and Monitoring**

a. **Initial Loading Dose**

- In order to achieve rapid attainment of the target concentration for seriously ill patients, a loading dose may be considered.
- 20-25 mg/kg based on ABW
  - 40-60kg = 1000 – 1500mg IV X 1
  - 61-80kg = 1500 – 2000mg IV X 1
  - 81-100kg = 2000mg IV X 1
  - >100kg (see morbidly obese guidelines below)

b. **Initial Maintenance Dose**

- **Modified Matzke Nomogram:** Dose = 15 - 20 mg/kg using ABW and Dosing Interval (τ) should maintain serum trough concentrations of 15 mcg/ml. Each dose should be infused over at least 1 hour.

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Dosing interval (τ)</th>
<th>Dosing interval (τ)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DAYS (τ)</td>
<td>HOURS</td>
</tr>
<tr>
<td>≥120</td>
<td>0.35</td>
<td>8-12</td>
</tr>
<tr>
<td>100</td>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>80</td>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>60</td>
<td>0.75</td>
<td>18</td>
</tr>
<tr>
<td>40</td>
<td>1.0</td>
<td>24</td>
</tr>
<tr>
<td>30</td>
<td>1.5</td>
<td>36</td>
</tr>
<tr>
<td>20</td>
<td>2.0</td>
<td>48</td>
</tr>
<tr>
<td>≤10</td>
<td>≥4.0</td>
<td>Determined by concentrations</td>
</tr>
</tbody>
</table>


**Nomogram* for vancomycin in patients with various degrees of renal function**

**Hemodialysis**

Not significantly removed by conventional hemodialysis. Initial dose = 20-25 mg/kg then suggest checking “random” serum concentration in 3-4 days. Redose with 15mg/kg when concentration is 15mg/L.
• Young adults <30yo who have estimated Clcr ≥120 may warrant every 8 hour dosing to maintain therapeutic trough concentrations in certain indications (e.g., endocarditis).

• For **morbidly obese patients** (> 90% over their IBW) with **normal renal function**: 15-20 mg/kg/dose X ABW every 12 hours. Consider maximum initial dose of 2000mg and assess concentrations to determine dosing interval.

  NOTE: Obese patients may require larger total daily doses at less frequent intervals (i.e., q8hrs) in order to avoid low trough concentrations for prolonged periods.


• For **morbidly obese patients** with **renal insufficiency** (estimated Clcr using the Salazar-Corcoran equation): Use 15mg/kg X ABW every $\tau$ determined from the table above (Matzke nomogram). Consider maximum initial dose of 2000mg and assess concentrations to determine dosing interval.

  Alternative dosing method using estimated pharmacokinetic parameters (Vd and K) and Sawchuk-Zaske Method (refer to aminoglycoside section for equations):

  Normal Vd range: 0.5 – 0.9 L/kg (use average 0.7 L/kg)

  Estimate K using Clcr: $K (hr^{-1}) = 0.00083 \times Clcr + 0.0044$ (Matzke)

c. **Dosage Adjustment with trough concentration only:**
   Assumptions: Concentration obtained at steady-state; 1-compartment model; principle of superposition; linear elimination

   1. Verify administration and sampling times. When documenting a vancomycin concentration, include the time before the dose, the time after last dose, and the assessment whether the concentration represents a steady-state condition.
   2. If the concentration is above target, consider holding the subsequent dose if not already given or administer the new dosage at a time the concentration is estimated to be within the therapeutic range.
   3. Adjust either dose (e.g., decrease dose by % to achieve target concentration) and/or adjust interval (e.g. extend interval).
d. **Dosage Adjustments Using Sawchuk-Zaske Method:**
Assumptions: 2 concentrations obtained at steady-state; 1-compartment model; principle of superposition; linear elimination.

1. Verify administration and sampling times.
2. Calculate K:
   \[
   K = \frac{\ln \left( \frac{C_{ss}^{\text{pk}}}{C_{ss}^{\text{tr}}} \right)}{T'}
   \]
   T' is determined by subtracting the time difference between \(C_{pk}\) and \(C_{tr}\) from the Tau. For example, if the time difference between \(C_{pk}\) and \(C_{tr}\) was 1.5hrs and the Tau = q8hrs, then \(T' = (8 - 1.5) = 6.5hrs.\)

3. Calculate \(t/2\):
   \[
   t/2 = \frac{0.693}{K}
   \]

4. IF peak concentration is drawn late, calculate if drawn at correct time:
   \[
   C_{ss}^{\text{pk}} = C_{pk} \cdot e^{-Kt'}
   \]
   where \(C_{ss}^{\text{pk}}\) = peak concentration drawn at appropriate time;
   \(C_{pk}\) = peak concentration drawn late; \(t'\) = time between late \(C_{pk}\) and \(C_{ss}^{\text{pk}}\)

5. IF trough concentration is drawn early (e.g., >30min prior to dose), calculate if drawn at correct time:
   \[
   C_{ss}^{\text{tr}} = C_{tr} \cdot e^{Kt'}
   \]
   where \(C_{ss}^{\text{tr}}\) = trough concentration drawn at appropriate time
   (e.g., suggest use dose administration time)
   \(C_{tr}\) = trough concentration drawn early; \(t'\) = time between early \(C_{tr}\) and \(C_{ss}^{\text{tr}}\)

6. Calculate Vd:

   If doses have reached **steady state** (e.g., previous doses on time, concentrations drawn appropriately), use:

   \[
   Vd = \frac{K_o \left(1 - e^{-Kt}\right) e^{-KT}}{C_{ss}^{\text{pk}} \cdot K \left(1 - e^{-Kt}\right)}
   \]
   \(t =\) infusion time (e.g., 1hr) \(T =\) time between end of infusion & \(C_{ss}^{\text{pk}}\) (e.g., 1hr)

   If doses have **NOT** reached **steady state** AND there are at least 3 concentrations after a multiple dose (e.g., trough, peak, & random) or 2 concentrations after the 1st dose (e.g., peak and random or 2 random concentrations) use:
Vancomycin

\[ V_d = \frac{K_o (1-e^{-Kt})}{K (C_{pk}^{max} - C_{tr} e^{-Kt'})} \]

\[ C_{pk}^{max} = \frac{C_{pk}}{e^{-KT}} \quad T = \text{time between } C_{pk} \text{ and } C_{pk}^{max} \]

7. IF measured \( C_tr \) is high, calculate time required to achieve desired \( C_tr \):

\[ t' = \frac{\ln \left( \frac{C_{tr_1}}{C_{tr_2}} \right)}{K} \quad \text{Ctr}_1 = \text{high } Ctr; \quad \text{Ctr}_2 = \text{desired } Ctr \]

8. Calculate new dosing interval (\( \tau \)):

\[ \tau = \frac{\ln(C_{pk}/C_{tr})}{K} + t + T \quad t = \text{infusion time (e.g., 1hr)} \]

9. Calculate new dosing rate:

\[ K_o = \frac{C_{pk}^{ss} V_d K(1-e^{-Kt})}{(1-e^{-Kt}) e^{-KT}} \quad t = \text{infusion time (e.g., 1hr)} \]

10. Round dose (FOR ADULTS: round dose to nearest 250mg) then recalculate the actual \( C_{pk} \):

\[ \text{desired } C_{pk} \times \frac{\text{actual (rounded) dose}}{\text{calculated dose}} = \text{actual } C_{pk} \]

11. Estimate trough to be obtained with above \( K_o \) and \( \tau \):

\[ C_{tr} = C_{pk}^{ss} e^{-KT'} \]

12. Document the pharmacokinetic assessment in the medical records.

WRITE A CHART NOTE. Document pertinent clinical monitoring parameters, dose recommendations and estimated and/or calculated pharmacokinetic parameters in the medical record. (Also refer to Department of Pharmacy Guidelines for Writing Notes in Patient Charts, PH-02-04)

- Briefly describe the rationale of the drug and determine if warranted based on clinical and patient information. Refer to UK Hospital guidelines for appropriate use of vancomycin.
- Document the current day of therapy and goal length of therapy (e.g., Day #2/14 vancomycin), and any concomitant antibiotics.
- Document the collect times of the reported concentrations and note if the samples were obtained appropriately. For example, if actual C_{pk} was drawn late, also document the estimated C_{pk} if drawn correctly.
- Include the calculate PK parameters: K (hr^{-1}), t\frac{1}{2} (hrs), V_d (L) and V_d (L/kg – DBW).
- Write a new dosage in mg and mg/kg-DBW/dose (e.g., vancomycin 1000 mg IV q12hrs, 15mg/kg/dose).
- When changing a dosage, include the start time of new dosing regimen with the order (very helpful for the pharmacist entering the order and the nurse administering the drug).
- Include a range for the predicted concentrations with the new dosage recommendation: (e.g., C_{pk} = 8-10mg/L; C_{tr} <2mg/L, ~1mg/L).
- Include other pertinent information used to assess the patient: weight (ABW, IBW, DBW), height, BSA, Scr, Clcr, BUN, urine output, I/Os, cultures, Tmax, WBC, differential, allergies, and other nephrotoxic medications (e.g., furosemide, amphotericin, aminoglycosides).
- Refer to the sample note on the next page.
## Sample Note

### PHYSICAL/HISTORY/PROGRESS NOTES

<table>
<thead>
<tr>
<th>Date</th>
<th>Clinical Pharmacokinetics Service RE: Vancomycin Day #2/14</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/2/20XX 14:30</td>
<td>Patient is 40yo WM being treated with vancomycin 1000mg IV q12hrs (12.5 mg/kg/dose) for staphylococcal bacteremia based on positive blood cultures (9/1, both bottles) for <em>Staphylococcus aureus</em>. Current Tmax 102.5, WBC = 15K. Vancomycin therapy meets approval criteria. ID service is following patient and recommends Cpk ~ 35-40mg/L and Ctr = 10-15 mg/L (discussed with ID resident).</td>
</tr>
</tbody>
</table>
| ABW = 80kg Ht = 6'0" IBW = 77.6kg Scr = 1.2 (today) Clcr = 93ml/min | Vancomycin concs drawn around 3rd dose on 9/2:
  - Trough = 8.7 mg/L C: 07:30
  - Dose = 1200 mg IV infused from 08:00 – 09:00
  - Peak = 22 mg/L C: 11:00
  
  **Assessment of concs:** Previous doses administered on time & represent steady-state; Ctr drawn appropriately; Cpk drawn 1hr late & if drawn correctly @ 10:00 = 24.6 mg/L; Cpk and Ctr below recommended range. Renal function stable.
  
  **PK parameters:** K = 0.11hr⁻¹; t½ = 6.3 hrs; Vd = 47.1L (0.6 L/kg) |
  
  **Recommendations:**
  1. Suggest changing vancomycin to 1500mg IV q12hrs (18.75 mg/kg/dose) to yield a Cpk ~35-40 mg/L & Ctr ~ 12mg/L; begin next dose at scheduled time (9/2 @ 20:00); discussed with ID resident and primary team.
  2. Not necessary to recheck Cpk & Ctr unless change in clinical status or renal function; if continue therapy > 7 days, would suggest checking Ctr each week to assess for drug accumulation.
  3. Suggest checking Scr/BUN at least 2X/week to assess renal function.

XXXXXX, PharmD
Pager #
1. Pediatric Recommendations

### Neonatal Empiric Vancomycin Dosing (Assuming normal renal function)

<table>
<thead>
<tr>
<th>Gestational Age*</th>
<th>Postnatal Age#</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 28 wks</td>
<td>≤ 2 wks old</td>
<td>15 mg/kg q24 hr</td>
</tr>
<tr>
<td>≤ 28 wks</td>
<td>&gt; 2 wks old</td>
<td>15 mg/kg q18 hr</td>
</tr>
<tr>
<td>29-32 wks</td>
<td>≤ 2 wks old</td>
<td>15 mg/kg q18 hr</td>
</tr>
<tr>
<td>29-32 wks</td>
<td>&gt; 2 wks old</td>
<td>15 mg/kg q12 hr</td>
</tr>
<tr>
<td>≥ 33 wks</td>
<td>≤ 2 wks old</td>
<td>15 mg/kg q12 hr</td>
</tr>
<tr>
<td>≥ 33 wks</td>
<td>&gt; 2 wks old</td>
<td>15 mg/kg q8 hr</td>
</tr>
</tbody>
</table>

### Infants and Children Empiric Vancomycin Dosing (Assuming normal renal function)\(^1,2,3\)

<table>
<thead>
<tr>
<th>Based on Goal Trough and Age</th>
<th>For 10-15 mg/L</th>
<th>For 15-20 mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>1mo – 12 yrs</td>
<td>70 mg/kg/day divided q6hr</td>
<td>90 mg/kg/day divided q6hr</td>
</tr>
<tr>
<td>13 – 16 yrs</td>
<td>60 mg/kg/day divided q8hr</td>
<td>70 mg/kg/day divided q6hr</td>
</tr>
<tr>
<td>&gt; 16 yrs</td>
<td>15 – 20 mg/kg q8-12 hr (Similar to adult dose)</td>
<td></td>
</tr>
</tbody>
</table>

### Dosing Pearls

- **Goal Trough**: 10-15 mcg/mL (uncomplicated infections) 15-20 mcg/mL (serious infections: endocarditis, sepsis, osteomyelitis, CNS infections, *S. aureus* pneumonia)
- **Renal Impairment**: Dosing interval should be extended
- **Creatinine Clearance**: Calculate with Bedside Schwartz equation (refer to pg 18)
- **Obesity**: BMI >95\(^{th}\) percentile, use actual body weight\(^4,5\). Consider obtaining peak and trough concentrations
- **Infusion Time**: Infuse all doses over at least 1 hour
- **Administration**: Final concentration must be <5 mg/mL; may use 10mg/mL through central line if fluid restricted
- **Monitoring**: Renal function, UOP, strict ins/outs, infusion reactions (i.e. Redmans requiring prolonged infusion ±pre-medication), clinical status (fever curve, WBC, culture results), drug interactions

*Gestational Age = weeks of pregnancy when patient is born

#Postnatal Age = Age after birth

Parenteral administration of vancomycin should be administered over at least 60 minutes at a final concentration <5mg/mL (10mg/mL per central line for fluid restriction patients); CNS = central nervous system


2. Vancomycin- Hemodialysis

**Dose**
1. Loading dose of 15-20 mg/kg based on ABW
2. Enter “intermittent” vancomycin order as an active order between doses

**Effect of hemodialysis at UK Chandler Hospital**
3. With full hemodialysis session (e.g., 3-4 hours with dialysate flow rate
5. Average half-life in ESRD patients is 4-5 days depending on residual kidney function.

**Concentrations**
1. Usually drawn 3-5 days post-dose ordered as a random level.
2. Redose when level is expected to be < 15 mg/L.
3. Levels drawn 10-12 hours following high-flux hemodialysis may be misleading. Obtaining level prior to hemodialysis is preferred.

**References (Drug dosing in renal failure/dialysis):**

3. **Suggested References for Influences of Pathophysiologic States on Vancomycin Kinetics**


4. **Other Suggested Readings**
Guidelines to Anticoagulation

UNIVERSITY OF KENTUCKY HOSPITAL
CHANDLER MEDICAL CENTER

Department of Pharmacy Policy

SUBJECT: Anticoagulation Management Service Policy/Procedures

SEE ALSO: PH02-04 Guidelines for Writing Notes in Patient’s Chart; PH02-05 Clinical Pharmacokinetics Service Policy/Procedures; PH02-08 Patient Education-Inpatients; PH02-11 Prescribing Guidelines; HP-2-14 Discharge Medication Planning, Education, and Procurement, PH02-17 Role of the Pharmacist in the Electronic record, CN-08-01E Drug-Nutrient Interactions

PURPOSE: To establish a standard approach to the management of inpatients receiving medications used for anticoagulation at the University of Kentucky Chandler Medical Center.

STAFF AFFECTED: Clinical Pharmacist Specialists, Clinical Staff Pharmacists, Staff Pharmacists, Pharmacy Residents, and Pharmacy Students under the supervision of a licensed pharmacist.

GENERAL: The Anticoagulation Management Service (AMS) Policy/Procedures were developed to ensure the safe and efficacious use of medications used for anticoagulation. The policy/procedure manual outlines recommended guidelines which should be followed when providing clinical monitoring of the following drugs: warfarin, heparin, low molecular weight heparins (LMWH), and direct thrombin inhibitors.

Monitoring Responsibility
Within the pharmaceutical care process, the primary pharmacist/resident who attends rounds or precepts pharmacy students on the primary medical team is responsible for providing appropriate and cost-effective monitoring and provision of clinical anticoagulation evaluations. Patients on a service without a rounding service will be identified and followed according to the pharmacy monthly service coverage list. The pharmacist is available on a consultant basis as well for assistance with anticoagulation issues via pager 330-4325 M-F 0800-1700 or pager 330-7400 (PharmD on-call) after-hours and weekends.

Ordering
Pharmacists consulted via pharmacist to dose orders within SCM are authorized to order lab tests pertinent to the management of a patient’s anticoagulation. These orders must state “Per Protocol”. Lab tests will be limited to those pertinent to the monitoring of the medication (i.e. PT, INR, aPTT, anti-factor Xa concentrations, SCr, BUN, CBC, and Albumin). In addition, pharmacists are able to order dosage adjustments for heparin, LMWH, direct thrombin inhibitors, and warfarin in consultation with the prescribing physician.

Order Verification
Pharmacists involved in the order verification process will evaluate the following when verifying a warfarin order:

1. Ensure that a recent INR is available for evaluation prior to order verification (INR within 72 hours prior to order)
2. Review the INR and ordered warfarin dose to ensure appropriateness of therapy according to known previous dosing for that patient. For warfarin naïve patients, dosing recommendation are available in the University of Kentucky Chandler Medical Center Anticoagulation Guideline.

**Documentation in the Patient Medical Record**

When a pharmacist is providing a consult on a patient on anticoagulation therapy, the pharmacist should write a “Pharmacy Anticoagulation Note” in the patient’s medical record to indicate recommendations in dosage or monitoring and to indicate changes in these recommendations. Alternatively, this note may be included as a component of the daily physician progress note. For laboratory values or dosages that are supratherapeutic, the medical team should be notified immediately if clinically warranted and appropriate recommendations should be documented. Patients receiving warfarin should receive an anticoagulation note within 72 hours of admission or restart of their warfarin therapy. The pharmacist managing the patient should also document dosage change recommendations and patient education prior to discharge.

**Education**

The nurse and/or pharmacist will provide patient education for patients receiving anticoagulant therapy prior to discharge. In addition, pharmacist provided patient counseling will be available through consultation. This education will consist of the Krames warfarin education packet and will include such items as importance of compliance with taking the medication and being adherent with laboratory monitoring, drug-drug and drug-nutrient interactions, as well as potential adverse reactions and increased risk for bleeding.

**Anticoagulation Management Guideline**

See the University of Kentucky Chandler Medical Center Anticoagulation Guide. This guideline will be used by healthcare practitioners to assist in dosing of warfarin, heparin, direct thrombin inhibitor and LMWH regimens.

**Continuous Quality Improvement (CQI)**

The AMS will report annually to the P&T Committee. Areas included in this review are appropriate indications for anticoagulation, appropriate dosing, appropriate laboratory monitoring, evaluation of excessive INRs, and adverse drug reactions. These results will be included in Pharmacy Services annual CQI activities.
Warfarin

Mechanism of Action:
- Inhibits reduction of vitamin K epoxide, thereby limiting activation of vitamin K dependent clotting factors: II (prothrombin), VII, IX, X. *Antithrombotic effect primarily due to reduction in prothrombin.*
- Inhibits synthesis of anticoagulant proteins C and S (potential procoagulant effects).

Pharmacokinetics:

Warfarin is a racemic mixture of two active isomers, R and S. The S-isomer is approximately five times more potent than the R-isomer.

Oral Administration
- Absorption: rapidly and completely absorbed
- Distribution: primarily intravascular, highly protein bound
- Half-life: 36-42 hours
  - Time to steady state = approximately 10 days

Half-lives of Clotting Factors:
- Factor II = 60 hrs
- Factor VII = 6 hrs
- Factor IX = 24 hrs
- Factor X = 40 hrs

Metabolism: Hepatic microsomal enzymes to inactive metabolites
- S-isomer is metabolized primarily by cytochrome P450 (CYP) 2C9
- R-isomer is metabolized by CYP 1A2 and CYP 3A4
- Reduce dose with hepatic dysfunction and with hypermetabolic states (increased catabolism of vitamin-K dependent factors)
- Not significantly affected by dialysis

Dosing and Monitoring:
Dose that is required is variable and dependent on a number of patient-specific and environmental factors. Refer to dosing guidelines on following page.

Baseline INR within 72 hours of warfarin initiation should be reviewed to assess sensitivity. If an INR is not present, the pharmacist will contact the physician or enter an order to obtain an INR prior to verification of the order. Collect INR daily in hospitalized patients being initiated on warfarin until INR is within the desired therapeutic range, then two or three times weekly.
- Consider holding warfarin therapy if INR > 4
### Warfarin Anticoagulation Initiation Dosing for Warfarin Naïve Patients

<table>
<thead>
<tr>
<th>Day</th>
<th>INR Baseline</th>
<th>Warfarin High Sensitivity*</th>
<th>Warfarin Moderate Sensitivity**</th>
<th>Warfarin Low Sensitivity***</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>2.5-5 mg</td>
<td>5-7.5 mg</td>
<td>7.5-10 mg</td>
</tr>
<tr>
<td>2</td>
<td>&lt;1.5</td>
<td>2.5-5 mg</td>
<td>5-7.5 mg</td>
<td>7.5-10 mg</td>
</tr>
<tr>
<td></td>
<td>1.5-1.9</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
</tr>
<tr>
<td></td>
<td>2-2.5</td>
<td>1-2.5 mg</td>
<td>1-2.5 mg</td>
<td>1-2.5 mg</td>
</tr>
<tr>
<td></td>
<td>&gt;2.5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Continue for all patients

<table>
<thead>
<tr>
<th>Day</th>
<th>INR</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>&lt;1.5</td>
<td>5-10 mg</td>
</tr>
<tr>
<td></td>
<td>1.5-1.9</td>
<td>2.5-5 mg</td>
</tr>
<tr>
<td></td>
<td>2-2.5</td>
<td>0-2.5 mg</td>
</tr>
<tr>
<td></td>
<td>2.6-3</td>
<td>0-2.5 mg</td>
</tr>
<tr>
<td></td>
<td>&gt;3</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>&lt;1.5</td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>1.5-1.9</td>
<td>5-7.5 mg</td>
</tr>
<tr>
<td></td>
<td>2-3</td>
<td>2.5-5 mg</td>
</tr>
<tr>
<td></td>
<td>&gt;3</td>
<td>0-2.5 mg</td>
</tr>
<tr>
<td>5</td>
<td>&lt;1.5</td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>1.5-1.9</td>
<td>7.5-10 mg</td>
</tr>
<tr>
<td></td>
<td>2-3</td>
<td>2.5-5 mg</td>
</tr>
<tr>
<td></td>
<td>&gt;3</td>
<td>0-2.5 mg</td>
</tr>
<tr>
<td>6</td>
<td>&lt;1.5</td>
<td>7.5-12.5 mg</td>
</tr>
<tr>
<td></td>
<td>1.5-1.9</td>
<td>5-10 mg</td>
</tr>
<tr>
<td></td>
<td>2-3</td>
<td>2.5-5 mg</td>
</tr>
<tr>
<td></td>
<td>&gt;3</td>
<td>0-2.5 mg</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Make adjustment based on total weekly dose (Increase or decrease dose by 5-20% depending on current INR and target INR)</td>
</tr>
</tbody>
</table>

*High Sensitivity
Baseline INR >1.5
>65 years of age
Significant hepatic disease
 Decompensated CHF
 Malnourished
 Malabsorption syndrome/ chronic diarrhea
 Cancer
 Hypoalbuminemia (esp<2)
 Thyrotoxicosis
 Genetic polymorphism of CYP-450 2C9

**Moderate Sensitivity
Baseline INR 1.2-1.5
50-65 years of age
 Concurrent CYP-450 hepatic enzyme inhibitor
 (see table for details)

***Low Sensitivity
Baseline INR <1.2
<50 years of age and no other risk factors
Adverse reactions
Warfarin:
- Over Anticoagulation / Bleeding

### Guidelines on Vitamin K₁ Administration for Reversal of Warfarin

<table>
<thead>
<tr>
<th>INR</th>
<th>Action/Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than therapeutic but &lt; 5 with no significant bleeding</td>
<td>Continue with lower warfarin dose, OR omit a dose and resume therapy at a lower dose.</td>
</tr>
<tr>
<td>5-9 (No significant bleeding) OR If patient is at risk of bleeding</td>
<td>Omit 1 or 2 doses (monitoring INR more frequently), and resume therapy at a lower dose when INR therapeutic, OR omit a dose and administer vitamin K₁ 1.25 to 2.5 mg PO</td>
</tr>
<tr>
<td>5-9 (Rapid reversal required for urgent surgery)*</td>
<td>Administer vitamin K₁ 2.5 mg PO (INR to normalize in 24 hours); if INR still high, administer additional 1.25 to 2.5 mg of vitamin K₁ PO.</td>
</tr>
<tr>
<td>&gt;9 (No significant bleeding)</td>
<td>Hold warfarin therapy AND administer vitamin K₁ 2.5-5 mg PO, administer additional vitamin K₁ in 24-48 hours if necessary; resume therapy at a lower dose when INR therapeutic.</td>
</tr>
<tr>
<td>Significant bleeding at any INR value</td>
<td>Hold warfarin therapy AND administer vitamin K₁ 10 mg by slow IV infusion (1 mg/min) diluted in D5W or NS; may repeat every 12 hours if needed. (Supplement with fresh frozen plasma, depending on urgency)</td>
</tr>
<tr>
<td>Life threatening bleeding</td>
<td>Hold warfarin therapy AND administer fresh frozen plasma AND administer vitamin K₁ 10 mg by slow IV infusion (1 mg/min) diluted in D5W or NS.</td>
</tr>
</tbody>
</table>

*For patients with INR >1.5 but <5 requiring reversal for urgent surgery administer vitamin K₁ 2.5 to 5 mg PO, or for patients NPO, 1 mg IV. Reduction in INR may take 24hrs.

In general oral route is preferred over subcutaneous
### Selected Factors Altering Warfarin Pharmacokinetics and Pharmacodynamics

<table>
<thead>
<tr>
<th>Increased Warfarin effect</th>
<th>Decrease Warfarin effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (high doses)</td>
<td>Alcohol (chronic ingestion)</td>
</tr>
<tr>
<td>Alcohol (acute ingestion)</td>
<td>Aminoglutethimide</td>
</tr>
<tr>
<td>Aminosalicylic acid</td>
<td>Barbiturates</td>
</tr>
<tr>
<td>Allopurinol</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Cholestyramine</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Dicloxacillin</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Griseofulvin</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Nafcillin</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Dexamethasone (≥20 mg)</td>
<td>Rifampin</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>Sucralfate</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Vitamin K</td>
</tr>
<tr>
<td>Fluconazole</td>
<td></td>
</tr>
<tr>
<td>Flu vaccine</td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td></td>
</tr>
<tr>
<td>Isoniazid (600 mg/day)</td>
<td>Increased Bleeding</td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>NSAIDs</td>
</tr>
<tr>
<td>Omeprazole</td>
<td></td>
</tr>
<tr>
<td>Phenytoin (long term)</td>
<td>Ticlopidine</td>
</tr>
<tr>
<td>Propoxyphene</td>
<td>Clopidogrel</td>
</tr>
<tr>
<td>Quinidine</td>
<td></td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td></td>
</tr>
<tr>
<td>Tetracycline</td>
<td></td>
</tr>
<tr>
<td>TMP/SMX</td>
<td></td>
</tr>
</tbody>
</table>
Optimal Therapeutic Range for Oral Anticoagulation

<table>
<thead>
<tr>
<th>Indication</th>
<th>INR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atrial Fibrillation</strong></td>
<td></td>
</tr>
<tr>
<td>Atrial Fibrillation with high risk factors</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>(age &gt;75 years, history of TIA or stroke, hypertension, history systemic embolus, mitral stenosis, bioprosthetic cardiac valve, thyrotoxicosis, left ventricular dysfunction, CHF, rheumatic mitral valve disease)</td>
<td></td>
</tr>
<tr>
<td>Atrial Fibrillation with &gt; 2 moderate risk factors</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>(Age 65-75 years, diabetes mellitus, coronary artery disease)</td>
<td></td>
</tr>
<tr>
<td>Pre-cardioversion (for Afib &gt;48 hours)</td>
<td>2-3 (3 weeks)</td>
</tr>
<tr>
<td>Post-cardioversion</td>
<td>2-3 (4 weeks)</td>
</tr>
<tr>
<td><strong>Cardioembolic Stroke</strong></td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td><strong>Left Ventricular Dysfunction</strong></td>
<td></td>
</tr>
<tr>
<td>Ejection Fraction &lt; 30%</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>Following embolic event despite anticoagulation</td>
<td>2-3 (chronic) plus ASA 81 mg</td>
</tr>
<tr>
<td><strong>Myocardial Infarction (MI)</strong></td>
<td></td>
</tr>
<tr>
<td>Following anterior MI</td>
<td>2-3 (1-3 months)</td>
</tr>
<tr>
<td>Following MI with continued risk factors</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>(Afib, LV dysfunction, CHF, mural thrombosis, history of embolism)</td>
<td></td>
</tr>
<tr>
<td><strong>Thromboembolism (DVT, PE)</strong></td>
<td></td>
</tr>
<tr>
<td>Treatment/prevention of recurrence</td>
<td>2-3 (3 months)</td>
</tr>
<tr>
<td>(reversible or time-limited risk factors)</td>
<td></td>
</tr>
<tr>
<td>Treatment/prevention of recurrence</td>
<td>2-3 (6 months)</td>
</tr>
<tr>
<td>(first episode of idiopathic thrombus)</td>
<td></td>
</tr>
<tr>
<td>Continued presence of risk factors</td>
<td>2-3 (12 months-chronic)</td>
</tr>
<tr>
<td>(AT-III, protein C or S deficiency, malignancy)</td>
<td></td>
</tr>
<tr>
<td>Symptomatic calf vein thrombosis</td>
<td>2-3 (6-12 weeks)</td>
</tr>
<tr>
<td>Prophylaxis of venous thrombosis (high risk surgery)</td>
<td>2-3</td>
</tr>
</tbody>
</table>
## Optimal Therapeutic Range for Oral Anticoagulation

<table>
<thead>
<tr>
<th>Indication</th>
<th>INR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valvular Disease</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Aortic valve disease</strong></td>
<td></td>
</tr>
<tr>
<td>with concurrent mitral valve disease</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with associated atrial fibrillation</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td><strong>Mitral annular calcification</strong></td>
<td></td>
</tr>
<tr>
<td>with associated atrial fibrillation</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with history of systemic embolization</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td><strong>Mitral valve prolapse</strong></td>
<td></td>
</tr>
<tr>
<td>with associated atrial fibrillation</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with history of systemic embolization</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with history of TIA despite Aspirin therapy</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>s/p embolic event despite anticoagulation</td>
<td>2-3 (chronic) plus ASA 325 mg</td>
</tr>
<tr>
<td><strong>Patent foramen ovale/atrial septal aneurysm</strong></td>
<td></td>
</tr>
<tr>
<td>with history of systemic embolization</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with history of TIA</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td><strong>Rheumatic mitral valve disease</strong></td>
<td></td>
</tr>
<tr>
<td>with left atrial diameter &gt; 5.5 cm</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with associated atrial fibrillation</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>with history of systemic embolization</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>s/p embolic event despite anticoagulation</td>
<td>2.5-3.5 (chronic) or 2-3 (chronic) plus ASA 81 mg or clopidogrel 75mg</td>
</tr>
<tr>
<td><strong>Valve Replacement</strong></td>
<td></td>
</tr>
<tr>
<td>Mechanical valve prosthesis</td>
<td>2.5-3.5 (chronic)</td>
</tr>
<tr>
<td>(tilting disk valves, bileaflet mechanical valves in the mitral position or aortic position with atrial fibrillation)</td>
<td></td>
</tr>
<tr>
<td>Bileaflet aortic mechanical valve</td>
<td>2-3 (chronic)</td>
</tr>
<tr>
<td>(provided normal sinus rhythm, normal ejection fraction, and normal sized atrium)</td>
<td></td>
</tr>
<tr>
<td>Mechanical valve following systemic embolization or risk factors</td>
<td>2.5-3.5 (chronic)</td>
</tr>
<tr>
<td>(Concurrent atrial fibrillation, history of systemic embolization left atrial thrombus, severe left ventricular dysfunction)</td>
<td>plus ASA 81 mg</td>
</tr>
<tr>
<td>Tissue valve prosthesis</td>
<td>2-3 (3 months)</td>
</tr>
<tr>
<td>Tissue valve with history of systemic embolization</td>
<td>2.5-3 (3-12 months)</td>
</tr>
<tr>
<td>Tissue valve with atrial fibrillation or pacemaker</td>
<td>2-3 (chronic)</td>
</tr>
</tbody>
</table>
**Unfractionated Heparin**

**Mechanism of Action**
- Binds to and causes conformational change in anti-thrombin III thereby accelerating inactivation of activated clotting factors IIa (thrombin), IXa, Xa, XIa and XIIa, subsequently halting coagulation.
- Low dose predominantly affects factor Xa (prophylaxis)
- Full-dose predominantly affects factor IIa (thrombin) (established clot)

**Pharmacokinetics**

**Unfractionated Heparin (IV or SQ):**
- Absorption (SQ): completely absorbed (at treatment doses); peak concentrations at 2-4 hrs
- Distribution: primarily intravascular
- Half-life: 90 minutes (range 0.5-2 hours)
  - Mean time to steady state = 6 hours (3-5 half-lives)
  - Increases with larger doses (non-linear)
  - Decreases with PE, massive thrombus, or new clot (increased clearance)
- Metabolism: degraded by reticuloendothelial system
  - No dose adjustment necessary for hepatic or renal dysfunction
  - Not significantly affected by dialysis

**Prophylaxis Dosing**

General Surgery / Medicine Patients
- Unfractionated enoxaparin 40mg SQ q24hrs (preferable if eGFR > 30 mL/min) or heparin (UFH) 5000 units sq q8h or q12h

**Overlapping with Oral Anticoagulation:**

Oral anticoagulation (e.g. warfarin) should typically be started on Day 1 of enoxaparin or heparin treatment and should be continued along with warfarin for a minimum of five days and until the INR is within the desired therapeutic range on 2 consecutive occasions at least 24 hours apart.

**Therapeutics Unfractionated Heparin Protocols using Anti-Xa Monitoring:**

- Refer to UK CareWeb Anticoagulation Stewardship Site link in the OrderSets/Protocols section for current heparin protocol information since may have been updated since this was updated.

**Heparin Reversal Recommendations**

**Protamine**
- Binds to heparin forming a stable complex devoid of anticoagulant activity.
- Reserved for patients with clinically significant bleeding episodes while receiving heparin therapy. The drug is not indicated in cases of minor bleeding as withdrawal of heparin will generally result in correction of bleeding within several hours.
- Use with supportive care of the patient and possible transfusion therapy.
- Dosing
  - 1 mg of protamine will reverse approximately 100 units of heparin
  - Initial doses rarely exceed 50mg
- Infusion related adverse effects including hypotension and bradycardia can be minimized by extending the infusion time (10 minutes)
- Follow-up anti-Xa should be drawn 15 min post-dose to assess response
**Enoxaparin**

**Mechanism of Action**
- Low molecular weight heparin (LMWH) derived from porcine heparin with an average molecular weight of 4500 daltons.
- Both heparin and LMWH binds to and causes a conformational change in anti-thrombin III thereby accelerating inactivation of activated clotting factors. Due to its smaller size, enoxaparin preferentially inhibits factor Xa, with an anti-Xa:anti-IIa ratio of 3.6:1.

**Pharmacokinetics**

**Absorption (SQ)**
- 90% absorbed by subcutaneous route
- Peak anti-factor Xa activity 3-5 hours after injection

**Distribution**
- Similar to intravascular volume

**Elimination**
- Primarily renal, follows linear, first order kinetics

**Half-Life (based on anti-factor Xa activity)**
- 6 hours (multiple doses)
- Prolonged in patients with renal insufficiency due to decreased clearance

**Prophylaxis Dosing**

- 40 mg SQ every 24 hours
  - General Surgery / Medicine patients
  - Orthopedic hip replacement
- 30 mg SQ every 12 hours
  - Orthopedic Trauma patients
  - Orthopedic knee replacement

**Treatment Dosing**

- 1 mg/kg SQ every 12 hours (Actual body weight)
  - DVT/PE treatment
  - Unstable angina and NSTEMI
  - Bridge therapy to warfarin
  - 1mg/kg SQ bid preferred in following patients
    - Proximal DVT
    - Obesity
    - Hypercoagulable state
    - Increased bleeding risk
- 1.5 mg/kg SQ every 24 hours
  - DVT/PE treatment

**Monitoring**

Not generally necessary
- May be considered in special populations. Those at extremes of body weight or with renal insufficiency (defined as Clcr < 30 ml/min).
- Limited data are available that correlate a specific anti-factor Xa range to antithrombotic activity or bleeding risk. Appropriate surrogate marker of antithrombotic effect when the clinical situation dictates monitoring.
Anti-factor Xa levels
- Concentrations measured by the clinical lab daily
- Collect peak concentration 3-5 hours after the subcutaneous dose
- Enoxaparin should be at steady state to account for accumulation, typically prior to third dose
- Therapeutic Range (peak concentration):
  - 0.6-1.2 Unit/ml (1mg/kg dosing)
Dosage adjustment
- Changes in dose can be calculated by using a ratio of dose and anti-factor Xa level
  - Assumes current Xa level is at steady state
  - Goal Xa level for treatment doses in therapeutic range

\[
\text{New Dose} = \frac{(\text{Current Dose}) \cdot (\text{Goal anti-factor Xa level})}{\text{Current anti-factor Xa level}}
\]

Renal Insufficiency
- Enoxaparin is primarily eliminated renally. Its use in patients with severe renal dysfunction will prolong the elimination half-life and may increase bleeding risk.
- Inverse correlation exists between Clcr and anti-factor Xa levels. Patients with severe renal impairment (Clcr < 30 ml/min) require dosage adjustment due to reduced clearance.
  - Prophylaxis dosing: Enoxaparin 30mg SQ daily
  - Treatment dosing: Enoxaparin 1mg/kg SQ daily
- UFH is recommended for dialysis patients or patients with renal insufficiency at high risk of bleeding.

Extremes of Body Weight
Underweight (<45 kg): Consider monitoring anti-factor Xa levels

**Obesity:** No dosage adjustment is necessary in patients with a BMI < 40 kg/m2. Data on the use and monitoring of enoxaparin in patients >150 kg is limited. Capping the enoxaparin dose at 150 mg for patients > 150 kg should NOT be done.
  - Peak concentrations may be delayed in this population (4-6 hours)
  - When compared to non-obese patients, overall exposure at steady state was 16% higher in obese population receiving the same weight-based dose (1.5mg/kg daily).
  - Use with caution in patients > 150kg
  - Consider treatment with UFH in these patients
  - If LMWH used, consider dose adjustment with anti-factor Xa monitoring.

Enoxaparin Reversal Recommendations

Protamine
- Reverses the antithrombin activity of enoxaparin but ≤ 60% of the anti-Xa activity.
  - No accepted method available to neutralize all effects of enoxaparin
- Reserved for patients with clinically significant bleeding episodes while receiving enoxaparin therapy. Reversal may be incomplete due to lack of anti-factor Xa neutralization. Use with supportive care of the patient and possible transfusion therapy.
- Dosing (within 8 hours of SQ dose)
  - 1 mg of protamine will reverse approximately 100 anti-factor Xa units (1 mg of enoxaparin = 100 anti-factor Xa units).
Repeat dose of protamine 0.5 mg per 100 anti-factor Xa units may be given if bleeding continues.

**Direct Thrombin Inhibitors (Intravenous Therapy)**

**Argatroban**

**Mechanism of Action**
- A direct, selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.

**Pharmacokinetics**

Immediate onset with IV infusion

**Metabolism**
- Hepatic
- requires initial dosage adjustment in patients with moderate to severe hepatic dysfunction

**Half-Life**
- 40 minutes
- Prolonged in patients with hepatic insufficiency due to decreased clearance

**Treatment (initial dosing)**

**General Considerations**
- Initial doses based on using actual body weight
- See argatroban protocol for additional dosing adjustment and monitoring recommendations

**Management of Heparin Induced Thrombocytopenia (HIT)**
- Initial Infusion rate - Standard
  - 2 mcg/kg/min
- Initial Infusion rate - Critically ill patient
  - 0.5-1 mcg/kg/min
- Initial Infusion rate – moderate-severe hepatic insufficiency (Child-Pugh score >6)
  - 0.5 mcg/kg/min

**Monitoring**

Baseline LFTs and PT/INR
- assess hepatic function prior to initiation
- Patients with hepatic dysfunction may exhibit prolonged half-lives

Activated partial thromboplastin time (aPTT)
- Collect 2 hours after initiation then every 4 hours (after rate change or if in range) until two consecutively in range, and then daily with AM labs. Adjust per protocol

**Argatroban Interaction with INR**

Argatroban can cause an elevation in INR beyond that seen with warfarin alone (reversal with vitamin K and/or Fresh Froze Plasma is not necessary)
- Collect baseline INR prior to initiation of infusion and again once on argatroban prior to initiation of warfarin
Accurate INR can be obtained by holding argatroban infusion for approx 4 hours prior to checking INR (Refer to argatroban to warfarin conversion guidelines)

**Bivalirudin**

**Mechanism of Action**
Specific and reversible direct thrombin inhibitor; it binds to the catalytic and anionic exosite of both circulating and clot-bound thrombin. Inhibits coagulant effects by preventing thrombin-mediated cleavage of fibrinogen to fibrin monomers, and activation of factors V, VIII, and XIII.

**Pharmacokinetics**
Immediate onset with IV infusion

**Elimination**
- Proteolytic cleavage
- Renal - requires initial dosage adjustment in patients with severe renal dysfunction, CrCl < 30 ml/min

**Half-Life**
- 25 minutes
- Prolonged in patients with severe renal insufficiency

**Treatment (initial dosing)**

**General Considerations**
- Initial doses based on using actual body weight
- See bivalirudin protocol for dosing adjustment and monitoring recommendations

**Management of Heparin Induced Thrombocytopenia (HIT)**
- Initial Infusion rate - Standard
  - 0.2 mg/kg/hr
- Initial Infusion rate - Critically ill patient
  - 0.1 mg/kg/hr
- Renal insufficiency
  - 0.08–0.12 mg/kg/hour (CrCl 30–60 ml/min)
  - 0.05–0.08 mg/kg/hour (CrCl below 30 ml/min, also consider argatroban)


**Management of Acute Coronary Syndrome**
- Prior to PCI (management on the floor)
  - Initial Bolus: 0.1 mg/kg followed by 0.25 mg/kg/hr infusion until PCI
  - No aPTT/ACT monitoring necessary if < 48hrs
  - Should not be used for this indication if CrCl < 30 ml/min
- Management of PCI (For use IN CATH LAB ONLY)
  - Larger initial bolus (0.75 mg/kg) followed by CI (>1.7 mg/kg/hr) for duration of catheterization and up to 4 hours post procedure.

**Monitoring**
Baseline serum creatinine
- assess creatinine clearance prior to initiation
Management of HIT or prolonged infusion: Activated partial thromboplastin time (aPTT)
- Collect 2 hours after initiation then every 4 hours (after rate change or if in range) until two consecutively in range, and then daily with AM labs. Adjust per protocol

**DTI Reversal**
No antidote or reversal agent is available for direct thrombin inhibitors
- Bivalirudin and dabigatran are removed via hemodialysis/filtration and can be considered in patients actively bleeding with elevated aPTT (Argatroban is not significantly removed)
- Consider fresh frozen plasma (FFP), FEIBA, or Factor VII for refractory/life threatening bleeding
**Guidelines to Anticoagulation**

**Adult Heparin Induced Thrombocytopenia (HIT) Guidelines**

HIT should be considered in patients exhibiting a decrease in platelet count after 5 days of receiving a heparin/LMWH product (may be seen much sooner if previous exposure to heparin), and one of the following:

- Platelet count of less than 150000/μL OR 50% drop in baseline platelet count
- Development of a new arterial or venous thrombus
- Inflammation or necrosis at heparin injection site
- Patient with previous documented HIT or heparin induced thrombocytopenia thrombotic syndrome (HITTS) requiring treatment

**Initial Assessment and labs:**

- Discontinue all heparin/LMWH products (IV, SC, flushes, and coated catheters)
- Collect HIT assay (ELISA), preferably >4 hrs after heparin discontinued.
  - May collect earlier if lab turnaround time will be significantly improved.
- Collect baseline CMP (renal and hepatic function) and CBC
- Collect baseline aPTT, INR/PT
- Consider initiation of treatment for suspected HIT/HITTS (see below)

The decision to administer DTI therapy for HIT is based on a clinical-pathologic diagnosis. Clinical probability can be assessed using the 4T scoring system below:

- Consider HIT in patients with intermediate to high probability

### The “4 Ts” Estimation of pretest probability of heparin-induced thrombocytopenia

<table>
<thead>
<tr>
<th></th>
<th>2 Points</th>
<th>1 Points</th>
<th>0 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombocytopenia</td>
<td>&gt;50% platelet fall to nadir &gt;20</td>
<td>30-50% platelet fall, or nadir 10-19</td>
<td>&lt;30% platelet fall, or nadir &lt;10</td>
</tr>
<tr>
<td>Timing of onset of platelet fall</td>
<td>Days 5-10, or &lt;1 day with recent heparin (past 30 days)</td>
<td>&gt;10 days or timing unclear, or &lt;1 day with recent heparin (past 31-100 days)</td>
<td>&lt; Day 4 (no recent heparin)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>Proven new thrombosis, skin necrosis, or acute systemic reaction after IV UFH bolus</td>
<td>Progressive or recurrent thrombosis, erythematous skin lesions, suspected thrombosis (unproven)</td>
<td>None</td>
</tr>
<tr>
<td>Other causes of platelet fall</td>
<td>None evident</td>
<td>Possible</td>
<td>Definite</td>
</tr>
</tbody>
</table>

**Pretest probability scores:** 6-8 indicates high; 4-5 intermediate; and 0-3 low.


Laboratory tests for HIT should be interpreted within the context of the clinical probability assessment obtained from the 4T scoring system:

- Collect HIT assay (ELISA)
  - Positive – Possible HIT, consider direct thrombin inhibitor (DTI)
    - If available, consider optical density value in the interpretation of positive ELISA
      - Optical density (OD) value of 0.4-1.0 are associated with a relatively low risk of HIT and should be interpreted within the context of the clinical estimate for the probability of HIT
• OD value of >1 demonstrate nearly a 6-fold increased risk of thrombosis over those less than 1.
  o Negative – HIT diagnosis very unlikely consider other causes for thrombocytopenia, DTI NOT INDICATED
  o Serotonin release assay (SRA) should be sent to confirm ALL positive Elisa

Guidelines for initiation of DTI

<table>
<thead>
<tr>
<th>4T Score/risk for HIT</th>
<th>ELISA Result</th>
<th>Interpretation</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Positive</td>
<td>Evaluate OD value Low probability</td>
<td>Discuss options DTI not indicated</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>Positive</td>
<td>Intermediate prob, eval OD Low probability</td>
<td>Initiate DTI DTI not indicated</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>Positive</td>
<td>High probability Low probability</td>
<td>Initiate DTI DTI not indicated unless thrombosis</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initial treatment for HIT/HITTS:

UKCMC Preferred agent based on indication

<table>
<thead>
<tr>
<th></th>
<th>Argatroban</th>
<th>Bivalirudin</th>
<th>Fondiparinux*</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIT / HITTS</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>HIT w/ hepatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>insufficiency</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIT w/ renal</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>insufficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIT and PCI</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIT and CABG</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subacute HIT and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VTE prophylaxis</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*Fondaparinux should not be used in acute HIT, but may be considered for management of patients with previous HIT diagnosis requiring anticoagulation

Warfarin is not indicated as initial therapy and should be withheld until platelet count resolves.

Direct Thrombin Inhibitors (DTI):

  o **Argatroban** continuous IV infusion, initial rate of 2 mcg/kg/min
  o Requires dosage adjustment in patients with hepatic insufficiency, (Child-Pugh score >6) initial dose 0.5 mcg/kg/min, or critically ill patients, initial dose 0.5-1 mcg/kg/min.

  OR

  o **Bivalirudin** continuous IV infusion, initial rate of 0.2 mg/kg/hr
Guidelines to Anticoagulation

- Requires dosage adjustment in patients with renal insufficiency (Clcr < 60 ml/min) or critically ill patients (see above)

OR

Factor Xa Inhibitor (hematology/oncology consultation required):
  - Fondaparinux (Arixtra®), therapeutic weight based dosing (actual body weight)
    - <50 kg: 5 mg SC once daily
    - 50-100 kg: 7.5 mg SC once daily
    - >100 kg: 10 mg SC once daily
  - Contraindicated in patients with a Clcr < 30 ml/min
  - Assess patient for appropriateness of SC route and use of agent with long half-life
  - Monitor CBC to assess platelet count and evidence of bleeding

Routine labs/monitoring (direct thrombin inhibitors):
  - Collect aPTT 2 hours after initiation of therapy
  - Adjust direct thrombin inhibitor (DTI) dose according to nomogram to achieve a goal aPTT of 1.5-2.5x baseline, capping the aPTT target range at 80 seconds.
  - Collect aPTT 2 hours after initiation of infusion then every 4 hours.
  - After 2 consecutive aPTTs in the therapeutic range, collect aPTT daily
  - Monitor CBC daily to assess platelet count and evidence of bleeding

This is not intended as a nurse-managed protocol

<table>
<thead>
<tr>
<th>Argatroban nomogram for HIT</th>
<th>Bivalirudin nomogram for HIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT based on goal range of 1.5-2.5x baseline (See above for initial rate)</td>
<td>aPTT based on goal range of 1.5-2.5x baseline (See above for initial rate)</td>
</tr>
<tr>
<td><strong>aPTT</strong></td>
<td><strong>Dosage Adjustment</strong></td>
</tr>
<tr>
<td>&lt;1.2x control</td>
<td>increase rate by 40%</td>
</tr>
<tr>
<td>1.2-1.5x control</td>
<td>increase rate by 20%</td>
</tr>
<tr>
<td>1.5 – 2.5x control (upper limit 80)</td>
<td>No Change</td>
</tr>
<tr>
<td>2.5 – 4x control (less than 100)</td>
<td>decrease rate by 20%</td>
</tr>
<tr>
<td>&gt;4x control or aPTT &gt; 100</td>
<td>Hold for 1 hour, reassess aPTT; decrease rate by 50% once aPTT &lt; 100</td>
</tr>
</tbody>
</table>

Initiation of warfarin:
  - Should be held until platelet count returns to above 150000/μL
  - Combined therapy of a DTI with warfarin should be continued for a minimum of 4 days and until the INR is in the desired range
  - Argatroban can cause an elevation in INR beyond that seen with warfarin alone (reversal with vitamin K not necessary)
    - Collect baseline INR on argatroban prior to initiation of warfarin
    - Refer to argatroban to warfarin conversion guidelines
Argatroban to warfarin conversion guidelines

- Patient with HIT on argatroban
  - titrate to aPTT of 50-80s; send baseline INR

- After patient is stabilized, check platelets; if within normal limits initiate warfarin

- Add warfarin therapy not exceed 5 mg;
  Continue at least 4 days of combination therapy.

- Collect daily INR

- For INR is \(<4\), continue concomitant therapy and consider increasing warfarin dose

- For INR is \(>4\), stop argatroban infusion, and repeat INR with aPTT in 4-6 hours

  - If INR and aPTT are in therapeutic range*, continue warfarin monotherapy
  - If INR is below therapeutic range*, resume argatroban combination therapy

* Supratherapeutic aPTT may indicate Argatroban effects on INR are still present.
**Falsely elevated. Do not give Vit K for increased INR, only give if bleeding, s/s hemorrhage, etc.
DTIs directly interfere with PT/INR.
Patients with HIT/HITTS Undergoing Percutaneous Coronary Intervention (PCI)

Bivalirudin Dosing (CATH LAB ONLY)
- Patient currently on infusion of bivalirudin
  - Initial bolus of bivalirudin 0.5 mg/kg, increase infusion rate to 1.75 mg/kg/hr
- Patient not currently on infusion of bivalirudin
  - Initial bolus of bivalirudin 0.75 mg/kg, initiate infusion rate of 1.75 mg/kg/hr
  - Check activated clotting time (ACT) 5 minutes after bolus
    - If less than 225s, give additional 0.3 mg/kg bolus
    - Continue infusion for up to 4 hours post-procedure
  - If additional anticoagulation is necessary for bridging to warfarin or other indication, continue at a rate of 0.2 mg/kg/hr
    - Adjust according to nomogram to achieve goal aPTT of 1.5-2.5x baseline.

Patients with HIT/HITTS Undergoing On-Pump Coronary Artery Bypass Surgery

Bivalirudin:
- 1 mg/kg IV bolus, followed by 2.5 mg/kg/hr infusion for the duration of the procedure
  - In addition, bivalirudin 50 mg is added to the pump prime
  - Discontinue infusion 15 min prior to expected separation from CPB
  - Goal to maintain ACT > 2.5-times baseline
    - Administer additional 0.1-0.5 mg/kg boluses if subtherapeutic

* Infusion rate may need to be reduced by as much as 50% in patients with renal insufficiency (Clcr < 30 ml/min) or critically ill patients

Patients with HIT/HITTS Undergoing Off-Pump Coronary Artery Bypass Surgery (OPCAB)

Bivalirudin:
- 0.75 mg/kg IV bolus, starting dose of 1.75 mg/kg/hr infusion for the duration of the procedure
  - Goal to maintain ACT above 300 seconds
  - Adjust infusion rate by 0.25 mg/kg/hr increments to maintain ACT within desired range

* Reduce initial infusion rate by 50% in patients with renal insufficiency (Clcr < 30 ml/min)

Patients required VTE prophylaxis with history of HIT or patients with resolved HIT/HITTS:

Factor Xa Inhibitor:
- Fondaparinux 2.5 mg SC daily
  - Caution in patients with a CrCl < 30 ml/min
  - Monitor CBC daily to assess platelet count and evidence of bleeding
### Direct Oral Anticoagulants (DOACs) - (apixaban, dabigatran, edoxaban, rivaroxaban)

<table>
<thead>
<tr>
<th></th>
<th><strong>Dabigatran (Pradaxa)</strong></th>
<th><strong>Rivaroxaban (Xarelto)</strong></th>
<th><strong>Apixaban (Eliquis)</strong></th>
<th><strong>Edoxaban (Salvaysa)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Class</strong></td>
<td>Direct Factor IIa Inhibitor</td>
<td>Direct Factor Xa Inhibitor</td>
<td>Direct Factor Xa Inhibitor</td>
<td>Direct Factor Xa Inhibitor</td>
</tr>
<tr>
<td><strong>Initial US Approval Year</strong></td>
<td>2010</td>
<td>2011</td>
<td>2012</td>
<td>2015</td>
</tr>
<tr>
<td><strong>Approved Indication</strong></td>
<td>Reduce risk of stroke in NONVALVULAR atrial fibrillation (SPAF) Reduce risk of recurrence of DVT/PE DVT/PE treatment after parenteral anticoagulant for 5-10 days</td>
<td>Reduce risk of stroke in NONVALVULAR atrial fibrillation (SPAF) VTE Prophylaxis for hip/knee replacement DVT/PE treatment</td>
<td>Reduce risk of stroke in NONVALVULAR atrial fibrillation (SPAF) VTE Prophylaxis for hip/knee replacement DVT/PE Treatment (2014)</td>
<td>Reduce risk of stroke in NONVALVULAR atrial fibrillation (SPAF) DVT/PE treatment after parenteral anticoagulant for 5-10 days</td>
</tr>
<tr>
<td><strong>UK Formulary Status (June 2015)</strong></td>
<td>Approved for SPAF and continuation of home medication for VTE</td>
<td>Approved for SPAF and acute treatment of VTE</td>
<td>Approved for SPAF and acute treatment of VTE</td>
<td>Not approved on formulary except for continuation of home medication as non-formulary</td>
</tr>
</tbody>
</table>

Need to consider indication, age, renal/liver function, body weight, and drug-drug interactions when determining appropriate dosage.

See below for general dosing recommendation but refer to manufacturer recommendations for specific recommendations, warnings, precautions, and drug-drug interactions.

*For any assistance with DOAC benefit/risk assessment, determination of appropriate indication, dosing, or reversal management; please consider consulting UK HealthCare Anticoagulation Consult Service at 330-2093.*
### Guidelines to Anticoagulation

#### General Dosing information per manufacturer recommendations for DOACs:

**Nonvalvular Atrial Fibrillation**

<table>
<thead>
<tr>
<th>DOAC</th>
<th>Dosing Information</th>
<th>VTE Prevention for HIP or Knee Replacement Surgery</th>
<th>VTE Treatment or Reduction in Risk of Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dabigatran (Pradaxa)</strong></td>
<td>Clcr ≥ 30 ml/min: 150mg BID; Clcr 15-30 ml/min or 30-50 ml/min and strong P-gp inhibitor: 75mg BID Clcr &lt;50 mL/min with concomitant use of P-gp inhibitors: Avoid co-administration Clcr &lt; 15: Avoid use</td>
<td>Clcr≥30 mL/min: 150 mg BID after 5-10 days of parenteral anticoagulation Clcr &lt;30 ml/min: No recommendations Clcr &lt;50 mL/min with concomitant use of P-gp inhibitors: Avoid co-administration</td>
<td></td>
</tr>
<tr>
<td><strong>Rivaroxaban (Xarelto)</strong></td>
<td>Clcr &gt; 50 ml/min: 20mg daily; Clcr 15-50 ml/min: 15mg daily; Clcr &lt; 15 ml/min: Avoid use</td>
<td>Clcr≥30 mL/min: 10mg daily Clcr &lt;30 ml/min: Avoid use</td>
<td>Clcr≥30 mL/min: Clcr 15mg BID x 21 days then 20mg daily Clcr &lt;30 ml/min: Avoid use</td>
</tr>
<tr>
<td><strong>Apixaban (Eliquis)</strong></td>
<td>5mg twice BID; Dose adjusted to 2.5mg BID if the patient is taking a strong dual inhibitor of CYP3A4 and P-gp, or has two or more of: ≥80 years age, body weight ≤60 kg, or Scr ≥ 1.5 mg/dL</td>
<td>2.5mg BID</td>
<td>10mg BID X 7 days then 5mg BID Prevention: 2.5mg BID</td>
</tr>
<tr>
<td><strong>Edoxaban (Savaysa)</strong></td>
<td>60 mg once daily in patients with CrCL &gt;50 to ≤ 95 mL/min. Do not use in patients with CrCL &gt; 95 mL/min Reduce dose to 30 mg once daily in patients with creatinine clearance 15 to 50 mL/min</td>
<td>N/A</td>
<td>60 mg once daily 30 mg once daily for patients with CrCL 15-50 mL/min or body weight less than or equal to 60 kg or who use certain P-gp inhibitors</td>
</tr>
</tbody>
</table>

---

*For any assistance with DOAC benefit/risk assessment, determination of appropriate indication, dosing, or reversal management; please consider consulting UK HealthCare Anticoagulation Consult Service at 330-2093.*
**Guidelines to Anticoagulation**

**VTE PROPHYLAXIS ASSESSMENT AND MANAGEMENT**

All adult patients are assessed at the point of admission for their individualized risk for venous thromboembolism (VTE). Clinicians will be asked to utilize their judgment at times to ensure that all patients are assessed to ensure sufficient and safe prophylaxis orders.

**Procedure:**

**VTE risk assessment completion**

1. The physician will be prompted to complete the assessment upon patient admission as a component of the admission order set.
2. Physician is ultimately responsible for completing initial assessment for every patient with admission orders to the hospital.

**Components of the risk assessment form: (user will be prompted to complete each of the following)**

1. **VTE risk Category** (See table below for risk assessment and suggested therapies)
   a. Low risk
   b. Moderate Risk
   c. High Risk

2. **VTE chemical prophylaxis contraindications**
   a. Active bleeding
   b. Coagulopathy / Severe Liver Disease
   c. Heparin Induced Thrombocytopenia (HIT)
   d. Platelet Count < 20K without coagulopathy
   e. LP, spinal injection or epidural catheter removal within past 2 hours
   f. Multiple trauma with high bleeding risk
   g. Other high risk for bleeding or active bleeding, (list:___)

3. Admission order set will preselect therapies based on defined risk and presence of any contraindications. Prescribers have the option to override these selections prior to submission of the order.
   a. Low risk = no selection of VTE prophylaxis
   b. Moderate risk = heparin 5000 units SQ q8h
   c. High risk = enoxaparin 30 mg SQ q12h (q24h if eGFR < 30 ml/min)
   d. Selection of a contraindication will replace chemical prophylaxis with an order for sequential compression devices
Guidelines to Anticoagulation

Risk Assessment Guideline for Medical Patients:
Patients with limited mobility and at least one additional risk factor: consider VTE prophylaxis (moderate to high risk)

UK HealthCare VTE PROPHYLAXIS GUIDELINES - ADULTS

At time of hospital admission (UK HealthCare Admit-Adult Order Set), assess VTE risk as LOW, MODERATE, or HIGH using VTE Risk Assessment Tools:
- Medicine Patients: UK HealthCare VTE Risk Tool (Figure 1)
- Surgical Patients: Caprini VTE Risk Tool (Figure 2)

LOW RISK
- Default selection: SCDS
- If selected SCDS, must document Reason Medical Prophylaxis Not Ordered: "If LOW RISK with ACTIVE Ambulation, No VTE Prophylaxis Needed"
- Document lack of risk
- Reassess daily for new risk factors or prolonged length of stay

MODERATE RISK
- Default 1st Line Selection: Enoxaparin 40mg SQ q24hrs
- 2nd Line Option (manual selection): Heparin 5000 units SQ q8hrs
  - If selected all pharmacological therapy, SCDS are default selection (cannot deselect) and must document Reason Medical Prophylaxis Not Ordered: Coagulopathy or Therapeutically Anticoagulated
  - If Therapeutically Anticoagulated is selected, SCDS will deselect

HIGH RISK
- Default 1st Line Selection: Enoxaparin 60mg SQ q24hrs and SCDS
- 2nd Line Option (manual selection): Heparin 5000 units SQ q8hrs or Enoxaparin 50mg SQ q12hrs
  - If selected all pharmacological therapy, SCDS are default selection (cannot deselect) and must document Reason Medical Prophylaxis Not Ordered: Coagulopathy or Therapeutically Anticoagulated
  - If Therapeutically Anticoagulated is selected, SCDS will deselect

Contraindications to VTE Chemical Prophylaxis?
- No prophylaxis needed (Old or psychiatric nursing patients)
- Coagulopathy
- Severe liver disease
- Neoplastic induced thrombocytopenia (M.T)
- Platelet count < 20,000
- Lumbar puncture, spinal injection or epidural catheter removal within past 2 hours
- Multiple trauma with high bleeding risk
- Other: Document in record set

eGFR < 30 ml/min or eGFR not available?

LDN = low dose unfractionated heparin; SCDS = sequential compression devices
## Medical Patients VTE Risk Assessment

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Low Risk</th>
<th>Moderate Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Acute medical illness</td>
<td>- Mobile medical patients or minor surgery patients</td>
<td>- Medical patients with limited mobility and one risk factor</td>
<td>- Hip or knee arthroplasty</td>
</tr>
<tr>
<td>- Age &gt;65 years</td>
<td>- Perceived admit &lt;48 hours</td>
<td>- Most general surgery patients</td>
<td>- Hip fracture surgery</td>
</tr>
<tr>
<td>- Cancer (active or occult)</td>
<td></td>
<td></td>
<td>- Major trauma</td>
</tr>
<tr>
<td>- Cancer therapy (hormonal, chemo- or radiotherapy, angiogenesis inhibitors)</td>
<td></td>
<td></td>
<td>- Spinal cord injury</td>
</tr>
<tr>
<td>- Estrogen-based oral contraceptives or hormone replacement therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Erythropoiesis-stimulating agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Immobility, lower-extremity paresis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Indwelling central venous catheter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Inflammatory bowel disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Inherited or acquired thrombophilia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Myeloproliferative disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Nephrotic syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Obesity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Paroxysmal nocturnal hemoglobinuria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Pregnancy and post-partum period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Previous venous thromboembolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Selective estrogen receptor modulators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Trauma (major or lower extremity)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Venous compression (tumor, hematoma, arterial abnormality)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contraindications</th>
<th>Low Risk</th>
<th>Moderate Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Coagulopathy</td>
<td>- Lumbar puncture, spinal injection, or epidural catheter removal within past 2 hours</td>
<td>- Multiple trauma with high bleeding risk</td>
<td></td>
</tr>
<tr>
<td>- Severe liver disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Heparin induced thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Platelet count &lt;20,000 without coagulopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Suggested Therapy

- Enoxaparin 40 mg SQ daily (preferred if eGFR > 30 mL/min)
- Heparin 5,000 units SQ q8h
- With or without SCDs

- Enoxaparin 30 mg SQ q12h
- Heparin 5,000 units SQ q8h
- With SCDs

Patients at moderate to high risk with bleeding risk should receive mechanical thromboprophylaxis.

Dosing adjustment should be considered for enoxaparin in patients with renal insufficiency (CrCl < 30 mL/min) and should be considered in morbidly obese patients (BMI > 40 kg/m²).

VTE = venous thromboembolism, SCDs = sequential compression devices, SQ = subcutaneously, q8h = every 8 hours, q12h = every 12 hours, CrCl = creatinine clearance, BMI = body mass index.
Perioperative Deep Vein Thrombosis (DVT) Prophylaxis Risk Stratification Guide

**Caprini DVT Risk Factor Assessment**

<table>
<thead>
<tr>
<th>Each Risk Factor Represents 1 Point</th>
<th>Each Risk Factor Represents 2 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 60 years</td>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>Swollen legs (current)</td>
<td>Congestive heart failure (≥1 month)</td>
</tr>
<tr>
<td>Varicose veins</td>
<td>Medical patient currently bed rest</td>
</tr>
<tr>
<td>Chest ≥ 2</td>
<td>History of inflammatory bowel disease</td>
</tr>
<tr>
<td>Minor surgery planned</td>
<td>History of prior major surgery (&lt;1 month)</td>
</tr>
<tr>
<td>Sepsis (&lt;1 month)</td>
<td>Abnormal pulmonary function (CPD)</td>
</tr>
<tr>
<td>Serious lung disease including pneumonia (&lt;1 month)</td>
<td></td>
</tr>
<tr>
<td>Oral contraceptives or hormone replacement therapy</td>
<td></td>
</tr>
<tr>
<td>Pregnancy or postpartum (&lt;1 month)</td>
<td></td>
</tr>
<tr>
<td>History of unexplained stillborn infant, recurrent spontaneous abortion (&gt;3), premature birth with toxemia or growth restricted infant</td>
<td></td>
</tr>
<tr>
<td>Other risk factors:</td>
<td></td>
</tr>
</tbody>
</table>

**Subtotal:**

<table>
<thead>
<tr>
<th>Each Risk Factor Represents 3 Points</th>
<th>Each Risk Factor Represents 5 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 75 years or older</td>
<td>Family History of thrombosis*</td>
</tr>
<tr>
<td>History of DVT/PE</td>
<td>Positive Prothrombin 202:1A</td>
</tr>
<tr>
<td>Positive Factor V Leiden</td>
<td>Positive Lupus anticoagulant</td>
</tr>
<tr>
<td>Elevated serum homocysteine</td>
<td>Heparin-induced thrombocytopenia HIT</td>
</tr>
<tr>
<td>Heparin-induced thrombocytopenia (HIT)</td>
<td>Do not use heparin or any low molecular weight heparin</td>
</tr>
<tr>
<td>Elevated anti-cardiolipin antibodies</td>
<td></td>
</tr>
<tr>
<td>Other congenital or acquired thrombophilia</td>
<td></td>
</tr>
<tr>
<td>If yes: Type:</td>
<td></td>
</tr>
<tr>
<td>*most frequently missed risk factor:</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL RISK FACTOR SCORE:**

**Contraindications to Pharmacologic Prophylaxis:**

- High Bleeding Risk
- Thrombocytopenia
- History of Heparin Induced Thrombocytopenia (HIT)
- Epidurals/Regional Pain Catheters
- ECMO/Cardiopulmonary Bypass
- Thoracoabdominal Aneurysm with Planned Spinal Drainage Placement
- Ocular Procedures
- Neurosurgery Procedures
- Other:

**Recommended Prophylaxis Regimens:**

<table>
<thead>
<tr>
<th>Total Risk Factor</th>
<th>DVT Risk Level</th>
<th>Incidence of DVT</th>
<th>PreOP PPX</th>
<th>PostOP PPX*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1</td>
<td>Low Risk</td>
<td>2%</td>
<td>Choose ONE of the following: Early Ambulation Sequential Compression Devices (SCDs)</td>
<td>Choose ONE of the following: Early Ambulation Sequential Compression Devices (SCDs)</td>
</tr>
<tr>
<td>2-4</td>
<td>Moderate Risk</td>
<td>10-40%</td>
<td>Choose ONE of the following: Sequential Compression Devices (SCDs) Heparin 5000 Units SQ in PreOP Holding</td>
<td>Choose ONE of the following: Sequential Compression Devices (SCDs) Heparin 5000 Units SQ q8Hours</td>
</tr>
<tr>
<td>5 or more</td>
<td>High Risk</td>
<td>40-80%</td>
<td>BOTH Required unless contraindicated: Sequential Compression Devices (SCDs) Heparin 5000 Units SQ in PreOP Holding</td>
<td>Choose SCDs and ONE Pharmacologic PPK: Sequential Compression Devices (SCDs) Heparin 5000 Units SQ q8Hours (If eGFR &lt;30) Enoxaparin 40mg SQ q24Hours (If eGFR &gt;30)</td>
</tr>
</tbody>
</table>

*Consider Pharmacy Consultation and Dosage Adjustment in the Supra-Obese Patient (>150kg)*
Guidelines to Anticoagulation

References (Warfarin)

References (Heparin/Enoxaparin)

References (Heparin Induced Thrombocytopenia)

Additional references available upon request.
Notes: